[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f48Z_z6Ug4DldL6y_vY99z6H5BfryI3Qk09NwfciSKH8":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":87,"rows":94},"Case Comprehensive Cancer Center",[4],486,false,77,12,33726,36,242,[14,17,20,23,25,28,31,34],{"name":15,"count":16},"Breast Cancer",56,{"name":18,"count":19},"Prostate Cancer",32,{"name":21,"count":22},"Lymphoma",27,{"name":24,"count":22},"Unspecified Adult Solid Tumor, Protocol Specific",{"name":26,"count":27},"Lung Cancer",24,{"name":29,"count":30},"Leukemia",21,{"name":32,"count":33},"Myelodysplastic Syndromes",19,{"name":35,"count":36},"Head and Neck Cancer",15,[38,43,48,53,58,63,68,73,77,82],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT03514069","Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma","2021-08-27","ruxolitinib",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT03535350","Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma","2023-04-04","Ibrutinib",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT04620603","Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer","2024-03-20","Standard-of-Care Immunotherapy",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT04668885","CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS","2025-10-10","CPX-351",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT03713580","Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin Lymphoma","2025-12","Venetoclax",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT03277638","Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)","2026-06","Pembrolizumab at 7 days prior",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT04332341","Study of Nicotinamide Riboside Supplementation in Allogeneic Hematopoietic Cell Transplantation","2026-07","Nicotinamide riboside",{"nctId":74,"briefTitle":75,"date":71,"intervention":76},"NCT05607407","Methimazole in Patients With Progressive Glioblastoma","Methimazole",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT06386887","Fasting During Neoadjuvant Chemotherapy in Patient With Epithelial Ovarian Cancer","2026-07-01","Neoadjuvant chemotherapy",{"nctId":83,"briefTitle":84,"date":85,"intervention":86},"NCT05209074","Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma","2026-07-15","Ivosidenib",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,133,228,391,424,452,478,496,523,550,568,592,612,639,657,675,697,715,733,759,784,802,849,923,941,967,985,1003,1025,1043,1061,1082,1105,1126,1163,1188,1210,1233,1391,1509,1634,1680,1734,1860,1916,1963,1984,2007,2033,2051,2069,2087,2105,2192,2381,2487,2552,2615,2652,2686,2732,2775,2811,2860,2890,2935,2972,3002,3030,3056,3097,3132,3168,3199,3227,3266,3292,3323,3357,3379,3403,3439,3468,3496,3518,3551,3580,3609,3637,3663,3684,3702,3720,3746,3764,3782,3800,3818,3836,3854,3872,3896,3914,3943,3961,3979,3997,4015,4041,4059,4077,4102,4127,4145,4171,4193,4211,4229,4256,4274,4292,4320,4344,4362,4380,4405,4427,4451,4474,4495,4513,4537,4563,4581,4599,4617,4635,4658,4676,4694,4712,4734,4760,4778,4796,4814,4832,4850,4868,4886,4907,4932,4950,4972,5006,5034,5066,5084,5108,5126,5144,5162,5180,5198,5220,5241,5259,5277,5302,5320,5338,5356,5374,5392,5416,5434,5452,5473,5494,5517,5535,5560,5578,5596,5614,5636,5661,5687,5710,5733,5870,5952,6022,6093,6151,6205,6247,6298,6340,6382,6444,6486,6528,6566,6631,6676,6710,6740,6773,6799,6838,6864,6890,6925,6951,6973,6995,7017,7044,7083,7106,7124,7142,7163,7187,7205,7234,7252,7270,7294],{"intervention":81,"totalTrials":96,"cells":97},2,{"EARLY_PHASE1":98,"PHASE1":101,"PHASE2":103,"PHASE3":120,"PHASE4":122,"NA":124},{"trials":99,"activeCount":100},[],0,{"trials":102,"activeCount":100},[],{"trials":104,"activeCount":119,"soonestReadout":110},[105],{"nctId":106,"briefTitle":107,"status":108,"phases":109,"primaryCompletion":110,"completion":111,"start":66,"enrollment":112,"conditions":113,"interventions":116},"NCT06290687","Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy","RECRUITING",[90],"2026-12-29","2027-12-29",40,[114,115],"Malignant Neoplasm of Bladder","Muscle Invasive Bladder Carcinoma",[117,118],"Neoadjuvant Chemotherapy","Adjuvant systemic therapy",1,{"trials":121,"activeCount":100},[],{"trials":123,"activeCount":100},[],{"trials":125,"activeCount":119,"soonestReadout":80},[126],{"nctId":78,"briefTitle":79,"status":108,"phases":127,"primaryCompletion":80,"completion":80,"start":128,"enrollment":129,"conditions":130,"interventions":132},[93],"2024-07-11",20,[131],"Epithelial Ovarian Cancer",[81],{"intervention":134,"totalTrials":135,"cells":136},"tacrolimus",4,{"EARLY_PHASE1":137,"PHASE1":139,"PHASE2":167,"PHASE3":204,"PHASE4":224,"NA":226},{"trials":138,"activeCount":100},[],{"trials":140,"activeCount":100},[141],{"nctId":142,"briefTitle":143,"status":144,"phases":145,"primaryCompletion":146,"completion":147,"start":148,"enrollment":149,"conditions":150,"interventions":162},"NCT02129582","Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies","COMPLETED",[89],"2019-03-15","2020-03-05","2014-11-05",14,[151,152,153,154,155,156,157,158,159,160,161],"Acute Myeloid Leukemia","Hematologic Malignancies","Acute Lymphocytic Leukemia","Non Hodgkin Lymphoma","Hodgkin Lymphoma","Multiple Myeloma","Myelodysplastic Syndrome","Chronic Lymphocytic Leukemia","Chronic Myeloid Leukemia","Myelofibrosis","Myeloproliferative Syndrome",[163,164,165,134,166],"fludarabine phosphate","busulfan","anti-thymocyte globulin","methotrexate",{"trials":168,"activeCount":119,"soonestReadout":194},[169,189],{"nctId":170,"briefTitle":171,"status":144,"phases":172,"primaryCompletion":173,"completion":174,"start":175,"enrollment":176,"conditions":177,"interventions":186},"NCT00109993","Campath-1H + FK506 and Methylprednisolone for GVHD",[90],"2006-06","2007-05","2005-01",34,[15,178,179,180,29,21,181,32,182,183,184,185],"Chronic Myeloproliferative Disorders","Gestational Trophoblastic Tumor","Graft Versus Host Disease","Multiple Myeloma and Plasma Cell Neoplasm","Myelodysplastic\u002FMyeloproliferative Diseases","Neuroblastoma","Ovarian Cancer","Testicular Germ Cell Tumor",[187,188,134],"alemtuzumab","methylprednisolone",{"nctId":190,"briefTitle":191,"status":192,"phases":193,"primaryCompletion":194,"completion":194,"start":195,"enrollment":129,"conditions":196,"interventions":200},"NCT06084780","Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)","NOT_YET_RECRUITING",[90],"2026-12-31","2026-08",[197,198,199],"Secondary Malignant Neoplasm of Retroperitoneum","Secondary Malignant Neoplasm of Peritoneum","Pseudomyxoma Peritonei",[201,202,203],"Alemtuzumab","Tacrolimus","Sirolimus",{"trials":205,"activeCount":100},[206],{"nctId":207,"briefTitle":208,"status":144,"phases":209,"primaryCompletion":210,"completion":211,"start":212,"enrollment":213,"conditions":214,"interventions":221},"NCT01951885","Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention",[91],"2020-10-09","2021-08-11","2014-07-07",101,[215,216,151,217,157,218,219,220,158,156],"Chronic Myelogenous Leukemia","Acute Lymphoblastic Leukemia","Acute Biphenotypic Leukemia","Myeloproliferative Neoplasm","Non-Hodgkin Lymphoma","Hodgkins Disease",[134,166,222,223],"Mycophenolate mofetil","Methotrexate",{"trials":225,"activeCount":100},[],{"trials":227,"activeCount":100},[],{"intervention":229,"totalTrials":230,"cells":231},"oxaliplatin",10,{"EARLY_PHASE1":232,"PHASE1":234,"PHASE2":285,"PHASE3":385,"PHASE4":387,"NA":389},{"trials":233,"activeCount":100},[],{"trials":235,"activeCount":100},[236,248,262,276],{"nctId":237,"briefTitle":238,"status":144,"phases":239,"primaryCompletion":240,"completion":241,"start":242,"enrollment":243,"conditions":244,"interventions":245},"NCT00006465","Combination Chemotherapy in Treating Patients With Advanced Solid Tumors",[89],"2003-11","2005-04","2000-12",22,[24],[246,247,229],"capecitabine","irinotecan hydrochloride",{"nctId":249,"briefTitle":250,"status":144,"phases":251,"primaryCompletion":252,"completion":252,"start":253,"enrollment":254,"conditions":255,"interventions":257},"NCT00118261","Erlotinib, Modified FOLFOX6, and Bevacizumab as First-Line Therapy Metastatic Colorectal Cancer",[89],"2011-01","2005-03",17,[256],"Colorectal Cancer",[258,259,260,261,229],"bevacizumab","erlotinib hydrochloride","fluorouracil","leucovorin calcium",{"nctId":263,"briefTitle":264,"status":265,"phases":266,"primaryCompletion":267,"start":268,"enrollment":269,"conditions":270,"interventions":273},"NCT00732745","Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction","TERMINATED",[89],"2010-06","2008-10",9,[271,272],"Adenocarcinoma of the Gastroesophageal Junction","Esophageal Cancer",[274,229,275],"docetaxel","vandetanib",{"nctId":277,"briefTitle":278,"status":265,"phases":279,"primaryCompletion":280,"completion":281,"start":282,"enrollment":9,"conditions":283,"interventions":284},"NCT00296062","Dose Dense Therapy and Bevacizumab in Solid Tumors and Colorectal Cancer",[89],"2009-10","2011-05","2006-03",[256,24],[258,246,247,229],{"trials":286,"activeCount":119,"soonestReadout":324},[287,306,320,335,348,366],{"nctId":288,"briefTitle":289,"status":265,"phases":290,"primaryCompletion":291,"completion":291,"start":292,"enrollment":119,"conditions":293,"interventions":300},"NCT02392377","Molecular Phenotyping in Predicting Response in Patients With Stage IB-III Esophageal Cancer Receiving Combination Chemotherapy",[90],"2015-12","2015-02",[294,295,296,297,298,299],"Stage IB Esophageal Adenocarcinoma","Stage IIA Esophageal Adenocarcinoma","Stage IIB Esophageal Adenocarcinoma","Stage IIIA Esophageal Adenocarcinoma","Stage IIIB Esophageal Adenocarcinoma","Stage IIIC Esophageal Adenocarcinoma",[301,302,303,304,305],"Paclitaxel","Carboplatin","Oxaliplatin","Leucovorin Calcium","Fluorouracil",{"nctId":307,"briefTitle":308,"status":144,"phases":309,"primaryCompletion":310,"completion":310,"start":311,"enrollment":312,"conditions":313,"interventions":318},"NCT01666730","Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer",[90],"2018-08-01","2013-02-21",50,[314,315,316,317],"Acinar Cell Adenocarcinoma of the Pancreas","Duct Cell Adenocarcinoma of the Pancreas","Recurrent Pancreatic Cancer","Stage IV Pancreatic Cancer",[319,229,261,260],"metformin hydrochloride",{"nctId":321,"briefTitle":322,"status":108,"phases":323,"primaryCompletion":324,"completion":325,"start":326,"enrollment":22,"conditions":327,"interventions":333},"NCT07146646","Trifluridine\u002FTipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer",[90],"2027-02","2027-04","2025-12-01",[328,329,330,331,332],"Biliary Tract Cancer","Biliary Tract Neoplasms","Cholangiocarcinoma","Gallbladder Cancer","Gallbladder Carcinoma",[334,303],"Trifluridine\u002Ftipiracil",{"nctId":336,"briefTitle":337,"status":144,"phases":338,"primaryCompletion":339,"completion":340,"start":341,"enrollment":342,"conditions":343,"interventions":345},"NCT00601705","Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach",[90],"2012-03-26","2015-01-23","2008-01-05",61,[272,344],"Gastric Cancer",[346,347,260,229],"cisplatin","epirubicin hydrochloride",{"nctId":349,"briefTitle":350,"status":351,"phases":352,"primaryCompletion":353,"completion":354,"start":355,"enrollment":356,"conditions":357,"interventions":363},"NCT02037048","FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma","UNKNOWN",[90],"2022-03-18","2025-10-01","2014-02-10",63,[358,271,359,360,361,362],"Adenocarcinoma of the Esophagus","Adenocarcinoma of the Gastric Cardia","Stage IIIA Esophageal Cancer","Stage IIIB Esophageal Cancer","Stage IIIC Esophageal Cancer",[229,261,260,364,365],"carboplatin","paclitaxel",{"nctId":367,"briefTitle":368,"status":265,"phases":369,"primaryCompletion":370,"completion":371,"start":372,"enrollment":119,"conditions":373,"interventions":383},"NCT02345460","Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study",[90],"2016-02","2016-03","2015-09",[374,375,376,377,378,379,380,381,382],"Pancreatic Adenocarcinoma","Poorly Differentiated Malignant Neoplasm","Resectable Pancreatic Cancer","Stage IA Pancreatic Cancer","Stage IB Pancreatic Cancer","Stage IIA Pancreatic Cancer","Stage IIB Pancreatic Cancer","Stage III Pancreatic Cancer","Undifferentiated Pancreatic Carcinoma",[384,303,304,305],"Irinotecan Hydrochloride",{"trials":386,"activeCount":100},[],{"trials":388,"activeCount":100},[],{"trials":390,"activeCount":100},[],{"intervention":57,"totalTrials":96,"cells":392},{"EARLY_PHASE1":393,"PHASE1":395,"PHASE2":397,"PHASE3":418,"PHASE4":420,"NA":422},{"trials":394,"activeCount":100},[],{"trials":396,"activeCount":100},[],{"trials":398,"activeCount":119,"soonestReadout":56},[399,409],{"nctId":54,"briefTitle":55,"status":400,"phases":401,"primaryCompletion":56,"completion":402,"start":403,"enrollment":404,"conditions":405,"interventions":408},"ACTIVE_NOT_RECRUITING",[90],"2026-10-10","2021-01-14",13,[406,407,32],"Refractory Acute Myeloid Leukemia","Relapsed Acute Myelomonocytic Leukemia",[57],{"nctId":410,"briefTitle":411,"status":265,"phases":412,"primaryCompletion":413,"completion":413,"start":414,"enrollment":135,"conditions":415,"interventions":417},"NCT03957876","CPX-351 Therapy for MDS After Hypomethylating Agent Failure",[90],"2022-12-20","2019-07-25",[416],"Myelodysplastic Syndrome (MDS)",[57],{"trials":419,"activeCount":100},[],{"trials":421,"activeCount":100},[],{"trials":423,"activeCount":100},[],{"intervention":425,"totalTrials":119,"cells":426},"Metronidazole",{"EARLY_PHASE1":427,"PHASE1":429,"PHASE2":431,"PHASE3":446,"PHASE4":448,"NA":450},{"trials":428,"activeCount":100},[],{"trials":430,"activeCount":100},[],{"trials":432,"activeCount":119,"soonestReadout":437},[433],{"nctId":434,"briefTitle":435,"status":108,"phases":436,"primaryCompletion":437,"completion":438,"start":439,"enrollment":440,"conditions":441,"interventions":445},"NCT06627270","Antibiotic Treatment Effects on Intratumoral Bacteria Modulation in Surgical Patients With Oral Cancer",[90],"2026-10-01","2027-10-01","2025-03-11",30,[442,443,35,444],"Oral Squamous Cell Carcinoma","Oral Cancer","Head and Neck Carcinoma",[425],{"trials":447,"activeCount":100},[],{"trials":449,"activeCount":100},[],{"trials":451,"activeCount":100},[],{"intervention":453,"totalTrials":119,"cells":454},"Haplo-Identical \u002F Cord Blood Transplant",{"EARLY_PHASE1":455,"PHASE1":457,"PHASE2":459,"PHASE3":472,"PHASE4":474,"NA":476},{"trials":456,"activeCount":100},[],{"trials":458,"activeCount":100},[],{"trials":460,"activeCount":119,"soonestReadout":465},[461],{"nctId":462,"briefTitle":463,"status":108,"phases":464,"primaryCompletion":465,"completion":466,"start":467,"enrollment":11,"conditions":468,"interventions":471},"NCT06904482","Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood",[90],"2027-02-24","2030-02-25","2025-08-13",[469,470,153,32],"aGVHD","Acute Myelogenous Leukemia",[453],{"trials":473,"activeCount":100},[],{"trials":475,"activeCount":100},[],{"trials":477,"activeCount":100},[],{"intervention":334,"totalTrials":119,"cells":479},{"EARLY_PHASE1":480,"PHASE1":482,"PHASE2":484,"PHASE3":490,"PHASE4":492,"NA":494},{"trials":481,"activeCount":100},[],{"trials":483,"activeCount":100},[],{"trials":485,"activeCount":119,"soonestReadout":324},[486],{"nctId":321,"briefTitle":322,"status":108,"phases":487,"primaryCompletion":324,"completion":325,"start":326,"enrollment":22,"conditions":488,"interventions":489},[90],[328,329,330,331,332],[334,303],{"trials":491,"activeCount":100},[],{"trials":493,"activeCount":100},[],{"trials":495,"activeCount":100},[],{"intervention":497,"totalTrials":119,"cells":498},"Sitagliptin",{"EARLY_PHASE1":499,"PHASE1":501,"PHASE2":503,"PHASE3":517,"PHASE4":519,"NA":521},{"trials":500,"activeCount":100},[],{"trials":502,"activeCount":100},[],{"trials":504,"activeCount":119,"soonestReadout":509},[505],{"nctId":506,"briefTitle":507,"status":108,"phases":508,"primaryCompletion":509,"completion":510,"start":511,"enrollment":512,"conditions":513,"interventions":516},"NCT07003542","A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas",[90],"2027-06","2028-06","2026-03-16",48,[514,515],"Glioblastoma","Brain Tumor",[497],{"trials":518,"activeCount":100},[],{"trials":520,"activeCount":100},[],{"trials":522,"activeCount":100},[],{"intervention":524,"totalTrials":119,"cells":525},"Androgen deprivation therapy",{"EARLY_PHASE1":526,"PHASE1":528,"PHASE2":530,"PHASE3":544,"PHASE4":546,"NA":548},{"trials":527,"activeCount":100},[],{"trials":529,"activeCount":100},[],{"trials":531,"activeCount":119,"soonestReadout":536},[532],{"nctId":533,"briefTitle":534,"status":108,"phases":535,"primaryCompletion":536,"completion":536,"start":537,"enrollment":538,"conditions":539,"interventions":542},"NCT06150417","MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)",[90],"2028-04-01","2024-07-01",200,[18,540,541],"Malignant Neoplasm of Prostate","Secondary Malignant Neoplasm of Prostate",[524,543],"Androgen receptor signaling inhibitor",{"trials":545,"activeCount":100},[],{"trials":547,"activeCount":100},[],{"trials":549,"activeCount":100},[],{"intervention":543,"totalTrials":119,"cells":551},{"EARLY_PHASE1":552,"PHASE1":554,"PHASE2":556,"PHASE3":562,"PHASE4":564,"NA":566},{"trials":553,"activeCount":100},[],{"trials":555,"activeCount":100},[],{"trials":557,"activeCount":119,"soonestReadout":536},[558],{"nctId":533,"briefTitle":534,"status":108,"phases":559,"primaryCompletion":536,"completion":536,"start":537,"enrollment":538,"conditions":560,"interventions":561},[90],[18,540,541],[524,543],{"trials":563,"activeCount":100},[],{"trials":565,"activeCount":100},[],{"trials":567,"activeCount":100},[],{"intervention":569,"totalTrials":119,"cells":570},"BCMA bispecific",{"EARLY_PHASE1":571,"PHASE1":573,"PHASE2":575,"PHASE3":586,"PHASE4":588,"NA":590},{"trials":572,"activeCount":100},[],{"trials":574,"activeCount":100},[],{"trials":576,"activeCount":119,"soonestReadout":581},[577],{"nctId":578,"briefTitle":579,"status":192,"phases":580,"primaryCompletion":581,"completion":581,"start":66,"enrollment":582,"conditions":583,"interventions":585},"NCT07524634","Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) Amyloidosis",[90],"2031-06",64,[584],"Amyloid Light-chain Amyloidosis",[569],{"trials":587,"activeCount":100},[],{"trials":589,"activeCount":100},[],{"trials":591,"activeCount":100},[],{"intervention":76,"totalTrials":119,"cells":593},{"EARLY_PHASE1":594,"PHASE1":596,"PHASE2":598,"PHASE3":606,"PHASE4":608,"NA":610},{"trials":595,"activeCount":100},[],{"trials":597,"activeCount":100},[],{"trials":599,"activeCount":119,"soonestReadout":71},[600],{"nctId":74,"briefTitle":75,"status":108,"phases":601,"primaryCompletion":71,"completion":71,"start":602,"enrollment":33,"conditions":603,"interventions":605},[90],"2023-01-30",[514,604],"Glioma",[76],{"trials":607,"activeCount":100},[],{"trials":609,"activeCount":100},[],{"trials":611,"activeCount":100},[],{"intervention":613,"totalTrials":119,"cells":614},"Cabazitaxel and carboplatin",{"EARLY_PHASE1":615,"PHASE1":617,"PHASE2":619,"PHASE3":633,"PHASE4":635,"NA":637},{"trials":616,"activeCount":100},[],{"trials":618,"activeCount":100},[],{"trials":620,"activeCount":119,"soonestReadout":625},[621],{"nctId":622,"briefTitle":623,"status":108,"phases":624,"primaryCompletion":625,"completion":625,"start":626,"enrollment":627,"conditions":628,"interventions":631},"NCT06738303","Cabazitaxel +\u002F- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer",[90],"2026-12","2025-07-14",44,[629,630],"Metastatic Prostate Cancer","Metastatic Castration-resistant Prostate Cancer",[613,632],"Lu-PSMA-617",{"trials":634,"activeCount":100},[],{"trials":636,"activeCount":100},[],{"trials":638,"activeCount":100},[],{"intervention":632,"totalTrials":119,"cells":640},{"EARLY_PHASE1":641,"PHASE1":643,"PHASE2":645,"PHASE3":651,"PHASE4":653,"NA":655},{"trials":642,"activeCount":100},[],{"trials":644,"activeCount":100},[],{"trials":646,"activeCount":119,"soonestReadout":625},[647],{"nctId":622,"briefTitle":623,"status":108,"phases":648,"primaryCompletion":625,"completion":625,"start":626,"enrollment":627,"conditions":649,"interventions":650},[90],[629,630],[613,632],{"trials":652,"activeCount":100},[],{"trials":654,"activeCount":100},[],{"trials":656,"activeCount":100},[],{"intervention":118,"totalTrials":119,"cells":658},{"EARLY_PHASE1":659,"PHASE1":661,"PHASE2":663,"PHASE3":669,"PHASE4":671,"NA":673},{"trials":660,"activeCount":100},[],{"trials":662,"activeCount":100},[],{"trials":664,"activeCount":119,"soonestReadout":110},[665],{"nctId":106,"briefTitle":107,"status":108,"phases":666,"primaryCompletion":110,"completion":111,"start":66,"enrollment":112,"conditions":667,"interventions":668},[90],[114,115],[117,118],{"trials":670,"activeCount":100},[],{"trials":672,"activeCount":100},[],{"trials":674,"activeCount":100},[],{"intervention":67,"totalTrials":119,"cells":676},{"EARLY_PHASE1":677,"PHASE1":679,"PHASE2":681,"PHASE3":691,"PHASE4":693,"NA":695},{"trials":678,"activeCount":100},[],{"trials":680,"activeCount":100},[],{"trials":682,"activeCount":119,"soonestReadout":66},[683],{"nctId":64,"briefTitle":65,"status":400,"phases":684,"primaryCompletion":66,"completion":66,"start":685,"enrollment":19,"conditions":686,"interventions":688},[89,90],"2017-11-29",[687],"Glioblastoma, Adult",[67,689,690],"Pembrolizumab at 14 days post","Pembrolizumab at 35 days post",{"trials":692,"activeCount":100},[],{"trials":694,"activeCount":100},[],{"trials":696,"activeCount":100},[],{"intervention":689,"totalTrials":119,"cells":698},{"EARLY_PHASE1":699,"PHASE1":701,"PHASE2":703,"PHASE3":709,"PHASE4":711,"NA":713},{"trials":700,"activeCount":100},[],{"trials":702,"activeCount":100},[],{"trials":704,"activeCount":119,"soonestReadout":66},[705],{"nctId":64,"briefTitle":65,"status":400,"phases":706,"primaryCompletion":66,"completion":66,"start":685,"enrollment":19,"conditions":707,"interventions":708},[89,90],[687],[67,689,690],{"trials":710,"activeCount":100},[],{"trials":712,"activeCount":100},[],{"trials":714,"activeCount":100},[],{"intervention":690,"totalTrials":119,"cells":716},{"EARLY_PHASE1":717,"PHASE1":719,"PHASE2":721,"PHASE3":727,"PHASE4":729,"NA":731},{"trials":718,"activeCount":100},[],{"trials":720,"activeCount":100},[],{"trials":722,"activeCount":119,"soonestReadout":66},[723],{"nctId":64,"briefTitle":65,"status":400,"phases":724,"primaryCompletion":66,"completion":66,"start":685,"enrollment":19,"conditions":725,"interventions":726},[89,90],[687],[67,689,690],{"trials":728,"activeCount":100},[],{"trials":730,"activeCount":100},[],{"trials":732,"activeCount":100},[],{"intervention":734,"totalTrials":119,"cells":735},"ALA",{"EARLY_PHASE1":736,"PHASE1":738,"PHASE2":740,"PHASE3":753,"PHASE4":755,"NA":757},{"trials":737,"activeCount":100},[],{"trials":739,"activeCount":100},[],{"trials":741,"activeCount":119,"soonestReadout":746},[742],{"nctId":743,"briefTitle":744,"status":400,"phases":745,"primaryCompletion":746,"completion":747,"start":748,"enrollment":749,"conditions":750,"interventions":752},"NCT05020912","Alteration of the Immune Microenvironment in Basal Cell Carcinoma Following Photodynamic Therapy",[90],"2027-09","2027-12","2021-12-13",18,[751],"Basal Cell Carcinoma",[734],{"trials":754,"activeCount":100},[],{"trials":756,"activeCount":100},[],{"trials":758,"activeCount":100},[],{"intervention":760,"totalTrials":119,"cells":761},"Memantine",{"EARLY_PHASE1":762,"PHASE1":764,"PHASE2":766,"PHASE3":778,"PHASE4":780,"NA":782},{"trials":763,"activeCount":100},[],{"trials":765,"activeCount":100},[],{"trials":767,"activeCount":119,"soonestReadout":772},[768],{"nctId":769,"briefTitle":770,"status":192,"phases":771,"primaryCompletion":772,"completion":773,"start":71,"enrollment":774,"conditions":775,"interventions":777},"NCT07248228","Memory Avoidance Whole Brain Radiotherapy vs Hippocampal Avoidance Whole Brain Radiotherapy (Athena 2 Trial)",[90],"2027-05","2028-11",90,[776],"Brain Metastases",[760],{"trials":779,"activeCount":100},[],{"trials":781,"activeCount":100},[],{"trials":783,"activeCount":100},[],{"intervention":203,"totalTrials":119,"cells":785},{"EARLY_PHASE1":786,"PHASE1":788,"PHASE2":790,"PHASE3":796,"PHASE4":798,"NA":800},{"trials":787,"activeCount":100},[],{"trials":789,"activeCount":100},[],{"trials":791,"activeCount":119,"soonestReadout":194},[792],{"nctId":190,"briefTitle":191,"status":192,"phases":793,"primaryCompletion":194,"completion":194,"start":195,"enrollment":129,"conditions":794,"interventions":795},[90],[197,198,199],[201,202,203],{"trials":797,"activeCount":100},[],{"trials":799,"activeCount":100},[],{"trials":801,"activeCount":100},[],{"intervention":187,"totalTrials":135,"cells":803},{"EARLY_PHASE1":804,"PHASE1":806,"PHASE2":824,"PHASE3":834,"PHASE4":836,"NA":838},{"trials":805,"activeCount":100},[],{"trials":807,"activeCount":100},[808],{"nctId":809,"briefTitle":810,"status":265,"phases":811,"primaryCompletion":812,"completion":813,"start":814,"enrollment":269,"conditions":815,"interventions":822},"NCT00947388","Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)",[89],"2012-09","2013-03","2008-11",[816,817,818,819,820,821],"Recurrent Small Lymphocytic Lymphoma","Refractory Chronic Lymphocytic Leukemia","Stage III Chronic Lymphocytic Leukemia","Stage III Small Lymphocytic Lymphoma","Stage IV Chronic Lymphocytic Leukemia","Stage IV Small Lymphocytic Lymphoma",[823,201],"Bendamustine Hydrochloride",{"trials":825,"activeCount":119,"soonestReadout":194},[826,830],{"nctId":170,"briefTitle":171,"status":144,"phases":827,"primaryCompletion":173,"completion":174,"start":175,"enrollment":176,"conditions":828,"interventions":829},[90],[15,178,179,180,29,21,181,32,182,183,184,185],[187,188,134],{"nctId":190,"briefTitle":191,"status":192,"phases":831,"primaryCompletion":194,"completion":194,"start":195,"enrollment":129,"conditions":832,"interventions":833},[90],[197,198,199],[201,202,203],{"trials":835,"activeCount":100},[],{"trials":837,"activeCount":100},[],{"trials":839,"activeCount":100},[840],{"nctId":841,"briefTitle":842,"status":144,"phases":843,"primaryCompletion":844,"completion":845,"start":846,"enrollment":96,"conditions":847,"interventions":848},"NCT00021151","Compassionate Use of Campath-1H in Treating Patients With Refractory Prolymphocytic Leukemia or Chronic Lymphocytic Leukemia",[93],"2001-04","2002-05","2000-01",[29],[187],{"intervention":850,"totalTrials":851,"cells":852},"Temozolomide",6,{"EARLY_PHASE1":853,"PHASE1":865,"PHASE2":907,"PHASE3":917,"PHASE4":919,"NA":921},{"trials":854,"activeCount":100},[855],{"nctId":856,"briefTitle":857,"status":144,"phases":858,"primaryCompletion":859,"completion":860,"start":861,"enrollment":404,"conditions":862,"interventions":864},"NCT02970448","Expedited Laser Interstitial Thermal Therapy + Chemoradiation For Newly Diagnosed High Grade Gliomas",[88],"2023-11-10","2024-10-25","2017-08-24",[863],"High Grade Glioma",[850],{"trials":866,"activeCount":96,"soonestReadout":41},[867,873,883,900],{"nctId":44,"briefTitle":45,"status":400,"phases":868,"primaryCompletion":46,"completion":869,"start":870,"enrollment":11,"conditions":871,"interventions":872},[89],"2025-12-30","2018-08-24",[514],[47,850],{"nctId":874,"briefTitle":875,"status":144,"phases":876,"primaryCompletion":877,"completion":877,"start":878,"enrollment":879,"conditions":880,"interventions":881},"NCT00892385","Methoxyamine and Temozolomide in Treating Patients With Advanced Solid Tumors",[89],"2017-03-08","2007-08-16",66,[24],[882,850],"Methoxyamine",{"nctId":884,"briefTitle":885,"status":265,"phases":886,"primaryCompletion":887,"completion":888,"start":889,"enrollment":890,"conditions":891,"interventions":893},"NCT00003567","Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma",[89],"2007-01","2007-02","1999-05",8,[892,21,24],"Brain and Central Nervous System Tumors",[894,895,896,897,898,899],"filgrastim","sargramostim","therapeutic autologous lymphocytes","O6-benzylguanine","carmustine","temozolomide",{"nctId":39,"briefTitle":40,"status":400,"phases":901,"primaryCompletion":41,"completion":902,"start":903,"enrollment":904,"conditions":905,"interventions":906},[89],"2026-05-31","2018-06-05",60,[604,514],[42,899],{"trials":908,"activeCount":100},[909],{"nctId":910,"briefTitle":911,"status":144,"phases":912,"primaryCompletion":913,"completion":913,"start":914,"enrollment":440,"conditions":915,"interventions":916},"NCT00006877","Temozolomide in Treating Patients With Metastatic Non-small Cell Lung Cancer",[90],"2003-09","2000-07",[26],[899],{"trials":918,"activeCount":100},[],{"trials":920,"activeCount":100},[],{"trials":922,"activeCount":100},[],{"intervention":47,"totalTrials":119,"cells":924},{"EARLY_PHASE1":925,"PHASE1":927,"PHASE2":933,"PHASE3":935,"PHASE4":937,"NA":939},{"trials":926,"activeCount":100},[],{"trials":928,"activeCount":119,"soonestReadout":46},[929],{"nctId":44,"briefTitle":45,"status":400,"phases":930,"primaryCompletion":46,"completion":869,"start":870,"enrollment":11,"conditions":931,"interventions":932},[89],[514],[47,850],{"trials":934,"activeCount":100},[],{"trials":936,"activeCount":100},[],{"trials":938,"activeCount":100},[],{"trials":940,"activeCount":100},[],{"intervention":942,"totalTrials":119,"cells":943},"Disulfiram",{"EARLY_PHASE1":944,"PHASE1":946,"PHASE2":959,"PHASE3":961,"PHASE4":963,"NA":965},{"trials":945,"activeCount":100},[],{"trials":947,"activeCount":119,"soonestReadout":952},[948],{"nctId":949,"briefTitle":950,"status":108,"phases":951,"primaryCompletion":952,"completion":194,"start":953,"enrollment":27,"conditions":954,"interventions":956},"NCT05210374","Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas",[89],"2026-09-01","2023-03-09",[955],"Relapsed Sarcomas",[942,957,958],"Copper Gluconate","Liposomal Doxorubicin",{"trials":960,"activeCount":100},[],{"trials":962,"activeCount":100},[],{"trials":964,"activeCount":100},[],{"trials":966,"activeCount":100},[],{"intervention":957,"totalTrials":119,"cells":968},{"EARLY_PHASE1":969,"PHASE1":971,"PHASE2":977,"PHASE3":979,"PHASE4":981,"NA":983},{"trials":970,"activeCount":100},[],{"trials":972,"activeCount":119,"soonestReadout":952},[973],{"nctId":949,"briefTitle":950,"status":108,"phases":974,"primaryCompletion":952,"completion":194,"start":953,"enrollment":27,"conditions":975,"interventions":976},[89],[955],[942,957,958],{"trials":978,"activeCount":100},[],{"trials":980,"activeCount":100},[],{"trials":982,"activeCount":100},[],{"trials":984,"activeCount":100},[],{"intervention":958,"totalTrials":119,"cells":986},{"EARLY_PHASE1":987,"PHASE1":989,"PHASE2":995,"PHASE3":997,"PHASE4":999,"NA":1001},{"trials":988,"activeCount":100},[],{"trials":990,"activeCount":119,"soonestReadout":952},[991],{"nctId":949,"briefTitle":950,"status":108,"phases":992,"primaryCompletion":952,"completion":194,"start":953,"enrollment":27,"conditions":993,"interventions":994},[89],[955],[942,957,958],{"trials":996,"activeCount":100},[],{"trials":998,"activeCount":100},[],{"trials":1000,"activeCount":100},[],{"trials":1002,"activeCount":100},[],{"intervention":86,"totalTrials":119,"cells":1004},{"EARLY_PHASE1":1005,"PHASE1":1007,"PHASE2":1017,"PHASE3":1019,"PHASE4":1021,"NA":1023},{"trials":1006,"activeCount":100},[],{"trials":1008,"activeCount":119,"soonestReadout":85},[1009],{"nctId":83,"briefTitle":84,"status":400,"phases":1010,"primaryCompletion":85,"completion":194,"start":1011,"enrollment":1012,"conditions":1013,"interventions":1015},[89],"2022-09-08",16,[1014,376],"Pancreatic Ductal Adenocarcinoma",[86,1016],"mFOLFIRINOX",{"trials":1018,"activeCount":100},[],{"trials":1020,"activeCount":100},[],{"trials":1022,"activeCount":100},[],{"trials":1024,"activeCount":100},[],{"intervention":1016,"totalTrials":119,"cells":1026},{"EARLY_PHASE1":1027,"PHASE1":1029,"PHASE2":1035,"PHASE3":1037,"PHASE4":1039,"NA":1041},{"trials":1028,"activeCount":100},[],{"trials":1030,"activeCount":119,"soonestReadout":85},[1031],{"nctId":83,"briefTitle":84,"status":400,"phases":1032,"primaryCompletion":85,"completion":194,"start":1011,"enrollment":1012,"conditions":1033,"interventions":1034},[89],[1014,376],[86,1016],{"trials":1036,"activeCount":100},[],{"trials":1038,"activeCount":100},[],{"trials":1040,"activeCount":100},[],{"trials":1042,"activeCount":100},[],{"intervention":42,"totalTrials":119,"cells":1044},{"EARLY_PHASE1":1045,"PHASE1":1047,"PHASE2":1053,"PHASE3":1055,"PHASE4":1057,"NA":1059},{"trials":1046,"activeCount":100},[],{"trials":1048,"activeCount":119,"soonestReadout":41},[1049],{"nctId":39,"briefTitle":40,"status":400,"phases":1050,"primaryCompletion":41,"completion":902,"start":903,"enrollment":904,"conditions":1051,"interventions":1052},[89],[604,514],[42,899],{"trials":1054,"activeCount":100},[],{"trials":1056,"activeCount":100},[],{"trials":1058,"activeCount":100},[],{"trials":1060,"activeCount":100},[],{"intervention":62,"totalTrials":119,"cells":1062},{"EARLY_PHASE1":1063,"PHASE1":1065,"PHASE2":1074,"PHASE3":1076,"PHASE4":1078,"NA":1080},{"trials":1064,"activeCount":100},[],{"trials":1066,"activeCount":119,"soonestReadout":61},[1067],{"nctId":59,"briefTitle":60,"status":400,"phases":1068,"primaryCompletion":61,"completion":61,"start":1069,"enrollment":1070,"conditions":1071,"interventions":1073},[89],"2019-03-12",25,[1072],"Non-hodgkin Lymphoma",[62],{"trials":1075,"activeCount":100},[],{"trials":1077,"activeCount":100},[],{"trials":1079,"activeCount":100},[],{"trials":1081,"activeCount":100},[],{"intervention":52,"totalTrials":119,"cells":1083},{"EARLY_PHASE1":1084,"PHASE1":1086,"PHASE2":1097,"PHASE3":1099,"PHASE4":1101,"NA":1103},{"trials":1085,"activeCount":100},[],{"trials":1087,"activeCount":119,"soonestReadout":51},[1088],{"nctId":49,"briefTitle":50,"status":400,"phases":1089,"primaryCompletion":51,"completion":952,"start":1090,"enrollment":1091,"conditions":1092,"interventions":1096},[89],"2021-05-27",5,[1093,1094,1095],"Cutaneous Malignant Melanoma","Renal Cell Cancer","Urothelial Cancer of Renal Pelvis",[52],{"trials":1098,"activeCount":100},[],{"trials":1100,"activeCount":100},[],{"trials":1102,"activeCount":100},[],{"trials":1104,"activeCount":100},[],{"intervention":72,"totalTrials":119,"cells":1106},{"EARLY_PHASE1":1107,"PHASE1":1116,"PHASE2":1118,"PHASE3":1120,"PHASE4":1122,"NA":1124},{"trials":1108,"activeCount":119,"soonestReadout":71},[1109],{"nctId":69,"briefTitle":70,"status":108,"phases":1110,"primaryCompletion":71,"completion":1111,"start":1112,"enrollment":129,"conditions":1113,"interventions":1115},[88],"2026-09","2020-05-19",[1114],"Allogeneic Hematopoietic Cell Transplantation",[72],{"trials":1117,"activeCount":100},[],{"trials":1119,"activeCount":100},[],{"trials":1121,"activeCount":100},[],{"trials":1123,"activeCount":100},[],{"trials":1125,"activeCount":100},[],{"intervention":1127,"totalTrials":96,"cells":1128},"chemotherapy",{"EARLY_PHASE1":1129,"PHASE1":1131,"PHASE2":1133,"PHASE3":1135,"PHASE4":1137,"NA":1139},{"trials":1130,"activeCount":100},[],{"trials":1132,"activeCount":100},[],{"trials":1134,"activeCount":100},[],{"trials":1136,"activeCount":100},[],{"trials":1138,"activeCount":100},[],{"trials":1140,"activeCount":119,"soonestReadout":437},[1141,1151],{"nctId":1142,"briefTitle":1143,"status":1144,"phases":1145,"start":1146,"enrollment":100,"conditions":1147,"interventions":1150},"NCT00873600","Outpatient Health Care Program for Older Patients Receiving Chemotherapy for Newly Diagnosed Breast Cancer or Colon Cancer","WITHDRAWN",[],"2007-10",[15,1148,256,1149],"Cognitive\u002FFunctional Effects","Psychosocial Effects of Cancer and Its Treatment",[1127],{"nctId":1152,"briefTitle":1153,"status":108,"phases":1154,"primaryCompletion":437,"completion":1155,"start":1156,"enrollment":1157,"conditions":1158,"interventions":1161},"NCT07044362","Histotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis",[93],"2028-10-01","2025-06-30",100,[256,1159,1160],"Liver Metastases","Liver Cancer",[1162],"Chemotherapy",{"intervention":1164,"totalTrials":119,"cells":1165},"WES via Illumina NextSeq 550 sequencing system",{"EARLY_PHASE1":1166,"PHASE1":1168,"PHASE2":1170,"PHASE3":1172,"PHASE4":1174,"NA":1176},{"trials":1167,"activeCount":100},[],{"trials":1169,"activeCount":100},[],{"trials":1171,"activeCount":100},[],{"trials":1173,"activeCount":100},[],{"trials":1175,"activeCount":100},[],{"trials":1177,"activeCount":119,"soonestReadout":1182},[1178],{"nctId":1179,"briefTitle":1180,"status":108,"phases":1181,"primaryCompletion":1182,"completion":1182,"start":1183,"enrollment":1184,"conditions":1185,"interventions":1187},"NCT04860453","Genomic Analysis of Families With a History of Discordant Cancers",[],"2028-07-01","2020-11-17",150,[1186],"Discordant Cancers",[1164],{"intervention":1189,"totalTrials":119,"cells":1190},"Novel probiotic",{"EARLY_PHASE1":1191,"PHASE1":1193,"PHASE2":1195,"PHASE3":1197,"PHASE4":1199,"NA":1201},{"trials":1192,"activeCount":100},[],{"trials":1194,"activeCount":100},[],{"trials":1196,"activeCount":100},[],{"trials":1198,"activeCount":100},[],{"trials":1200,"activeCount":100},[],{"trials":1202,"activeCount":119,"soonestReadout":625},[1203],{"nctId":1204,"briefTitle":1205,"status":108,"phases":1206,"primaryCompletion":625,"completion":625,"start":1207,"enrollment":1157,"conditions":1208,"interventions":1209},"NCT04362826","Study to Investigate Efficacy of a Novel Probiotic on the Bacteriome and Mycobiome of Breast Cancer",[93],"2026-03-20",[15],[1189],{"intervention":1211,"totalTrials":119,"cells":1212},"aldesleukin",{"EARLY_PHASE1":1213,"PHASE1":1215,"PHASE2":1217,"PHASE3":1219,"PHASE4":1221,"NA":1231},{"trials":1214,"activeCount":100},[],{"trials":1216,"activeCount":100},[],{"trials":1218,"activeCount":100},[],{"trials":1220,"activeCount":100},[],{"trials":1222,"activeCount":100},[1223],{"nctId":1224,"briefTitle":1225,"status":144,"phases":1226,"primaryCompletion":1227,"completion":1227,"start":914,"conditions":1228,"interventions":1230},"NCT00006864","Interleukin-2 in Treating Patients With Metastatic Kidney Cancer",[92],"2007-07",[1229],"Kidney Cancer",[1211],{"trials":1232,"activeCount":100},[],{"intervention":274,"totalTrials":36,"cells":1234},{"EARLY_PHASE1":1235,"PHASE1":1246,"PHASE2":1284,"PHASE3":1377,"PHASE4":1387,"NA":1389},{"trials":1236,"activeCount":100},[1237],{"nctId":1238,"briefTitle":1239,"status":144,"phases":1240,"primaryCompletion":1241,"completion":1241,"start":1242,"enrollment":129,"conditions":1243,"interventions":1244},"NCT00949247","Docetaxel,Carboplatin,Trastuzumab and Bevacizumab for Breast Cancer and Bone Marrow Micrometastases",[88],"2013-01","2009-12",[15],[258,1245,364,274],"trastuzumab",{"trials":1247,"activeCount":100},[1248,1259,1268,1272],{"nctId":1249,"briefTitle":1250,"status":144,"phases":1251,"primaryCompletion":1252,"completion":1253,"start":1254,"enrollment":1255,"conditions":1256,"interventions":1257},"NCT00253344","Lenalidomide and Docetaxel in Treating Patients With Advanced Solid Tumors",[89],"2008-01","2008-06","2005-06",33,[24],[274,1258],"lenalidomide",{"nctId":1260,"briefTitle":1261,"status":1144,"phases":1262,"primaryCompletion":1263,"completion":1263,"start":913,"enrollment":100,"conditions":1264,"interventions":1265},"NCT00074139","Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Advanced Breast Cancer",[89],"2003-12",[15],[1266,274,1267],"cyclophosphamide","doxorubicin hydrochloride",{"nctId":263,"briefTitle":264,"status":265,"phases":1269,"primaryCompletion":267,"start":268,"enrollment":269,"conditions":1270,"interventions":1271},[89],[271,272],[274,229,275],{"nctId":1273,"briefTitle":1274,"status":144,"phases":1275,"primaryCompletion":1276,"completion":1277,"start":1278,"enrollment":1279,"conditions":1280,"interventions":1282},"NCT00049296","Thalidomide and Docetaxel in Treating Patients With Advanced Cancer",[89],"2004-12","2006-01","2002-07",26,[1281],"Cancer",[274,1283],"thalidomide",{"trials":1285,"activeCount":100},[1286,1296,1306,1314,1330,1341,1350,1360,1367],{"nctId":1287,"briefTitle":1288,"status":144,"phases":1289,"primaryCompletion":1290,"completion":1291,"start":1292,"enrollment":1293,"conditions":1294,"interventions":1295},"NCT00027885","Phase II Bevacizumab + Tax In Advanced Breast Cancer",[90],"2005-12","2010-08","2001-11",49,[15],[258,1266,274,1267],{"nctId":1297,"briefTitle":1298,"status":144,"phases":1299,"primaryCompletion":1292,"completion":1241,"start":1300,"enrollment":1301,"conditions":1302,"interventions":1303},"NCT00003953","Chemotherapy Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer",[90],"1999-02",39,[15],[894,1304,274,1267,1305],"CMF regimen","tamoxifen citrate",{"nctId":1307,"briefTitle":1308,"status":1144,"phases":1309,"start":1310,"enrollment":100,"conditions":1311,"interventions":1312},"NCT00006261","Allogeneic Transplantation Using Mini-Conditioning for Treatment of Stage IV Breast Cancer",[90],"2000-05",[15],[1313,1266,274,1267,163],"therapeutic allogeneic lymphocytes",{"nctId":1315,"briefTitle":1316,"status":144,"phases":1317,"primaryCompletion":1318,"completion":1319,"start":1320,"enrollment":1012,"conditions":1321,"interventions":1326},"NCT01959490","Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer",[90],"2016-11-11","2017-03-29","2013-09-24",[1322,1323,1324,1325],"Stage II Breast Cancer","Stage IIIA Breast Cancer","Stage IIIB Breast Cancer","Stage IIIC Breast Cancer",[1245,1327,274,364,1328,1266,365,1329],"Pertuzumab","doxorubicin","Bevacizumab",{"nctId":1331,"briefTitle":1332,"status":144,"phases":1333,"primaryCompletion":1334,"completion":1334,"start":1335,"enrollment":1336,"conditions":1337,"interventions":1338},"NCT00720304","Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck",[90],"2015-11-13","2007-11-19",43,[35],[274,259,1339,1340],"fluorescence in situ hybridization","polymerase chain reaction",{"nctId":1342,"briefTitle":1343,"status":144,"phases":1344,"primaryCompletion":1345,"completion":1346,"start":1347,"enrollment":440,"conditions":1348,"interventions":1349},"NCT00281840","Bevacizumab, Docetaxel, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer",[90],"2012-04","2012-12","2005-09",[35],[258,274],{"nctId":1351,"briefTitle":1352,"status":144,"phases":1353,"primaryCompletion":1354,"completion":1354,"start":1355,"enrollment":1356,"conditions":1357,"interventions":1358},"NCT00276549","Gemcitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer",[90],"2008-03","2005-10",35,[18],[274,1359],"gemcitabine hydrochloride",{"nctId":1361,"briefTitle":1362,"status":144,"phases":1363,"primaryCompletion":241,"completion":241,"start":1364,"enrollment":851,"conditions":1365,"interventions":1366},"NCT00075374","Two Regimens of Docetaxel in Treating Patients Who Have Not Received Chemotherapy For Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer",[90],"2003-10",[26],[274],{"nctId":1368,"briefTitle":1369,"status":144,"phases":1370,"primaryCompletion":1371,"completion":1372,"start":1252,"enrollment":1373,"conditions":1374,"interventions":1375},"NCT00660816","Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer",[90],"2013-04","2015-07",46,[26],[259,1376,274],"pemetrexed disodium",{"trials":1378,"activeCount":100},[1379],{"nctId":1380,"briefTitle":1381,"status":144,"phases":1382,"primaryCompletion":1383,"completion":1384,"start":1364,"enrollment":254,"conditions":1385,"interventions":1386},"NCT00074204","Gemcitabine and Carboplatin Followed By Docetaxel in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer",[91],"2005-08","2008-04",[26],[364,274,1359],{"trials":1388,"activeCount":100},[],{"trials":1390,"activeCount":100},[],{"intervention":364,"totalTrials":9,"cells":1392},{"EARLY_PHASE1":1393,"PHASE1":1412,"PHASE2":1446,"PHASE3":1499,"PHASE4":1505,"NA":1507},{"trials":1394,"activeCount":100},[1395,1399],{"nctId":1238,"briefTitle":1239,"status":144,"phases":1396,"primaryCompletion":1241,"completion":1241,"start":1242,"enrollment":129,"conditions":1397,"interventions":1398},[88],[15],[258,1245,364,274],{"nctId":1400,"briefTitle":1401,"status":265,"phases":1402,"primaryCompletion":1403,"completion":1404,"start":1405,"enrollment":1406,"conditions":1407,"interventions":1410},"NCT02319889","Feasibility Study of SBRT Plus Chemotherapy for Non-Small Cell Lung Carcinoma",[88],"2016-07-06","2017-01-19","2016-02-02",3,[1408,1409],"Stage I Non-Small Cell Lung Cancer","Stage II Non-Small Cell Lung Cancer",[302,1411],"Paclitaxel Albumin-Stabilized Nanoparticle Formulation",{"trials":1413,"activeCount":100},[1414,1425],{"nctId":1415,"briefTitle":1416,"status":144,"phases":1417,"primaryCompletion":1418,"completion":1419,"start":1420,"enrollment":1421,"conditions":1422,"interventions":1423},"NCT00005593","Fludarabine, Carboplatin, and Topotecan in Treating Patients With Relapsed\u002FRefractory Acute Leukemia or Advanced Myelodysplastic Syndrome",[89],"2002-04","2003-03","1998-09",31,[29,32],[364,163,1424],"topotecan hydrochloride",{"nctId":1426,"briefTitle":1427,"status":144,"phases":1428,"primaryCompletion":1429,"completion":1430,"start":1431,"enrollment":9,"conditions":1432,"interventions":1445},"NCT01652794","Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer",[89],"2014-05","2015-03","2012-05",[1433,1434,1435,199,1436,1437,1438,1439,1440,1441,1442,1443,1444],"Leydig Cell Tumor","Ovarian Sarcoma","Ovarian Stromal Cancer","Recurrent Cervical Cancer","Recurrent Endometrial Carcinoma","Recurrent Fallopian Tube Cancer","Recurrent Ovarian Epithelial Cancer","Recurrent Ovarian Germ Cell Tumor","Recurrent Primary Peritoneal Cavity Cancer","Recurrent Uterine Sarcoma","Recurrent Vaginal Cancer","Recurrent Vulvar Cancer",[364,1359],{"trials":1447,"activeCount":100},[1448,1452,1456,1465,1469,1477,1487],{"nctId":288,"briefTitle":289,"status":265,"phases":1449,"primaryCompletion":291,"completion":291,"start":292,"enrollment":119,"conditions":1450,"interventions":1451},[90],[294,295,296,297,298,299],[301,302,303,304,305],{"nctId":1315,"briefTitle":1316,"status":144,"phases":1453,"primaryCompletion":1318,"completion":1319,"start":1320,"enrollment":1012,"conditions":1454,"interventions":1455},[90],[1322,1323,1324,1325],[1245,1327,274,364,1328,1266,365,1329],{"nctId":1457,"briefTitle":1458,"status":144,"phases":1459,"primaryCompletion":887,"completion":1460,"start":1461,"enrollment":1462,"conditions":1463,"interventions":1464},"NCT00053287","Fludarabine\u002FCarboplatin\u002FTopotecan w\u002FThalidomide for Relapsed\u002FRefractory AML, CML and MDS",[90],"2007-03","2002-09",42,[29,32,182],[364,163,1283,1424],{"nctId":349,"briefTitle":350,"status":351,"phases":1466,"primaryCompletion":353,"completion":354,"start":355,"enrollment":356,"conditions":1467,"interventions":1468},[90],[358,271,359,360,361,362],[229,261,260,364,365],{"nctId":1470,"briefTitle":1471,"status":144,"phases":1472,"primaryCompletion":1473,"completion":1473,"start":1474,"enrollment":1091,"conditions":1475,"interventions":1476},"NCT00006378","Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer",[90],"2003-04","1999-12",[26],[364,365],{"nctId":1478,"briefTitle":1479,"status":265,"phases":1480,"primaryCompletion":1481,"completion":1482,"start":1483,"enrollment":1406,"conditions":1484,"interventions":1486},"NCT02756013","Weight-based Dosing for Dense Weekly Paclitaxel and Carboplatin in Overweight Patients w\u002F Body Surface Area (BSA) > 2.0",[90],"2018-08-16","2019-01-24","2016-04-20",[1485],"Gynecologic Malignancies",[301,302],{"nctId":1488,"briefTitle":1489,"status":144,"phases":1490,"primaryCompletion":1491,"completion":1492,"start":1493,"enrollment":440,"conditions":1494,"interventions":1496},"NCT03121352","Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer",[90],"2022-02-20","2022-05-23","2017-05-19",[1495],"Metastatic Triple Negative Breast Cancer",[302,1497,1498],"Nab-paclitaxel","Pembrolizumab",{"trials":1500,"activeCount":100},[1501],{"nctId":1380,"briefTitle":1381,"status":144,"phases":1502,"primaryCompletion":1383,"completion":1384,"start":1364,"enrollment":254,"conditions":1503,"interventions":1504},[91],[26],[364,274,1359],{"trials":1506,"activeCount":100},[],{"trials":1508,"activeCount":100},[],{"intervention":346,"totalTrials":9,"cells":1510},{"EARLY_PHASE1":1511,"PHASE1":1513,"PHASE2":1537,"PHASE3":1613,"PHASE4":1630,"NA":1632},{"trials":1512,"activeCount":100},[],{"trials":1514,"activeCount":100},[1515,1528],{"nctId":1516,"briefTitle":1517,"status":144,"phases":1518,"primaryCompletion":1519,"completion":1520,"start":174,"enrollment":243,"conditions":1521,"interventions":1523},"NCT00498979","Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers",[89],"2010-05","2012-01",[1522],"Stage IV Melanoma",[1524,346,1525,1526,1527],"recombinant interferon alfa-2b","sodium stibogluconate","dacarbazine","vinblastine",{"nctId":1529,"briefTitle":238,"status":144,"phases":1530,"primaryCompletion":1531,"completion":1532,"start":1533,"enrollment":30,"conditions":1534,"interventions":1535},"NCT00005819",[89],"2005-05","2006-08","2000-04",[24],[346,1536,365],"fenretinide",{"trials":1538,"activeCount":100},[1539,1548,1558,1567,1571,1580,1588,1604],{"nctId":1540,"briefTitle":1541,"status":144,"phases":1542,"primaryCompletion":1227,"completion":1543,"start":1355,"enrollment":1544,"conditions":1545,"interventions":1546},"NCT00258323","Radiotherapy,Chemotherapy,Before and After Surgery in Advanced Esophageal or Gastroesophageal Junction Cancer",[90],"2010-02",80,[272],[346,260,1547],"Iressa",{"nctId":1549,"briefTitle":1550,"status":144,"phases":1551,"primaryCompletion":253,"start":1552,"enrollment":1553,"conditions":1554,"interventions":1555},"NCT00028665","Cyclophosphamide W\u002For W\u002FOut Rituximab and Peripheral Stem Cell Transplantation in Patients With Recurrent Non-Hodgkin's Lymphoma",[90],"2000-06",37,[21],[894,1556,898,346,1266,1557],"rituximab","etoposide",{"nctId":1559,"briefTitle":1560,"status":144,"phases":1561,"primaryCompletion":1562,"completion":1563,"start":1564,"enrollment":19,"conditions":1565,"interventions":1566},"NCT00003928","Gemcitabine Plus Cisplatin in Treating Patients With Metastatic Kidney Cancer",[90],"2005-02","2006-04","1999-01",[1229],[346,1359],{"nctId":336,"briefTitle":337,"status":144,"phases":1568,"primaryCompletion":339,"completion":340,"start":341,"enrollment":342,"conditions":1569,"interventions":1570},[90],[272,344],[346,347,260,229],{"nctId":1572,"briefTitle":1573,"status":265,"phases":1574,"primaryCompletion":888,"completion":1575,"start":240,"enrollment":135,"conditions":1576,"interventions":1577},"NCT00077103","Induction Chemotherapy Using Doxorubicin and Cisplatin Followed by Combretastatin A4 Phosphate and Radiation Therapy in Treating Patients With Newly Diagnosed Regionally Advanced Anaplastic Thyroid Cancer",[89,90],"2007-12",[35],[894,1578,346,1267,1579],"pegfilgrastim","fosbretabulin disodium",{"nctId":1581,"briefTitle":1582,"status":1144,"phases":1583,"primaryCompletion":1584,"completion":1584,"start":1585,"enrollment":100,"conditions":1586,"interventions":1587},"NCT00006374","Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer",[90],"2001-06","1999-10",[26],[894,346,1557,365,1424],{"nctId":1589,"briefTitle":1590,"status":1144,"phases":1591,"primaryCompletion":1592,"completion":1593,"start":1594,"enrollment":100,"conditions":1595,"interventions":1601},"NCT05608369","Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC",[90],"2025-08-01","2026-02-01","2025-06-01",[1596,1597,1598,1599,1600],"HPV-Related Squamous Cell Carcinoma","Squamous Cell Carcinoma of the Oral Cavity","Squamous Cell Carcinoma of the Larynx","Squamous Cell Carcinoma of the Oropharynx","Squamous Cell Carcinoma of the Hypopharynx",[1602,1603],"Cisplatin","Vorinostat",{"nctId":1605,"briefTitle":1606,"status":144,"phases":1607,"primaryCompletion":175,"start":1608,"enrollment":11,"conditions":1609,"interventions":1610},"NCT00006260","Combination Chemotherapy in Treating Patients With Metastatic Breast Cancer",[90],"1997-05",[15],[346,1557,1611,1612],"ifosfamide","Mesna",{"trials":1614,"activeCount":100},[1615,1622],{"nctId":1616,"briefTitle":1582,"status":144,"phases":1617,"primaryCompletion":1618,"completion":1618,"start":1619,"enrollment":135,"conditions":1620,"interventions":1621},"NCT00041015",[91],"2002-11","2001-09",[26],[346,1557,1424],{"nctId":1623,"briefTitle":1624,"status":144,"phases":1625,"primaryCompletion":812,"completion":1626,"start":1252,"enrollment":1627,"conditions":1628,"interventions":1629},"NCT00608205","Radiation Therapy Cisplatin With or Without Fluorouracil Patients With Stage III or Stage IV Head and Neck Cancer",[91],"2016-08",69,[35],[346,260],{"trials":1631,"activeCount":100},[],{"trials":1633,"activeCount":100},[],{"intervention":260,"totalTrials":890,"cells":1635},{"EARLY_PHASE1":1636,"PHASE1":1638,"PHASE2":1644,"PHASE3":1670,"PHASE4":1676,"NA":1678},{"trials":1637,"activeCount":100},[],{"trials":1639,"activeCount":100},[1640],{"nctId":249,"briefTitle":250,"status":144,"phases":1641,"primaryCompletion":252,"completion":252,"start":253,"enrollment":254,"conditions":1642,"interventions":1643},[89],[256],[258,259,260,261,229],{"trials":1645,"activeCount":100},[1646,1650,1654,1658,1662,1666],{"nctId":288,"briefTitle":289,"status":265,"phases":1647,"primaryCompletion":291,"completion":291,"start":292,"enrollment":119,"conditions":1648,"interventions":1649},[90],[294,295,296,297,298,299],[301,302,303,304,305],{"nctId":1540,"briefTitle":1541,"status":144,"phases":1651,"primaryCompletion":1227,"completion":1543,"start":1355,"enrollment":1544,"conditions":1652,"interventions":1653},[90],[272],[346,260,1547],{"nctId":307,"briefTitle":308,"status":144,"phases":1655,"primaryCompletion":310,"completion":310,"start":311,"enrollment":312,"conditions":1656,"interventions":1657},[90],[314,315,316,317],[319,229,261,260],{"nctId":336,"briefTitle":337,"status":144,"phases":1659,"primaryCompletion":339,"completion":340,"start":341,"enrollment":342,"conditions":1660,"interventions":1661},[90],[272,344],[346,347,260,229],{"nctId":349,"briefTitle":350,"status":351,"phases":1663,"primaryCompletion":353,"completion":354,"start":355,"enrollment":356,"conditions":1664,"interventions":1665},[90],[358,271,359,360,361,362],[229,261,260,364,365],{"nctId":367,"briefTitle":368,"status":265,"phases":1667,"primaryCompletion":370,"completion":371,"start":372,"enrollment":119,"conditions":1668,"interventions":1669},[90],[374,375,376,377,378,379,380,381,382],[384,303,304,305],{"trials":1671,"activeCount":100},[1672],{"nctId":1623,"briefTitle":1624,"status":144,"phases":1673,"primaryCompletion":812,"completion":1626,"start":1252,"enrollment":1627,"conditions":1674,"interventions":1675},[91],[35],[346,260],{"trials":1677,"activeCount":100},[],{"trials":1679,"activeCount":100},[],{"intervention":1424,"totalTrials":1681,"cells":1682},7,{"EARLY_PHASE1":1683,"PHASE1":1685,"PHASE2":1699,"PHASE3":1717,"PHASE4":1730,"NA":1732},{"trials":1684,"activeCount":100},[],{"trials":1686,"activeCount":100},[1687,1695],{"nctId":1688,"briefTitle":1689,"status":144,"phases":1690,"primaryCompletion":914,"completion":1691,"start":1692,"enrollment":440,"conditions":1693,"interventions":1694},"NCT00002588","Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia",[89],"2001-01","1994-08",[29],[1557,1424],{"nctId":1415,"briefTitle":1416,"status":144,"phases":1696,"primaryCompletion":1418,"completion":1419,"start":1420,"enrollment":1421,"conditions":1697,"interventions":1698},[89],[29,32],[364,163,1424],{"trials":1700,"activeCount":100},[1701,1709,1713],{"nctId":1702,"briefTitle":1703,"status":265,"phases":1704,"primaryCompletion":1705,"completion":1705,"start":1706,"enrollment":119,"conditions":1707,"interventions":1708},"NCT00087048","Topotecan in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer",[90],"2006-02","2004-04",[26],[1424],{"nctId":1457,"briefTitle":1458,"status":144,"phases":1710,"primaryCompletion":887,"completion":1460,"start":1461,"enrollment":1462,"conditions":1711,"interventions":1712},[90],[29,32,182],[364,163,1283,1424],{"nctId":1581,"briefTitle":1582,"status":1144,"phases":1714,"primaryCompletion":1584,"completion":1584,"start":1585,"enrollment":100,"conditions":1715,"interventions":1716},[90],[26],[894,346,1557,365,1424],{"trials":1718,"activeCount":100},[1719,1726],{"nctId":1720,"briefTitle":1721,"status":144,"phases":1722,"primaryCompletion":1292,"completion":1292,"start":1723,"enrollment":135,"conditions":1724,"interventions":1725},"NCT00003917","Topotecan in Treating Patients With Relapsed Small Cell Lung Cancer",[91],"1999-03",[26],[1424],{"nctId":1616,"briefTitle":1582,"status":144,"phases":1727,"primaryCompletion":1618,"completion":1618,"start":1619,"enrollment":135,"conditions":1728,"interventions":1729},[91],[26],[346,1557,1424],{"trials":1731,"activeCount":100},[],{"trials":1733,"activeCount":100},[],{"intervention":1735,"totalTrials":135,"cells":1736},"mycophenolate mofetil",{"EARLY_PHASE1":1737,"PHASE1":1754,"PHASE2":1769,"PHASE3":1850,"PHASE4":1856,"NA":1858},{"trials":1738,"activeCount":100},[1739],{"nctId":1740,"briefTitle":1741,"status":144,"phases":1742,"primaryCompletion":1743,"completion":1744,"start":1745,"enrollment":851,"conditions":1746,"interventions":1752},"NCT02181478","Intra-Osseous Co-Transplant of UCB and hMSC",[88],"2019-12-19","2020-02-07","2015-07-22",[216,470,32,160,1747,1748,155,1749,1750,817,1751,215],"Relapsed Non-Hodgkin Lymphoma","Refractory Non-Hodgkin Lymphoma","Refractory Hodgkin Lymphoma","Relapsed Chronic Lymphocytic Leukemia","Lymphoid Malignancies",[1266,163,1753,1735],"cyclosporine",{"trials":1755,"activeCount":100},[1756],{"nctId":1757,"briefTitle":1758,"status":265,"phases":1759,"primaryCompletion":1760,"completion":1760,"start":1761,"enrollment":890,"conditions":1762,"interventions":1767},"NCT01954784","Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma",[89],"2017-01-30","2013-10-07",[1763,1764,1765,1766],"Refractory Multiple Myeloma","Stage I Multiple Myeloma","Stage II Multiple Myeloma","Stage III Multiple Myeloma",[163,1753,1735,1768,1258],"bortezomib",{"trials":1770,"activeCount":100},[1771],{"nctId":1772,"briefTitle":1773,"status":144,"phases":1774,"primaryCompletion":291,"completion":291,"start":1775,"enrollment":149,"conditions":1776,"interventions":1849},"NCT01093586","Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies",[90],"2007-09",[1777,1778,1779,1780,1781,1782,1783,1784,1785,1786,1787,1788,1789,1790,1791,1792,1793,1794,1795,1796,1797,1798,1799,1800,1801,1802,1803,1804,1805,1806,1807,1808,1809,1810,1811,1812,1813,1814,1815,1816,1817,1818,1819,1820,1821,1822,1823,1824,1825,1826,1827,1828,1829,1830,1831,1832,1833,1834,1835,1836,1837,816,817,1838,1839,1840,1841,1842,1843,1844,818,820,1845,1846,1847,1848],"Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome","Adult Acute Lymphoblastic Leukemia in Remission","Adult Acute Megakaryoblastic Leukemia (M7)","Adult Acute Minimally Differentiated Myeloid Leukemia (M0)","Adult Acute Monoblastic Leukemia (M5a)","Adult Acute Monocytic Leukemia (M5b)","Adult Acute Myeloid Leukemia in Remission","Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities","Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)","Adult Erythroleukemia (M6a)","Adult Nasal Type Extranodal NK\u002FT-cell Lymphoma","Adult Pure Erythroid Leukemia (M6b)","B-cell Adult Acute Lymphoblastic Leukemia","B-cell Childhood Acute Lymphoblastic Leukemia","Blastic Phase Chronic Myelogenous Leukemia","Burkitt Lymphoma","Childhood Acute Erythroleukemia (M6)","Childhood Acute Lymphoblastic Leukemia in Remission","Childhood Acute Megakaryocytic Leukemia (M7)","Childhood Acute Minimally Differentiated Myeloid Leukemia (M0)","Childhood Acute Monoblastic Leukemia (M5a)","Childhood Acute Monocytic Leukemia (M5b)","Childhood Acute Myeloid Leukemia in Remission","Childhood Chronic Myelogenous Leukemia","Childhood Diffuse Large Cell Lymphoma","Childhood Immunoblastic Large Cell Lymphoma","Childhood Myelodysplastic Syndromes","Childhood Nasal Type Extranodal NK\u002FT-cell Lymphoma","Chronic Myelomonocytic Leukemia","Chronic Phase Chronic Myelogenous Leukemia","Cutaneous B-cell Non-Hodgkin Lymphoma","de Novo Myelodysplastic Syndromes","Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue","Juvenile Myelomonocytic Leukemia","Myelodysplastic\u002FMyeloproliferative Neoplasm, Unclassifiable","Nodal Marginal Zone B-cell Lymphoma","Previously Treated Myelodysplastic Syndromes","Prolymphocytic Leukemia","Recurrent Adult Acute Lymphoblastic Leukemia","Recurrent Adult Acute Myeloid Leukemia","Recurrent Adult Burkitt Lymphoma","Recurrent Adult Diffuse Large Cell Lymphoma","Recurrent Adult Diffuse Mixed Cell Lymphoma","Recurrent Adult Diffuse Small Cleaved Cell Lymphoma","Recurrent Adult Grade III Lymphomatoid Granulomatosis","Recurrent Adult Immunoblastic Large Cell Lymphoma","Recurrent Adult Lymphoblastic Lymphoma","Recurrent Childhood Acute Lymphoblastic Leukemia","Recurrent Childhood Acute Myeloid Leukemia","Recurrent Childhood Anaplastic Large Cell Lymphoma","Recurrent Childhood Grade III Lymphomatoid Granulomatosis","Recurrent Childhood Large Cell Lymphoma","Recurrent Childhood Lymphoblastic Lymphoma","Recurrent Childhood Small Noncleaved Cell Lymphoma","Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma","Recurrent Grade 1 Follicular Lymphoma","Recurrent Grade 2 Follicular Lymphoma","Recurrent Grade 3 Follicular Lymphoma","Recurrent Mantle Cell Lymphoma","Recurrent Marginal Zone Lymphoma","Recurrent Mycosis Fungoides\u002FSezary Syndrome","Relapsing Chronic Myelogenous Leukemia","Secondary Acute Myeloid Leukemia","Secondary Myelodysplastic Syndromes","Secondary Myelofibrosis","Splenic Marginal Zone Lymphoma","Stage I Chronic Lymphocytic Leukemia","Stage II Chronic Lymphocytic Leukemia","T-cell Adult Acute Lymphoblastic Leukemia","T-cell Childhood Acute Lymphoblastic Leukemia","T-cell Large Granular Lymphocyte Leukemia","Waldenstrom Macroglobulinemia",[164,1266,165,188,1753,1735],{"trials":1851,"activeCount":100},[1852],{"nctId":207,"briefTitle":208,"status":144,"phases":1853,"primaryCompletion":210,"completion":211,"start":212,"enrollment":213,"conditions":1854,"interventions":1855},[91],[215,216,151,217,157,218,219,220,158,156],[134,166,222,223],{"trials":1857,"activeCount":100},[],{"trials":1859,"activeCount":100},[],{"intervention":166,"totalTrials":1406,"cells":1861},{"EARLY_PHASE1":1862,"PHASE1":1864,"PHASE2":1870,"PHASE3":1906,"PHASE4":1912,"NA":1914},{"trials":1863,"activeCount":100},[],{"trials":1865,"activeCount":100},[1866],{"nctId":142,"briefTitle":143,"status":144,"phases":1867,"primaryCompletion":146,"completion":147,"start":148,"enrollment":149,"conditions":1868,"interventions":1869},[89],[151,152,153,154,155,156,157,158,159,160,161],[163,164,165,134,166],{"trials":1871,"activeCount":100},[1872],{"nctId":1873,"briefTitle":1874,"status":144,"phases":1875,"primaryCompletion":1876,"completion":1543,"start":1877,"enrollment":404,"conditions":1878,"interventions":1905},"NCT01177371","High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma",[90],"2000-02","1988-03",[1879,1778,1779,1781,1782,1880,1881,1783,1784,1882,1883,1884,1885,1886,1887,1888,1786,1787,1788,1889,1890,1792,1793,1794,1795,1797,1798,1891,1892,1799,1893,1894,1800,1803,1806,1807,1895,1809,1896,1897,1812,1898,1899,1813,1815,1816,1817,1818,1819,1820,1821,1900,1822,1823,1901,1902,1824,1825,1831,1832,1833,1834,1835,1836,1837,816,1763,1838,1840,1903,1842,1904,1848],"Accelerated Phase Chronic Myelogenous Leukemia","Adult Acute Myeloblastic Leukemia With Maturation (M2)","Adult Acute Myeloblastic Leukemia Without Maturation (M1)","Adult Acute Myeloid Leukemia With Del(5q)","Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)","Adult Acute Myeloid Leukemia With T(15;17)(q22;q12)","Adult Acute Myeloid Leukemia With T(16;16)(p13;q22)","Adult Acute Myeloid Leukemia With T(8;21)(q22;q22)","Adult Acute Myelomonocytic Leukemia (M4)","Adult Acute Promyelocytic Leukemia (M3)","Anaplastic Large Cell Lymphoma","Angioimmunoblastic T-cell Lymphoma","Childhood Acute Myeloblastic Leukemia With Maturation (M2)","Childhood Acute Myeloblastic Leukemia Without Maturation (M1)","Childhood Acute Myelomonocytic Leukemia (M4)","Childhood Acute Promyelocytic Leukemia (M3)","De Novo Myelodysplastic Syndromes","Hepatosplenic T-cell Lymphoma","Intraocular Lymphoma","Peripheral T-Cell Lymphoma","Post-transplant Lymphoproliferative Disorder","Recurrent Adult Hodgkin Lymphoma","Recurrent Adult Non-Hodgkin Lymphoma","Recurrent Adult T-cell Leukemia\u002FLymphoma","Small Intestine Lymphoma","Testicular Lymphoma",[164,1266,188,166,1753],{"trials":1907,"activeCount":100},[1908],{"nctId":207,"briefTitle":208,"status":144,"phases":1909,"primaryCompletion":210,"completion":211,"start":212,"enrollment":213,"conditions":1910,"interventions":1911},[91],[215,216,151,217,157,218,219,220,158,156],[134,166,222,223],{"trials":1913,"activeCount":100},[],{"trials":1915,"activeCount":100},[],{"intervention":1917,"totalTrials":1406,"cells":1918},"celecoxib",{"EARLY_PHASE1":1919,"PHASE1":1921,"PHASE2":1931,"PHASE3":1942,"PHASE4":1959,"NA":1961},{"trials":1920,"activeCount":100},[],{"trials":1922,"activeCount":100},[1923],{"nctId":1924,"briefTitle":1925,"status":265,"phases":1926,"primaryCompletion":1927,"completion":1562,"start":240,"enrollment":851,"conditions":1928,"interventions":1929},"NCT00075673","Vinorelbine and Celecoxib in Treating Women With Relapsed or Metastatic Breast Cancer",[89],"2004-09",[15],[1917,1930],"vinorelbine ditartrate",{"trials":1932,"activeCount":100},[1933],{"nctId":1934,"briefTitle":1935,"status":144,"phases":1936,"primaryCompletion":1937,"completion":1938,"start":282,"enrollment":254,"conditions":1939,"interventions":1941},"NCT01158534","Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery",[90],"2010-09","2010-10",[1094,1940],"Stage IV Renal Cell Cancer",[1917,1524],{"trials":1943,"activeCount":100},[1944],{"nctId":1945,"briefTitle":1946,"status":265,"phases":1947,"primaryCompletion":1948,"completion":1948,"start":1949,"enrollment":440,"conditions":1950,"interventions":1953},"NCT04176419","Perioperative Analgesia on Postoperative Opioid Usage and Pain Control in H&N Cancer Surgery",[91],"2021-06-23","2020-01-17",[1951,1952],"Postoperative Pain Control","Opioid Consumption",[1954,1955,1956,1957,1958],"Ketamine","Lidocaine","Acetaminophen","Gabapentin","Celecoxib",{"trials":1960,"activeCount":100},[],{"trials":1962,"activeCount":100},[],{"intervention":1964,"totalTrials":119,"cells":1965},"porfimer sodium",{"EARLY_PHASE1":1966,"PHASE1":1968,"PHASE2":1970,"PHASE3":1972,"PHASE4":1980,"NA":1982},{"trials":1967,"activeCount":100},[],{"trials":1969,"activeCount":100},[],{"trials":1971,"activeCount":100},[],{"trials":1973,"activeCount":100},[1974],{"nctId":1975,"briefTitle":1976,"status":144,"phases":1977,"primaryCompletion":282,"completion":282,"start":253,"enrollment":119,"conditions":1978,"interventions":1979},"NCT00118222","High Light and Low Light Dose PDT in Glioma",[91],[892],[1964],{"trials":1981,"activeCount":100},[],{"trials":1983,"activeCount":100},[],{"intervention":1985,"totalTrials":119,"cells":1986},"tamsulosin and\u002For dutasteride",{"EARLY_PHASE1":1987,"PHASE1":1989,"PHASE2":1991,"PHASE3":1993,"PHASE4":2003,"NA":2005},{"trials":1988,"activeCount":100},[],{"trials":1990,"activeCount":100},[],{"trials":1992,"activeCount":100},[],{"trials":1994,"activeCount":100},[1995],{"nctId":1996,"briefTitle":1997,"status":144,"phases":1998,"primaryCompletion":173,"completion":173,"start":1999,"enrollment":2000,"conditions":2001,"interventions":2002},"NCT00244309","Study of Tamsulosin and\u002For Dutasteride to Relieve Urinary Symptoms After Brachytherapy for Localized Prostate Cancer",[91],"2005-11",348,[18],[1985],{"trials":2004,"activeCount":100},[],{"trials":2006,"activeCount":100},[],{"intervention":2008,"totalTrials":119,"cells":2009},"doxorubicin HCL liposome",{"EARLY_PHASE1":2010,"PHASE1":2012,"PHASE2":2014,"PHASE3":2016,"PHASE4":2029,"NA":2031},{"trials":2011,"activeCount":100},[],{"trials":2013,"activeCount":100},[],{"trials":2015,"activeCount":100},[],{"trials":2017,"activeCount":100},[2018],{"nctId":2019,"briefTitle":2020,"status":144,"phases":2021,"primaryCompletion":1384,"completion":2022,"start":1706,"enrollment":176,"conditions":2023,"interventions":2028},"NCT00245050","Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer",[91],"2011-09",[15,2024,2025,2026,184,2027],"Drug\u002FAgent Toxicity by Tissue\u002FOrgan","Endometrial Cancer","Fallopian Tube Cancer","Peritoneal Cavity Cancer",[2008],{"trials":2030,"activeCount":100},[],{"trials":2032,"activeCount":100},[],{"intervention":1954,"totalTrials":119,"cells":2034},{"EARLY_PHASE1":2035,"PHASE1":2037,"PHASE2":2039,"PHASE3":2041,"PHASE4":2047,"NA":2049},{"trials":2036,"activeCount":100},[],{"trials":2038,"activeCount":100},[],{"trials":2040,"activeCount":100},[],{"trials":2042,"activeCount":100},[2043],{"nctId":1945,"briefTitle":1946,"status":265,"phases":2044,"primaryCompletion":1948,"completion":1948,"start":1949,"enrollment":440,"conditions":2045,"interventions":2046},[91],[1951,1952],[1954,1955,1956,1957,1958],{"trials":2048,"activeCount":100},[],{"trials":2050,"activeCount":100},[],{"intervention":1955,"totalTrials":119,"cells":2052},{"EARLY_PHASE1":2053,"PHASE1":2055,"PHASE2":2057,"PHASE3":2059,"PHASE4":2065,"NA":2067},{"trials":2054,"activeCount":100},[],{"trials":2056,"activeCount":100},[],{"trials":2058,"activeCount":100},[],{"trials":2060,"activeCount":100},[2061],{"nctId":1945,"briefTitle":1946,"status":265,"phases":2062,"primaryCompletion":1948,"completion":1948,"start":1949,"enrollment":440,"conditions":2063,"interventions":2064},[91],[1951,1952],[1954,1955,1956,1957,1958],{"trials":2066,"activeCount":100},[],{"trials":2068,"activeCount":100},[],{"intervention":1956,"totalTrials":119,"cells":2070},{"EARLY_PHASE1":2071,"PHASE1":2073,"PHASE2":2075,"PHASE3":2077,"PHASE4":2083,"NA":2085},{"trials":2072,"activeCount":100},[],{"trials":2074,"activeCount":100},[],{"trials":2076,"activeCount":100},[],{"trials":2078,"activeCount":100},[2079],{"nctId":1945,"briefTitle":1946,"status":265,"phases":2080,"primaryCompletion":1948,"completion":1948,"start":1949,"enrollment":440,"conditions":2081,"interventions":2082},[91],[1951,1952],[1954,1955,1956,1957,1958],{"trials":2084,"activeCount":100},[],{"trials":2086,"activeCount":100},[],{"intervention":1957,"totalTrials":119,"cells":2088},{"EARLY_PHASE1":2089,"PHASE1":2091,"PHASE2":2093,"PHASE3":2095,"PHASE4":2101,"NA":2103},{"trials":2090,"activeCount":100},[],{"trials":2092,"activeCount":100},[],{"trials":2094,"activeCount":100},[],{"trials":2096,"activeCount":100},[2097],{"nctId":1945,"briefTitle":1946,"status":265,"phases":2098,"primaryCompletion":1948,"completion":1948,"start":1949,"enrollment":440,"conditions":2099,"interventions":2100},[91],[1951,1952],[1954,1955,1956,1957,1958],{"trials":2102,"activeCount":100},[],{"trials":2104,"activeCount":100},[],{"intervention":258,"totalTrials":2106,"cells":2107},11,{"EARLY_PHASE1":2108,"PHASE1":2130,"PHASE2":2149,"PHASE3":2186,"PHASE4":2188,"NA":2190},{"trials":2109,"activeCount":100},[2110,2118,2126],{"nctId":2111,"briefTitle":2112,"status":144,"phases":2113,"primaryCompletion":2114,"completion":2114,"start":2115,"enrollment":749,"conditions":2116,"interventions":2117},"NCT02768389","Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma",[88],"2018-11","2016-09-06",[514,515],[1329],{"nctId":2119,"briefTitle":2120,"status":265,"phases":2121,"primaryCompletion":2122,"completion":2122,"start":1543,"enrollment":269,"conditions":2123,"interventions":2125},"NCT01086345","Radiosurgery Plus Bevacizumab in Glioblastoma",[88],"2014-12",[514,2124,515],"Gliosarcoma",[258,247],{"nctId":1238,"briefTitle":1239,"status":144,"phases":2127,"primaryCompletion":1241,"completion":1241,"start":1242,"enrollment":129,"conditions":2128,"interventions":2129},[88],[15],[258,1245,364,274],{"trials":2131,"activeCount":100},[2132,2141,2145],{"nctId":2133,"briefTitle":2134,"status":144,"phases":2135,"primaryCompletion":2136,"completion":2136,"start":2137,"enrollment":9,"conditions":2138,"interventions":2139},"NCT02669173","Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma",[89],"2025-01-07","2016-10-11",[514],[2140,1329],"Capecitabine",{"nctId":249,"briefTitle":250,"status":144,"phases":2142,"primaryCompletion":252,"completion":252,"start":253,"enrollment":254,"conditions":2143,"interventions":2144},[89],[256],[258,259,260,261,229],{"nctId":277,"briefTitle":278,"status":265,"phases":2146,"primaryCompletion":280,"completion":281,"start":282,"enrollment":9,"conditions":2147,"interventions":2148},[89],[256,24],[258,246,247,229],{"trials":2150,"activeCount":100},[2151,2155,2166,2170,2174],{"nctId":1287,"briefTitle":1288,"status":144,"phases":2152,"primaryCompletion":1290,"completion":1291,"start":1292,"enrollment":1293,"conditions":2153,"interventions":2154},[90],[15],[258,1266,274,1267],{"nctId":2156,"briefTitle":2157,"status":144,"phases":2158,"primaryCompletion":2159,"completion":2160,"start":2161,"enrollment":243,"conditions":2162,"interventions":2163},"NCT01083368","Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy",[89,90],"2011-12","2014-10","2009-01",[18],[2164,258,2165],"temsirolimus","polymorphism analysis",{"nctId":1315,"briefTitle":1316,"status":144,"phases":2167,"primaryCompletion":1318,"completion":1319,"start":1320,"enrollment":1012,"conditions":2168,"interventions":2169},[90],[1322,1323,1324,1325],[1245,1327,274,364,1328,1266,365,1329],{"nctId":1342,"briefTitle":1343,"status":144,"phases":2171,"primaryCompletion":1345,"completion":1346,"start":1347,"enrollment":440,"conditions":2172,"interventions":2173},[90],[35],[258,274],{"nctId":2175,"briefTitle":2176,"status":144,"phases":2177,"primaryCompletion":2178,"completion":2178,"start":2179,"enrollment":1070,"conditions":2180,"interventions":2185},"NCT01894061","NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma",[90],"2019-07-01","2013-09-18",[2181,2182,2183,2184],"Adult Giant Cell Glioblastoma","Adult Glioblastoma","Adult Gliosarcoma","Recurrent Adult Brain Tumor",[1329],{"trials":2187,"activeCount":100},[],{"trials":2189,"activeCount":100},[],{"trials":2191,"activeCount":100},[],{"intervention":164,"totalTrials":230,"cells":2193},{"EARLY_PHASE1":2194,"PHASE1":2311,"PHASE2":2317,"PHASE3":2375,"PHASE4":2377,"NA":2379},{"trials":2195,"activeCount":100},[2196],{"nctId":2197,"briefTitle":2198,"status":144,"phases":2199,"primaryCompletion":2200,"completion":2201,"start":2202,"enrollment":1255,"conditions":2203,"interventions":2310},"NCT01959477","Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant",[88],"2015-01","2015-04","2014-03",[2204,1787,1889,1890,2205,1801,2206,1802,1804,2207,2208,2209,2210,2211,2212,2213,2214,2215,2216,2217,2218,1807,1809,1896,1897,1812,2219,2220,2221,2222,2223,2224,2225,2226,2227,2228,2229,2230,2231,2232,1817,1818,1819,1820,1821,1900,1822,1823,1902,1826,1827,1828,1829,1830,1831,1832,1833,1834,1835,1836,1837,816,2233,2234,1903,1842,2235,2236,2237,2238,2239,2240,2241,2242,2243,2244,2245,2246,2247,2248,2249,2250,2251,2252,2253,2254,2255,2256,2257,2258,2259,2260,2261,2262,2263,2264,2265,2266,2267,2268,2269,2270,2271,2272,2273,2274,2275,2276,2277,2278,2279,2280,2281,2282,2283,2284,2285,819,2286,2287,2288,2289,2290,2291,2292,2293,2294,2295,2296,2297,2298,2299,2300,2301,2302,2303,2304,2305,2306,821,2307,2308,1847,1904,2309],"Adult Grade III Lymphomatoid Granulomatosis","Childhood Burkitt Lymphoma","Childhood Grade III Lymphomatoid Granulomatosis","Contiguous Stage II Adult Burkitt Lymphoma","Contiguous Stage II Adult Diffuse Large Cell Lymphoma","Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma","Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma","Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma","Contiguous Stage II Adult Lymphoblastic Lymphoma","Contiguous Stage II Grade 1 Follicular Lymphoma","Contiguous Stage II Grade 2 Follicular Lymphoma","Contiguous Stage II Grade 3 Follicular Lymphoma","Contiguous Stage II Mantle Cell Lymphoma","Contiguous Stage II Marginal Zone Lymphoma","Contiguous Stage II Small Lymphocytic Lymphoma","Noncontiguous Stage II Adult Burkitt Lymphoma","Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma","Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma","Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma","Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma","Noncontiguous Stage II Adult Lymphoblastic Lymphoma","Noncontiguous Stage II Grade 1 Follicular Lymphoma","Noncontiguous Stage II Grade 2 Follicular Lymphoma","Noncontiguous Stage II Grade 3 Follicular Lymphoma","Noncontiguous Stage II Mantle Cell Lymphoma","Noncontiguous Stage II Marginal Zone Lymphoma","Noncontiguous Stage II Small Lymphocytic Lymphoma","Noncutaneous Extranodal Lymphoma","Peripheral T-cell Lymphoma","Recurrent\u002FRefractory Childhood Hodgkin Lymphoma","Refractory Hairy Cell Leukemia","Stage I Adult Burkitt Lymphoma","Stage I Adult Diffuse Large Cell Lymphoma","Stage I Adult Diffuse Mixed Cell Lymphoma","Stage I Adult Diffuse Small Cleaved Cell Lymphoma","Stage I Adult Hodgkin Lymphoma","Stage I Adult Immunoblastic Large Cell Lymphoma","Stage I Adult Lymphoblastic Lymphoma","Stage I Adult T-cell Leukemia\u002FLymphoma","Stage I Childhood Anaplastic Large Cell Lymphoma","Stage I Childhood Hodgkin Lymphoma","Stage I Childhood Large Cell Lymphoma","Stage I Childhood Lymphoblastic Lymphoma","Stage I Childhood Small Noncleaved Cell Lymphoma","Stage I Cutaneous T-cell Non-Hodgkin Lymphoma","Stage I Grade 1 Follicular Lymphoma","Stage I Grade 2 Follicular Lymphoma","Stage I Grade 3 Follicular Lymphoma","Stage I Mantle Cell Lymphoma","Stage I Marginal Zone Lymphoma","Stage I Small Lymphocytic Lymphoma","Stage IA Mycosis Fungoides\u002FSezary Syndrome","Stage IB Mycosis Fungoides\u002FSezary Syndrome","Stage II Adult Hodgkin Lymphoma","Stage II Adult T-cell Leukemia\u002FLymphoma","Stage II Childhood Anaplastic Large Cell Lymphoma","Stage II Childhood Hodgkin Lymphoma","Stage II Childhood Large Cell Lymphoma","Stage II Childhood Lymphoblastic Lymphoma","Stage II Childhood Small Noncleaved Cell Lymphoma","Stage II Cutaneous T-cell Non-Hodgkin Lymphoma","Stage IIA Mycosis Fungoides\u002FSezary Syndrome","Stage IIB Mycosis Fungoides\u002FSezary Syndrome","Stage III Adult Burkitt Lymphoma","Stage III Adult Diffuse Large Cell Lymphoma","Stage III Adult Diffuse Mixed Cell Lymphoma","Stage III Adult Diffuse Small Cleaved Cell Lymphoma","Stage III Adult Hodgkin Lymphoma","Stage III Adult Immunoblastic Large Cell Lymphoma","Stage III Adult Lymphoblastic Lymphoma","Stage III Adult T-cell Leukemia\u002FLymphoma","Stage III Childhood Anaplastic Large Cell Lymphoma","Stage III Childhood Hodgkin Lymphoma","Stage III Childhood Large Cell Lymphoma","Stage III Childhood Lymphoblastic Lymphoma","Stage III Childhood Small Noncleaved Cell Lymphoma","Stage III Cutaneous T-cell Non-Hodgkin Lymphoma","Stage III Grade 1 Follicular Lymphoma","Stage III Grade 2 Follicular Lymphoma","Stage III Grade 3 Follicular Lymphoma","Stage III Mantle Cell Lymphoma","Stage III Marginal Zone Lymphoma","Stage IIIA Mycosis Fungoides\u002FSezary Syndrome","Stage IIIB Mycosis Fungoides\u002FSezary Syndrome","Stage IV Adult Burkitt Lymphoma","Stage IV Adult Diffuse Large Cell Lymphoma","Stage IV Adult Diffuse Mixed Cell Lymphoma","Stage IV Adult Diffuse Small Cleaved Cell Lymphoma","Stage IV Adult Hodgkin Lymphoma","Stage IV Adult Immunoblastic Large Cell Lymphoma","Stage IV Adult Lymphoblastic Lymphoma","Stage IV Adult T-cell Leukemia\u002FLymphoma","Stage IV Childhood Anaplastic Large Cell Lymphoma","Stage IV Childhood Hodgkin Lymphoma","Stage IV Childhood Large Cell Lymphoma","Stage IV Childhood Lymphoblastic Lymphoma","Stage IV Childhood Small Noncleaved Cell Lymphoma","Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma","Stage IV Grade 1 Follicular Lymphoma","Stage IV Grade 2 Follicular Lymphoma","Stage IV Grade 3 Follicular Lymphoma","Stage IV Mantle Cell Lymphoma","Stage IV Marginal Zone Lymphoma","Stage IVA Mycosis Fungoides\u002FSezary Syndrome","Stage IVB Mycosis Fungoides\u002FSezary Syndrome","Waldenström Macroglobulinemia",[164,1557,1266],{"trials":2312,"activeCount":100},[2313],{"nctId":142,"briefTitle":143,"status":144,"phases":2314,"primaryCompletion":146,"completion":147,"start":148,"enrollment":149,"conditions":2315,"interventions":2316},[89],[151,152,153,154,155,156,157,158,159,160,161],[163,164,165,134,166],{"trials":2318,"activeCount":100},[2319,2323,2332,2339,2343,2352,2360,2368],{"nctId":1873,"briefTitle":1874,"status":144,"phases":2320,"primaryCompletion":1876,"completion":1543,"start":1877,"enrollment":404,"conditions":2321,"interventions":2322},[90],[1879,1778,1779,1781,1782,1880,1881,1783,1784,1882,1883,1884,1885,1886,1887,1888,1786,1787,1788,1889,1890,1792,1793,1794,1795,1797,1798,1891,1892,1799,1893,1894,1800,1803,1806,1807,1895,1809,1896,1897,1812,1898,1899,1813,1815,1816,1817,1818,1819,1820,1821,1900,1822,1823,1901,1902,1824,1825,1831,1832,1833,1834,1835,1836,1837,816,1763,1838,1840,1903,1842,1904,1848],[164,1266,188,166,1753],{"nctId":2324,"briefTitle":2325,"status":144,"phases":2326,"primaryCompletion":2022,"completion":2022,"start":2327,"enrollment":176,"conditions":2328,"interventions":2329},"NCT00054327","Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer",[90],"2000-11",[29,21,32,182],[164,1266,2330,2331],"cytarabine","Etoposide",{"nctId":2333,"briefTitle":2334,"status":144,"phases":2335,"primaryCompletion":282,"completion":2336,"start":1608,"enrollment":879,"conditions":2337,"interventions":2338},"NCT00003116","High-Dose Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer",[90],"2009-06",[29,21,181,32,182],[894,164,1266,1753],{"nctId":1772,"briefTitle":1773,"status":144,"phases":2340,"primaryCompletion":291,"completion":291,"start":1775,"enrollment":149,"conditions":2341,"interventions":2342},[90],[1777,1778,1779,1780,1781,1782,1783,1784,1785,1786,1787,1788,1789,1790,1791,1792,1793,1794,1795,1796,1797,1798,1799,1800,1801,1802,1803,1804,1805,1806,1807,1808,1809,1810,1811,1812,1813,1814,1815,1816,1817,1818,1819,1820,1821,1822,1823,1824,1825,1826,1827,1828,1829,1830,1831,1832,1833,1834,1835,1836,1837,816,817,1838,1839,1840,1841,1842,1843,1844,818,820,1845,1846,1847,1848],[164,1266,165,188,1753,1735],{"nctId":2344,"briefTitle":2345,"status":144,"phases":2346,"primaryCompletion":2347,"completion":2347,"start":2348,"enrollment":2349,"conditions":2350,"interventions":2351},"NCT00941720","Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma",[90],"2013-02-28","2009-06-11",71,[181],[164,1266],{"nctId":2353,"briefTitle":2354,"status":144,"phases":2355,"primaryCompletion":1290,"completion":1705,"start":2356,"enrollment":851,"conditions":2357,"interventions":2358},"NCT00003336","Pilot Study Of Unrelated UCB Transplant for Non-Malignant Hematologic Conditions",[90],"1998-01",[29,32,182],[165,164,1266,2359,188],"melphalan",{"nctId":2361,"briefTitle":2362,"status":144,"phases":2363,"primaryCompletion":2364,"completion":2364,"start":2365,"enrollment":1462,"conditions":2366,"interventions":2367},"NCT00265889","Autologous Stem Cell Transplant in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma",[90],"2010-04","2002-02",[21],[894,164,1266,1557,2359],{"nctId":2369,"briefTitle":2370,"status":144,"phases":2371,"primaryCompletion":2372,"completion":1520,"start":2356,"enrollment":627,"conditions":2373,"interventions":2374},"NCT00003335","Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer",[90],"2007-11",[180,29,21,32,182],[165,164,1753,2359,188],{"trials":2376,"activeCount":100},[],{"trials":2378,"activeCount":100},[],{"trials":2380,"activeCount":100},[],{"intervention":1498,"totalTrials":269,"cells":2382},{"EARLY_PHASE1":2383,"PHASE1":2394,"PHASE2":2415,"PHASE3":2481,"PHASE4":2483,"NA":2485},{"trials":2384,"activeCount":100},[2385],{"nctId":2386,"briefTitle":2387,"status":1144,"phases":2388,"primaryCompletion":2389,"completion":2389,"start":2390,"enrollment":100,"conditions":2391,"interventions":2393},"NCT03574220","Pembrolizumab After Lung SBRT for Medically Inoperable Early Stage Non-small Cell Lung Cancer",[88],"2020-03-21","2019-02-19",[2392],"Non Small Cell Lung Cancer",[1498],{"trials":2395,"activeCount":100},[2396,2405],{"nctId":2397,"briefTitle":2398,"status":144,"phases":2399,"primaryCompletion":2400,"completion":2400,"start":2401,"enrollment":851,"conditions":2402,"interventions":2404},"NCT04357587","Safety and Feasibility of PD-1 Blockade in the Treatment of dMMR or MSI-H Rectal Cancer",[89],"2023-09-25","2020-08-06",[2403],"Rectal Neoplasms",[1498,2140],{"nctId":2406,"briefTitle":2407,"status":144,"phases":2408,"primaryCompletion":2409,"completion":2410,"start":2411,"enrollment":404,"conditions":2412,"interventions":2414},"NCT04323202","Neoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cell Carcinoma of H&N",[89],"2024-07-23","2025-06-25","2020-08-04",[2413],"Basal Cell Carcinoma of the Head and Neck",[1498],{"trials":2416,"activeCount":100},[2417,2428,2438,2448,2463,2477],{"nctId":2418,"briefTitle":2419,"status":1144,"phases":2420,"primaryCompletion":2421,"completion":2422,"start":2423,"enrollment":100,"conditions":2424,"interventions":2426},"NCT04197219","Pembrolizumab With Axitinib in Recurrent Endometrial Cancer",[90],"2025-01-01","2026-12-01","2021-02-01",[2425],"Recurrent Endometrial Cancer",[1498,2427],"Axitinib",{"nctId":2429,"briefTitle":2430,"status":144,"phases":2431,"primaryCompletion":2432,"completion":2433,"start":2434,"enrollment":749,"conditions":2435,"interventions":2437},"NCT03057613","The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and Neck",[90],"2020-06-26","2020-09-09","2017-05-10",[2436],"Squamous Cell Carcinoma of the Head and Neck",[1498],{"nctId":2439,"briefTitle":2440,"status":144,"phases":2441,"primaryCompletion":2442,"completion":2443,"start":2444,"enrollment":404,"conditions":2445,"interventions":2447},"NCT02658097","Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC",[90],"2022-02-26","2023-03-10","2017-06-07",[2446],"Stage IV Non-Small Cell Lung Cancer",[1498],{"nctId":2449,"briefTitle":2450,"status":1144,"phases":2451,"primaryCompletion":2452,"completion":2452,"start":2453,"enrollment":100,"conditions":2454,"interventions":2460},"NCT02661100","A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients",[89,90],"2018-07","2017-01",[2392,2455,2456,2457,2458,2459],"Advanced Triple Negative Breast Cancer","Small Cell Lung Cancer","Urothelial Cancer","Mesothelioma","Malignant Melanoma",[1498,2461,2462],"CDX-1401","Poly-ICLC",{"nctId":2464,"briefTitle":2465,"status":265,"phases":2466,"primaryCompletion":2467,"completion":2468,"start":2469,"enrollment":135,"conditions":2470,"interventions":2472},"NCT04322643","Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma",[90],"2022-08-08","2023-04-17","2020-03-23",[2471],"Urothelial Carcinoma",[1498,2473,2474,2475,2476],"Atezolizumab","Durvalumab","Nivolumab","Avelumab",{"nctId":1488,"briefTitle":1489,"status":144,"phases":2478,"primaryCompletion":1491,"completion":1492,"start":1493,"enrollment":440,"conditions":2479,"interventions":2480},[90],[1495],[302,1497,1498],{"trials":2482,"activeCount":100},[],{"trials":2484,"activeCount":100},[],{"trials":2486,"activeCount":100},[],{"intervention":1258,"totalTrials":851,"cells":2488},{"EARLY_PHASE1":2489,"PHASE1":2491,"PHASE2":2523,"PHASE3":2546,"PHASE4":2548,"NA":2550},{"trials":2490,"activeCount":100},[],{"trials":2492,"activeCount":100},[2493,2504,2508,2519],{"nctId":2494,"briefTitle":2495,"status":265,"phases":2496,"primaryCompletion":2497,"completion":2498,"start":2499,"enrollment":1091,"conditions":2500,"interventions":2502},"NCT01045928","Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma",[89],"2011-03","2012-03","2010-01",[2501,2204,2207,2208,2209,2210,2211,2212,2213,2214,2215,2216,2217,2218,1807,1809,1812,2219,2220,2221,2222,2223,2224,2225,2226,2227,2228,2229,2230,1817,1818,1819,1820,1821,1822,1823,1832,1833,1834,1835,1836,816,1842,2235,2236,2237,2238,2240,2241,2249,2250,2251,2252,2253,2254,2267,2268,2269,2270,2272,2273,2281,2282,2283,2284,2285,819,2288,2289,2290,2291,2293,2294,2302,2303,2304,2305,2306,821,1848],"Adult Non-Hodgkin Lymphoma",[1258,1556,1340,2503,2165],"nucleic acid sequencing",{"nctId":1249,"briefTitle":1250,"status":144,"phases":2505,"primaryCompletion":1252,"completion":1253,"start":1254,"enrollment":1255,"conditions":2506,"interventions":2507},[89],[24],[274,1258],{"nctId":2509,"briefTitle":2510,"status":265,"phases":2511,"primaryCompletion":2512,"completion":2513,"start":280,"enrollment":1406,"conditions":2514,"interventions":2517},"NCT01126450","Lenalidomide and Cetuximab in Treating Patients With Metastatic Colorectal Cancer",[89],"2010-11","2010-12",[2515,2516],"Colon Cancer","Rectal Cancer",[1258,2518,2165],"cetuximab",{"nctId":1757,"briefTitle":1758,"status":265,"phases":2520,"primaryCompletion":1760,"completion":1760,"start":1761,"enrollment":890,"conditions":2521,"interventions":2522},[89],[1763,1764,1765,1766],[163,1753,1735,1768,1258],{"trials":2524,"activeCount":100},[2525,2535],{"nctId":2526,"briefTitle":2527,"status":144,"phases":2528,"primaryCompletion":2529,"completion":2529,"start":2530,"enrollment":176,"conditions":2531,"interventions":2532},"NCT00460031","Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy",[90],"2010-08-31","2006-09-01",[18],[2533,1258,2534],"ketoconazole","therapeutic hydrocortisone",{"nctId":2536,"briefTitle":2537,"status":144,"phases":2538,"primaryCompletion":2539,"completion":2540,"start":267,"enrollment":2541,"conditions":2542,"interventions":2543},"NCT01155583","Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma",[89,90],"2016-05-28","2018-11-06",45,[1763],[2544,1258,2545],"azacitidine","dexamethasone",{"trials":2547,"activeCount":100},[],{"trials":2549,"activeCount":100},[],{"trials":2551,"activeCount":100},[],{"intervention":2475,"totalTrials":1091,"cells":2553},{"EARLY_PHASE1":2554,"PHASE1":2556,"PHASE2":2571,"PHASE3":2609,"PHASE4":2611,"NA":2613},{"trials":2555,"activeCount":100},[],{"trials":2557,"activeCount":100},[2558],{"nctId":2559,"briefTitle":2560,"status":1144,"phases":2561,"primaryCompletion":2562,"completion":2563,"start":2564,"enrollment":100,"conditions":2565,"interventions":2569},"NCT06357858","ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck",[89],"2025-02-28","2026-02-28","2024-06-01",[2566,2567,2568],"Recurrent Squamous Cell Carcinoma of the Head and Neck","Metastatic Squamous Cell Carcinoma","Head and Neck Squamous Cell Carcinoma",[2570,2475],"INQOVI",{"trials":2572,"activeCount":100},[2573,2583,2595,2599],{"nctId":2574,"briefTitle":2575,"status":144,"phases":2576,"primaryCompletion":2577,"completion":2577,"start":2578,"enrollment":1279,"conditions":2579,"interventions":2581},"NCT03126331","Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab",[90],"2023-10-24","2017-08-03",[2580],"Metastatic Renal Cell Carcinoma",[2475,2582],"Ipilimumab",{"nctId":2584,"briefTitle":2585,"status":144,"phases":2586,"primaryCompletion":2587,"completion":2588,"start":2589,"enrollment":404,"conditions":2590,"interventions":2592},"NCT02664181","Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With NSCLC: PRECISE Trial",[90],"2019-07-02","2024-05-19","2017-06-06",[26,2591],"Non-small Cell Lung Cancer",[2475,2593,2594],"oral decitabine","Tetrahydrouridine",{"nctId":2464,"briefTitle":2465,"status":265,"phases":2596,"primaryCompletion":2467,"completion":2468,"start":2469,"enrollment":135,"conditions":2597,"interventions":2598},[90],[2471],[1498,2473,2474,2475,2476],{"nctId":2600,"briefTitle":2601,"status":144,"phases":2602,"primaryCompletion":2603,"completion":2603,"start":2604,"enrollment":890,"conditions":2605,"interventions":2607},"NCT04187833","Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes",[90],"2023-10-13","2020-06-05",[2606],"Metastatic or Unresectable Melanoma",[2475,2608],"Talazoparib",{"trials":2610,"activeCount":100},[],{"trials":2612,"activeCount":100},[],{"trials":2614,"activeCount":100},[],{"intervention":247,"totalTrials":1091,"cells":2616},{"EARLY_PHASE1":2617,"PHASE1":2623,"PHASE2":2633,"PHASE3":2646,"PHASE4":2648,"NA":2650},{"trials":2618,"activeCount":100},[2619],{"nctId":2119,"briefTitle":2120,"status":265,"phases":2620,"primaryCompletion":2122,"completion":2122,"start":1543,"enrollment":269,"conditions":2621,"interventions":2622},[88],[514,2124,515],[258,247],{"trials":2624,"activeCount":100},[2625,2629],{"nctId":237,"briefTitle":238,"status":144,"phases":2626,"primaryCompletion":240,"completion":241,"start":242,"enrollment":243,"conditions":2627,"interventions":2628},[89],[24],[246,247,229],{"nctId":277,"briefTitle":278,"status":265,"phases":2630,"primaryCompletion":280,"completion":281,"start":282,"enrollment":9,"conditions":2631,"interventions":2632},[89],[256,24],[258,246,247,229],{"trials":2634,"activeCount":100},[2635,2642],{"nctId":2636,"briefTitle":2637,"status":144,"phases":2638,"primaryCompletion":914,"completion":1691,"start":2639,"enrollment":30,"conditions":2640,"interventions":2641},"NCT00002933","Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer",[90],"1996-09",[256],[247],{"nctId":367,"briefTitle":368,"status":265,"phases":2643,"primaryCompletion":370,"completion":371,"start":372,"enrollment":119,"conditions":2644,"interventions":2645},[90],[374,375,376,377,378,379,380,381,382],[384,303,304,305],{"trials":2647,"activeCount":100},[],{"trials":2649,"activeCount":100},[],{"trials":2651,"activeCount":100},[],{"intervention":261,"totalTrials":1091,"cells":2653},{"EARLY_PHASE1":2654,"PHASE1":2656,"PHASE2":2662,"PHASE3":2680,"PHASE4":2682,"NA":2684},{"trials":2655,"activeCount":100},[],{"trials":2657,"activeCount":100},[2658],{"nctId":249,"briefTitle":250,"status":144,"phases":2659,"primaryCompletion":252,"completion":252,"start":253,"enrollment":254,"conditions":2660,"interventions":2661},[89],[256],[258,259,260,261,229],{"trials":2663,"activeCount":100},[2664,2668,2672,2676],{"nctId":288,"briefTitle":289,"status":265,"phases":2665,"primaryCompletion":291,"completion":291,"start":292,"enrollment":119,"conditions":2666,"interventions":2667},[90],[294,295,296,297,298,299],[301,302,303,304,305],{"nctId":307,"briefTitle":308,"status":144,"phases":2669,"primaryCompletion":310,"completion":310,"start":311,"enrollment":312,"conditions":2670,"interventions":2671},[90],[314,315,316,317],[319,229,261,260],{"nctId":349,"briefTitle":350,"status":351,"phases":2673,"primaryCompletion":353,"completion":354,"start":355,"enrollment":356,"conditions":2674,"interventions":2675},[90],[358,271,359,360,361,362],[229,261,260,364,365],{"nctId":367,"briefTitle":368,"status":265,"phases":2677,"primaryCompletion":370,"completion":371,"start":372,"enrollment":119,"conditions":2678,"interventions":2679},[90],[374,375,376,377,378,379,380,381,382],[384,303,304,305],{"trials":2681,"activeCount":100},[],{"trials":2683,"activeCount":100},[],{"trials":2685,"activeCount":100},[],{"intervention":898,"totalTrials":1091,"cells":2687},{"EARLY_PHASE1":2688,"PHASE1":2690,"PHASE2":2706,"PHASE3":2726,"PHASE4":2728,"NA":2730},{"trials":2689,"activeCount":100},[],{"trials":2691,"activeCount":100},[2692,2702],{"nctId":2693,"briefTitle":2694,"status":144,"phases":2695,"primaryCompletion":914,"completion":2696,"start":2697,"enrollment":2698,"conditions":2699,"interventions":2700},"NCT00002604","O(6)-Benzylguanine and Carmustine in Treating Patients With Solid Tumors",[89],"2004-02","1996-01",28,[24],[897,898,2701],"chemosensitization\u002Fpotentiation therapy",{"nctId":884,"briefTitle":885,"status":265,"phases":2703,"primaryCompletion":887,"completion":888,"start":889,"enrollment":890,"conditions":2704,"interventions":2705},[89],[892,21,24],[894,895,896,897,898,899],{"trials":2707,"activeCount":100},[2708,2712,2720],{"nctId":1549,"briefTitle":1550,"status":144,"phases":2709,"primaryCompletion":253,"start":1552,"enrollment":1553,"conditions":2710,"interventions":2711},[90],[21],[894,1556,898,346,1266,1557],{"nctId":2713,"briefTitle":2714,"status":144,"phases":2715,"primaryCompletion":2716,"completion":1927,"start":2717,"enrollment":254,"conditions":2718,"interventions":2719},"NCT00004072","O6-benzylguanine And Carmustine in Treating Patients With Multiple Myeloma",[90],"2004-08","1999-09",[181],[897,898],{"nctId":2721,"briefTitle":2722,"status":144,"phases":2723,"primaryCompletion":240,"completion":240,"start":1552,"enrollment":404,"conditions":2724,"interventions":2725},"NCT00005981","Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer",[90],[256],[897,898],{"trials":2727,"activeCount":100},[],{"trials":2729,"activeCount":100},[],{"trials":2731,"activeCount":100},[],{"intervention":2330,"totalTrials":135,"cells":2733},{"EARLY_PHASE1":2734,"PHASE1":2736,"PHASE2":2757,"PHASE3":2769,"PHASE4":2771,"NA":2773},{"trials":2735,"activeCount":100},[],{"trials":2737,"activeCount":100},[2738,2749],{"nctId":2739,"briefTitle":2740,"status":144,"phases":2741,"primaryCompletion":2742,"completion":2743,"start":2744,"enrollment":440,"conditions":2745,"interventions":2746},"NCT02070458","Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia",[89],"2017-03-17","2017-08-15","2014-10-08",[1816,406],[2747,2748,1557,2330],"ixazomib","mitoxantrone hydrochloride",{"nctId":2750,"briefTitle":2751,"status":144,"phases":2752,"primaryCompletion":1429,"completion":1429,"start":2753,"enrollment":1406,"conditions":2754,"interventions":2756},"NCT01127009","Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia",[89],"2010-07",[1779,1780,1781,1782,1880,1881,1784,1882,1883,1785,2755,1887,1786,1788,1816],"Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)",[1768,2748,1557,2330],{"trials":2758,"activeCount":100},[2759,2765],{"nctId":2760,"briefTitle":2761,"status":144,"phases":2762,"primaryCompletion":1383,"completion":1347,"start":1292,"enrollment":1406,"conditions":2763,"interventions":2764},"NCT00047021","Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia or Lymphoma",[90],[29,21],[895,2330,2748],{"nctId":2324,"briefTitle":2325,"status":144,"phases":2766,"primaryCompletion":2022,"completion":2022,"start":2327,"enrollment":176,"conditions":2767,"interventions":2768},[90],[29,21,32,182],[164,1266,2330,2331],{"trials":2770,"activeCount":100},[],{"trials":2772,"activeCount":100},[],{"trials":2774,"activeCount":100},[],{"intervention":1283,"totalTrials":135,"cells":2776},{"EARLY_PHASE1":2777,"PHASE1":2779,"PHASE2":2785,"PHASE3":2805,"PHASE4":2807,"NA":2809},{"trials":2778,"activeCount":100},[],{"trials":2780,"activeCount":100},[2781],{"nctId":1273,"briefTitle":1274,"status":144,"phases":2782,"primaryCompletion":1276,"completion":1277,"start":1278,"enrollment":1279,"conditions":2783,"interventions":2784},[89],[1281],[274,1283],{"trials":2786,"activeCount":100},[2787,2794,2798],{"nctId":2788,"briefTitle":2789,"status":144,"phases":2790,"primaryCompletion":1999,"completion":2364,"start":2791,"enrollment":440,"conditions":2792,"interventions":2793},"NCT00053300","Thalidomide in Treating Patients With Extensive-Stage Small Cell Lung Cancer",[90],"2002-08",[26],[1283],{"nctId":1457,"briefTitle":1458,"status":144,"phases":2795,"primaryCompletion":887,"completion":1460,"start":1461,"enrollment":1462,"conditions":2796,"interventions":2797},[90],[29,32,182],[364,163,1283,1424],{"nctId":2799,"briefTitle":2800,"status":144,"phases":2801,"primaryCompletion":1775,"completion":1146,"start":1355,"enrollment":36,"conditions":2802,"interventions":2803},"NCT00274820","Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis\u002FMyeloproliferative Disorder",[90],[178,29,32,182],[2804,2545,1283],"arsenic trioxide",{"trials":2806,"activeCount":100},[],{"trials":2808,"activeCount":100},[],{"trials":2810,"activeCount":100},[],{"intervention":2812,"totalTrials":135,"cells":2813},"lomustine",{"EARLY_PHASE1":2814,"PHASE1":2816,"PHASE2":2818,"PHASE3":2854,"PHASE4":2856,"NA":2858},{"trials":2815,"activeCount":100},[],{"trials":2817,"activeCount":100},[],{"trials":2819,"activeCount":100},[2820,2830,2838,2846],{"nctId":2821,"briefTitle":2822,"status":144,"phases":2823,"primaryCompletion":1355,"completion":2824,"start":2825,"enrollment":2826,"conditions":2827,"interventions":2828},"NCT00049439","Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma",[90],"2008-02","1998-03",54,[21],[894,1266,1557,2812,2829],"procarbazine hydrochloride",{"nctId":2831,"briefTitle":2832,"status":265,"phases":2833,"primaryCompletion":2834,"completion":2834,"start":2835,"enrollment":851,"conditions":2836,"interventions":2837},"NCT00003113","Oral Combination Chemotherapy in Treating Elderly Patients With Intermediate or High-Grade Non-Hodgkin's Lymphomas",[90],"2002-12","1997-07",[21],[894,1266,1557,2812,2829],{"nctId":2839,"briefTitle":2840,"status":1144,"phases":2841,"primaryCompletion":2842,"start":2843,"enrollment":100,"conditions":2844,"interventions":2845},"NCT00003929","Chemotherapy, Filgrastim, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma",[90],"2000-03","1998-06",[21],[894,2812,2829],{"nctId":2847,"briefTitle":2848,"status":144,"phases":2849,"primaryCompletion":2850,"completion":2851,"start":2835,"enrollment":1091,"conditions":2852,"interventions":2853},"NCT00003114","Combination Chemotherapy in Treating Patients With AIDS-Related Hodgkin's Disease",[90],"2002-06","2003-02",[21],[894,1266,1557,2812,2829],{"trials":2855,"activeCount":100},[],{"trials":2857,"activeCount":100},[],{"trials":2859,"activeCount":100},[],{"intervention":2829,"totalTrials":135,"cells":2861},{"EARLY_PHASE1":2862,"PHASE1":2864,"PHASE2":2866,"PHASE3":2884,"PHASE4":2886,"NA":2888},{"trials":2863,"activeCount":100},[],{"trials":2865,"activeCount":100},[],{"trials":2867,"activeCount":100},[2868,2872,2876,2880],{"nctId":2821,"briefTitle":2822,"status":144,"phases":2869,"primaryCompletion":1355,"completion":2824,"start":2825,"enrollment":2826,"conditions":2870,"interventions":2871},[90],[21],[894,1266,1557,2812,2829],{"nctId":2831,"briefTitle":2832,"status":265,"phases":2873,"primaryCompletion":2834,"completion":2834,"start":2835,"enrollment":851,"conditions":2874,"interventions":2875},[90],[21],[894,1266,1557,2812,2829],{"nctId":2839,"briefTitle":2840,"status":1144,"phases":2877,"primaryCompletion":2842,"start":2843,"enrollment":100,"conditions":2878,"interventions":2879},[90],[21],[894,2812,2829],{"nctId":2847,"briefTitle":2848,"status":144,"phases":2881,"primaryCompletion":2850,"completion":2851,"start":2835,"enrollment":1091,"conditions":2882,"interventions":2883},[90],[21],[894,1266,1557,2812,2829],{"trials":2885,"activeCount":100},[],{"trials":2887,"activeCount":100},[],{"trials":2889,"activeCount":100},[],{"intervention":259,"totalTrials":135,"cells":2891},{"EARLY_PHASE1":2892,"PHASE1":2894,"PHASE2":2900,"PHASE3":2929,"PHASE4":2931,"NA":2933},{"trials":2893,"activeCount":100},[],{"trials":2895,"activeCount":100},[2896],{"nctId":249,"briefTitle":250,"status":144,"phases":2897,"primaryCompletion":252,"completion":252,"start":253,"enrollment":254,"conditions":2898,"interventions":2899},[89],[256],[258,259,260,261,229],{"trials":2901,"activeCount":100},[2902,2921,2925],{"nctId":2903,"briefTitle":2904,"status":265,"phases":2905,"primaryCompletion":2906,"completion":2906,"start":252,"enrollment":96,"conditions":2907,"interventions":2920},"NCT01192815","Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck",[90],"2012-10",[2908,2909,2910,2911,2912,2913,2914,2915,2916,2917,2918,2919],"Stage III Squamous Cell Carcinoma of the Hypopharynx","Stage III Squamous Cell Carcinoma of the Larynx","Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage III Squamous Cell Carcinoma of the Oropharynx","Stage III Verrucous Carcinoma of the Larynx","Stage III Verrucous Carcinoma of the Oral Cavity","Stage IV Squamous Cell Carcinoma of the Hypopharynx","Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IV Squamous Cell Carcinoma of the Nasopharynx","Stage IV Squamous Cell Carcinoma of the Oropharynx","Stage IV Verrucous Carcinoma of the Larynx","Stage IV Verrucous Carcinoma of the Oral Cavity",[259],{"nctId":1331,"briefTitle":1332,"status":144,"phases":2922,"primaryCompletion":1334,"completion":1334,"start":1335,"enrollment":1336,"conditions":2923,"interventions":2924},[90],[35],[274,259,1339,1340],{"nctId":1368,"briefTitle":1369,"status":144,"phases":2926,"primaryCompletion":1371,"completion":1372,"start":1252,"enrollment":1373,"conditions":2927,"interventions":2928},[90],[26],[259,1376,274],{"trials":2930,"activeCount":100},[],{"trials":2932,"activeCount":100},[],{"trials":2934,"activeCount":100},[],{"intervention":2359,"totalTrials":135,"cells":2936},{"EARLY_PHASE1":2937,"PHASE1":2939,"PHASE2":2941,"PHASE3":2966,"PHASE4":2968,"NA":2970},{"trials":2938,"activeCount":100},[],{"trials":2940,"activeCount":100},[],{"trials":2942,"activeCount":100},[2943,2954,2958,2962],{"nctId":2944,"briefTitle":2945,"status":144,"phases":2946,"primaryCompletion":2947,"completion":2947,"start":2948,"enrollment":112,"conditions":2949,"interventions":2950},"NCT03342196","Thiotepa Plus Fludarabine+ Melphalan as the Preparative Regime for Alternative Donor Transplantation",[90],"2024-06-12","2018-03-21",[29],[2951,2952,2953],"Melphalan","Thiotepa","Fludarabine",{"nctId":2353,"briefTitle":2354,"status":144,"phases":2955,"primaryCompletion":1290,"completion":1705,"start":2356,"enrollment":851,"conditions":2956,"interventions":2957},[90],[29,32,182],[165,164,1266,2359,188],{"nctId":2361,"briefTitle":2362,"status":144,"phases":2959,"primaryCompletion":2364,"completion":2364,"start":2365,"enrollment":1462,"conditions":2960,"interventions":2961},[90],[21],[894,164,1266,1557,2359],{"nctId":2369,"briefTitle":2370,"status":144,"phases":2963,"primaryCompletion":2372,"completion":1520,"start":2356,"enrollment":627,"conditions":2964,"interventions":2965},[90],[180,29,21,32,182],[165,164,1753,2359,188],{"trials":2967,"activeCount":100},[],{"trials":2969,"activeCount":100},[],{"trials":2971,"activeCount":100},[],{"intervention":897,"totalTrials":135,"cells":2973},{"EARLY_PHASE1":2974,"PHASE1":2976,"PHASE2":2986,"PHASE3":2996,"PHASE4":2998,"NA":3000},{"trials":2975,"activeCount":100},[],{"trials":2977,"activeCount":100},[2978,2982],{"nctId":2693,"briefTitle":2694,"status":144,"phases":2979,"primaryCompletion":914,"completion":2696,"start":2697,"enrollment":2698,"conditions":2980,"interventions":2981},[89],[24],[897,898,2701],{"nctId":884,"briefTitle":885,"status":265,"phases":2983,"primaryCompletion":887,"completion":888,"start":889,"enrollment":890,"conditions":2984,"interventions":2985},[89],[892,21,24],[894,895,896,897,898,899],{"trials":2987,"activeCount":100},[2988,2992],{"nctId":2713,"briefTitle":2714,"status":144,"phases":2989,"primaryCompletion":2716,"completion":1927,"start":2717,"enrollment":254,"conditions":2990,"interventions":2991},[90],[181],[897,898],{"nctId":2721,"briefTitle":2722,"status":144,"phases":2993,"primaryCompletion":240,"completion":240,"start":1552,"enrollment":404,"conditions":2994,"interventions":2995},[90],[256],[897,898],{"trials":2997,"activeCount":100},[],{"trials":2999,"activeCount":100},[],{"trials":3001,"activeCount":100},[],{"intervention":895,"totalTrials":1406,"cells":3003},{"EARLY_PHASE1":3004,"PHASE1":3006,"PHASE2":3012,"PHASE3":3024,"PHASE4":3026,"NA":3028},{"trials":3005,"activeCount":100},[],{"trials":3007,"activeCount":100},[3008],{"nctId":884,"briefTitle":885,"status":265,"phases":3009,"primaryCompletion":887,"completion":888,"start":889,"enrollment":890,"conditions":3010,"interventions":3011},[89],[892,21,24],[894,895,896,897,898,899],{"trials":3013,"activeCount":100},[3014,3018],{"nctId":2760,"briefTitle":2761,"status":144,"phases":3015,"primaryCompletion":1383,"completion":1347,"start":1292,"enrollment":1406,"conditions":3016,"interventions":3017},[90],[29,21],[895,2330,2748],{"nctId":3019,"briefTitle":3020,"status":144,"phases":3021,"primaryCompletion":267,"completion":2753,"start":173,"enrollment":254,"conditions":3022,"interventions":3023},"NCT00908141","GM-CSF in Treating Patients With Relapsed Prostate Cancer",[90],[18],[895],{"trials":3025,"activeCount":100},[],{"trials":3027,"activeCount":100},[],{"trials":3029,"activeCount":100},[],{"intervention":2748,"totalTrials":1406,"cells":3031},{"EARLY_PHASE1":3032,"PHASE1":3034,"PHASE2":3044,"PHASE3":3050,"PHASE4":3052,"NA":3054},{"trials":3033,"activeCount":100},[],{"trials":3035,"activeCount":100},[3036,3040],{"nctId":2739,"briefTitle":2740,"status":144,"phases":3037,"primaryCompletion":2742,"completion":2743,"start":2744,"enrollment":440,"conditions":3038,"interventions":3039},[89],[1816,406],[2747,2748,1557,2330],{"nctId":2750,"briefTitle":2751,"status":144,"phases":3041,"primaryCompletion":1429,"completion":1429,"start":2753,"enrollment":1406,"conditions":3042,"interventions":3043},[89],[1779,1780,1781,1782,1880,1881,1784,1882,1883,1785,2755,1887,1786,1788,1816],[1768,2748,1557,2330],{"trials":3045,"activeCount":100},[3046],{"nctId":2760,"briefTitle":2761,"status":144,"phases":3047,"primaryCompletion":1383,"completion":1347,"start":1292,"enrollment":1406,"conditions":3048,"interventions":3049},[90],[29,21],[895,2330,2748],{"trials":3051,"activeCount":100},[],{"trials":3053,"activeCount":100},[],{"trials":3055,"activeCount":100},[],{"intervention":1578,"totalTrials":1406,"cells":3057},{"EARLY_PHASE1":3058,"PHASE1":3060,"PHASE2":3062,"PHASE3":3091,"PHASE4":3093,"NA":3095},{"trials":3059,"activeCount":100},[],{"trials":3061,"activeCount":100},[],{"trials":3063,"activeCount":100},[3064,3070,3087],{"nctId":3065,"briefTitle":3066,"status":144,"phases":3067,"primaryCompletion":1347,"completion":2513,"start":2850,"enrollment":36,"conditions":3068,"interventions":3069},"NCT00253500","Epirubicin in Treating Women Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Breast Cancer",[90],[15],[1578,347],{"nctId":3071,"briefTitle":3072,"status":144,"phases":3073,"primaryCompletion":3074,"completion":3075,"start":3076,"enrollment":512,"conditions":3077,"interventions":3078},"NCT02073097","Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma",[89,90],"2021-07-20","2023-06-29","2015-01-28",[2208,2220,2236,2268,2289],[3079,3080,3081,3082,3083,3084,3085,3086],"Carfilzomib","Rituximab","Cyclophosphamide","Doxorubicin hydrochloride","Vincristine sulfate","Prednisone","Pegfilgrastim","Acyclovir",{"nctId":1572,"briefTitle":1573,"status":265,"phases":3088,"primaryCompletion":888,"completion":1575,"start":240,"enrollment":135,"conditions":3089,"interventions":3090},[89,90],[35],[894,1578,346,1267,1579],{"trials":3092,"activeCount":100},[],{"trials":3094,"activeCount":100},[],{"trials":3096,"activeCount":100},[],{"intervention":319,"totalTrials":1406,"cells":3098},{"EARLY_PHASE1":3099,"PHASE1":3111,"PHASE2":3120,"PHASE3":3126,"PHASE4":3128,"NA":3130},{"trials":3100,"activeCount":100},[3101],{"nctId":3102,"briefTitle":3103,"status":144,"phases":3104,"primaryCompletion":3105,"completion":3106,"start":3107,"enrollment":890,"conditions":3108,"interventions":3110},"NCT02153450","Stereotactic Radiosurgery and Metformin in Patients With Borderline-Resectable or Locally-Advanced Pancreatic Cancer",[88],"2018-08-03","2020-06-13","2015-05-08",[314,315,316,3109],"Stage I-III Pancreatic Cancer",[319],{"trials":3112,"activeCount":100},[3113],{"nctId":3114,"briefTitle":3115,"status":1144,"phases":3116,"primaryCompletion":1430,"completion":1430,"start":3117,"enrollment":100,"conditions":3118,"interventions":3119},"NCT01954732","Metformin Hydrochloride in Treating Patients With Pancreatic Cancer That Can be Removed by Surgery",[89],"2014-01",[377,378,379,380],[319],{"trials":3121,"activeCount":100},[3122],{"nctId":307,"briefTitle":308,"status":144,"phases":3123,"primaryCompletion":310,"completion":310,"start":311,"enrollment":312,"conditions":3124,"interventions":3125},[90],[314,315,316,317],[319,229,261,260],{"trials":3127,"activeCount":100},[],{"trials":3129,"activeCount":100},[],{"trials":3131,"activeCount":100},[],{"intervention":1524,"totalTrials":1406,"cells":3133},{"EARLY_PHASE1":3134,"PHASE1":3136,"PHASE2":3142,"PHASE3":3162,"PHASE4":3164,"NA":3166},{"trials":3135,"activeCount":100},[],{"trials":3137,"activeCount":100},[3138],{"nctId":1516,"briefTitle":1517,"status":144,"phases":3139,"primaryCompletion":1519,"completion":1520,"start":174,"enrollment":243,"conditions":3140,"interventions":3141},[89],[1522],[1524,346,1525,1526,1527],{"trials":3143,"activeCount":100},[3144,3158],{"nctId":3145,"briefTitle":3146,"status":144,"phases":3147,"primaryCompletion":3148,"completion":3149,"start":3150,"enrollment":3151,"conditions":3152,"interventions":3157},"NCT01100528","Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance",[90],"2015-07-25","2017-12-14","2009-11-11",38,[3153,3154,3155,3156],"Ciliary Body and Choroid Melanoma, Medium\u002FLarge Size","Ciliary Body and Choroid Melanoma, Small Size","Iris Melanoma","Recurrent Intraocular Melanoma",[1524,1526],{"nctId":1934,"briefTitle":1935,"status":144,"phases":3159,"primaryCompletion":1937,"completion":1938,"start":282,"enrollment":254,"conditions":3160,"interventions":3161},[90],[1094,1940],[1917,1524],{"trials":3163,"activeCount":100},[],{"trials":3165,"activeCount":100},[],{"trials":3167,"activeCount":100},[],{"intervention":1579,"totalTrials":1406,"cells":3169},{"EARLY_PHASE1":3170,"PHASE1":3172,"PHASE2":3181,"PHASE3":3193,"PHASE4":3195,"NA":3197},{"trials":3171,"activeCount":100},[],{"trials":3173,"activeCount":100},[3174],{"nctId":3175,"briefTitle":3176,"status":144,"phases":3177,"primaryCompletion":3178,"completion":3178,"start":1420,"enrollment":1070,"conditions":3179,"interventions":3180},"NCT00003768","Combretastatin A4 Phosphate in Treating Patients With Advanced Solid Tumors",[89],"2001-07",[24],[1579],{"trials":3182,"activeCount":100},[3183,3187],{"nctId":1572,"briefTitle":1573,"status":265,"phases":3184,"primaryCompletion":888,"completion":1575,"start":240,"enrollment":135,"conditions":3185,"interventions":3186},[89,90],[35],[894,1578,346,1267,1579],{"nctId":3188,"briefTitle":3189,"status":144,"phases":3190,"primaryCompletion":888,"completion":1252,"start":2851,"enrollment":1279,"conditions":3191,"interventions":3192},"NCT00060242","Combretastatin A4 Phosphate in Treating Patients With Advanced Anaplastic Thyroid Cancer",[90],[35],[1579],{"trials":3194,"activeCount":100},[],{"trials":3196,"activeCount":100},[],{"trials":3198,"activeCount":100},[],{"intervention":1768,"totalTrials":1406,"cells":3200},{"EARLY_PHASE1":3201,"PHASE1":3203,"PHASE2":3213,"PHASE3":3221,"PHASE4":3223,"NA":3225},{"trials":3202,"activeCount":100},[],{"trials":3204,"activeCount":100},[3205,3209],{"nctId":2750,"briefTitle":2751,"status":144,"phases":3206,"primaryCompletion":1429,"completion":1429,"start":2753,"enrollment":1406,"conditions":3207,"interventions":3208},[89],[1779,1780,1781,1782,1880,1881,1784,1882,1883,1785,2755,1887,1786,1788,1816],[1768,2748,1557,2330],{"nctId":1757,"briefTitle":1758,"status":265,"phases":3210,"primaryCompletion":1760,"completion":1760,"start":1761,"enrollment":890,"conditions":3211,"interventions":3212},[89],[1763,1764,1765,1766],[163,1753,1735,1768,1258],{"trials":3214,"activeCount":100},[3215],{"nctId":3216,"briefTitle":3217,"status":1144,"phases":3218,"primaryCompletion":1626,"start":2201,"enrollment":100,"conditions":3219,"interventions":3220},"NCT02082405","Bortezomib, Dexamethasone, and Cyclophosphamide in Treating Older Patients With Multiple Myeloma",[90],[1764,1765,1766],[1768,1266,2545],{"trials":3222,"activeCount":100},[],{"trials":3224,"activeCount":100},[],{"trials":3226,"activeCount":100},[],{"intervention":2474,"totalTrials":1406,"cells":3228},{"EARLY_PHASE1":3229,"PHASE1":3240,"PHASE2":3242,"PHASE3":3260,"PHASE4":3262,"NA":3264},{"trials":3230,"activeCount":100},[3231],{"nctId":3232,"briefTitle":3233,"status":265,"phases":3234,"primaryCompletion":3235,"completion":3235,"start":3236,"enrollment":1681,"conditions":3237,"interventions":3239},"NCT03818776","Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable NSCLC",[88],"2022-01-27","2019-08-30",[3238],"Non-Small Cell Lung Cancer",[2474],{"trials":3241,"activeCount":100},[],{"trials":3243,"activeCount":100},[3244,3256],{"nctId":3245,"briefTitle":3246,"status":1144,"phases":3247,"primaryCompletion":3248,"completion":3249,"start":3250,"enrollment":100,"conditions":3251,"interventions":3253},"NCT06608940","BC3402 w\u002F Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma",[89,90],"2027-01-01","2028-01-01","2025-11",[3252],"Hepato Cellular Carcinoma (HCC)",[3254,2474,3255],"BC3402","Tremelimumab",{"nctId":2464,"briefTitle":2465,"status":265,"phases":3257,"primaryCompletion":2467,"completion":2468,"start":2469,"enrollment":135,"conditions":3258,"interventions":3259},[90],[2471],[1498,2473,2474,2475,2476],{"trials":3261,"activeCount":100},[],{"trials":3263,"activeCount":100},[],{"trials":3265,"activeCount":100},[],{"intervention":2545,"totalTrials":1406,"cells":3267},{"EARLY_PHASE1":3268,"PHASE1":3270,"PHASE2":3272,"PHASE3":3286,"PHASE4":3288,"NA":3290},{"trials":3269,"activeCount":100},[],{"trials":3271,"activeCount":100},[],{"trials":3273,"activeCount":100},[3274,3278,3282],{"nctId":2799,"briefTitle":2800,"status":144,"phases":3275,"primaryCompletion":1775,"completion":1146,"start":1355,"enrollment":36,"conditions":3276,"interventions":3277},[90],[178,29,32,182],[2804,2545,1283],{"nctId":2536,"briefTitle":2537,"status":144,"phases":3279,"primaryCompletion":2539,"completion":2540,"start":267,"enrollment":2541,"conditions":3280,"interventions":3281},[89,90],[1763],[2544,1258,2545],{"nctId":3216,"briefTitle":3217,"status":1144,"phases":3283,"primaryCompletion":1626,"start":2201,"enrollment":100,"conditions":3284,"interventions":3285},[90],[1764,1765,1766],[1768,1266,2545],{"trials":3287,"activeCount":100},[],{"trials":3289,"activeCount":100},[],{"trials":3291,"activeCount":100},[],{"intervention":3293,"totalTrials":96,"cells":3294},"becatecarin",{"EARLY_PHASE1":3295,"PHASE1":3297,"PHASE2":3299,"PHASE3":3317,"PHASE4":3319,"NA":3321},{"trials":3296,"activeCount":100},[],{"trials":3298,"activeCount":100},[],{"trials":3300,"activeCount":100},[3301,3308],{"nctId":3302,"briefTitle":3303,"status":144,"phases":3304,"primaryCompletion":3305,"completion":175,"start":1310,"enrollment":1462,"conditions":3306,"interventions":3307},"NCT00006017","Two Rebeccamycin Analogue Regimens in Treating Patients With Advanced or Recurrent Non-small Cell Lung Cancer",[90],"2003-07",[26],[3293],{"nctId":3309,"briefTitle":3310,"status":265,"phases":3311,"primaryCompletion":241,"completion":1999,"start":3312,"enrollment":3313,"conditions":3314,"interventions":3316},"NCT00005997","Rebeccamycin Analogue in Treating Patients With Advanced Liver and\u002For Biliary Cancer",[90],"1999-04",72,[3315,331,1160],"Extrahepatic Bile Duct Cancer",[3293],{"trials":3318,"activeCount":100},[],{"trials":3320,"activeCount":100},[],{"trials":3322,"activeCount":100},[],{"intervention":3324,"totalTrials":96,"cells":3325},"Regorafenib",{"EARLY_PHASE1":3326,"PHASE1":3328,"PHASE2":3330,"PHASE3":3351,"PHASE4":3353,"NA":3355},{"trials":3327,"activeCount":100},[],{"trials":3329,"activeCount":100},[],{"trials":3331,"activeCount":100},[3332,3340],{"nctId":3333,"briefTitle":3334,"status":144,"phases":3335,"primaryCompletion":51,"completion":51,"start":3336,"enrollment":149,"conditions":3337,"interventions":3339},"NCT04051606","Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma",[90],"2019-07-31",[3338],"Recurrent Glioblastoma",[3324],{"nctId":3341,"briefTitle":3342,"status":265,"phases":3343,"primaryCompletion":3344,"completion":3345,"start":3346,"enrollment":96,"conditions":3347,"interventions":3349},"NCT02383433","Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer",[90],"2017-09-01","2018-05-10","2016-06-14",[3348],"Metastatic Pancreatic Adenocarcinoma",[3324,3350],"Gemcitabine Hydrochloride",{"trials":3352,"activeCount":100},[],{"trials":3354,"activeCount":100},[],{"trials":3356,"activeCount":100},[],{"intervention":347,"totalTrials":96,"cells":3358},{"EARLY_PHASE1":3359,"PHASE1":3361,"PHASE2":3363,"PHASE3":3373,"PHASE4":3375,"NA":3377},{"trials":3360,"activeCount":100},[],{"trials":3362,"activeCount":100},[],{"trials":3364,"activeCount":100},[3365,3369],{"nctId":3065,"briefTitle":3066,"status":144,"phases":3366,"primaryCompletion":1347,"completion":2513,"start":2850,"enrollment":36,"conditions":3367,"interventions":3368},[90],[15],[1578,347],{"nctId":336,"briefTitle":337,"status":144,"phases":3370,"primaryCompletion":339,"completion":340,"start":341,"enrollment":342,"conditions":3371,"interventions":3372},[90],[272,344],[346,347,260,229],{"trials":3374,"activeCount":100},[],{"trials":3376,"activeCount":100},[],{"trials":3378,"activeCount":100},[],{"intervention":1305,"totalTrials":96,"cells":3380},{"EARLY_PHASE1":3381,"PHASE1":3383,"PHASE2":3385,"PHASE3":3397,"PHASE4":3399,"NA":3401},{"trials":3382,"activeCount":100},[],{"trials":3384,"activeCount":100},[],{"trials":3386,"activeCount":100},[3387,3391],{"nctId":1297,"briefTitle":1298,"status":144,"phases":3388,"primaryCompletion":1292,"completion":1241,"start":1300,"enrollment":1301,"conditions":3389,"interventions":3390},[90],[15],[894,1304,274,1267,1305],{"nctId":3392,"briefTitle":3393,"status":144,"phases":3394,"primaryCompletion":173,"completion":812,"start":914,"enrollment":1012,"conditions":3395,"interventions":3396},"NCT00007904","Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes",[90],[15],[894,1266,1267,365,1305],{"trials":3398,"activeCount":100},[],{"trials":3400,"activeCount":100},[],{"trials":3402,"activeCount":100},[],{"intervention":3404,"totalTrials":96,"cells":3405},"Vitamin D3",{"EARLY_PHASE1":3406,"PHASE1":3418,"PHASE2":3420,"PHASE3":3433,"PHASE4":3435,"NA":3437},{"trials":3407,"activeCount":100},[3408],{"nctId":3409,"briefTitle":3410,"status":144,"phases":3411,"primaryCompletion":370,"completion":370,"start":1519,"enrollment":1279,"conditions":3412,"interventions":3415},"NCT01465113","Vitamin D Supplementation on 15-Prostaglandin Dehydrogenase Expression in Barrett's Esophagus",[88],[3413,3414],"Short Segment Barrett's Esophagus","Long Segment Barrett's Esophagus",[3416,3404,3404,3417],"Omeprazole","Metformin",{"trials":3419,"activeCount":100},[],{"trials":3421,"activeCount":100},[3422],{"nctId":3423,"briefTitle":3424,"status":144,"phases":3425,"primaryCompletion":3426,"completion":1090,"start":3427,"enrollment":3428,"conditions":3429,"interventions":3431},"NCT04140292","Vitamin D Supplementation as a Neoadjuvant for Photodynamic Therapy of Actinic Keratoses",[90],"2020-11-24","2020-01-13",75,[3430],"Actinic Keratosis",[3432,3404],"Photodynamic therapy",{"trials":3434,"activeCount":100},[],{"trials":3436,"activeCount":100},[],{"trials":3438,"activeCount":100},[],{"intervention":3440,"totalTrials":96,"cells":3441},"sorafenib tosylate",{"EARLY_PHASE1":3442,"PHASE1":3444,"PHASE2":3454,"PHASE3":3462,"PHASE4":3464,"NA":3466},{"trials":3443,"activeCount":100},[],{"trials":3445,"activeCount":100},[3446],{"nctId":3447,"briefTitle":3448,"status":265,"phases":3449,"primaryCompletion":1519,"completion":267,"start":3450,"enrollment":1406,"conditions":3451,"interventions":3452},"NCT00873002","Panobinostat and Sorafenib in Treating Patients With Liver Cancer That is Metastatic and\u002For Cannot Be Removed by Surgery",[89],"2009-03",[1160],[3453,3440],"panobinostat",{"trials":3455,"activeCount":100},[3456],{"nctId":3457,"briefTitle":3458,"status":144,"phases":3459,"primaryCompletion":1242,"completion":1242,"start":1705,"enrollment":1293,"conditions":3460,"interventions":3461},"NCT00866320","Sorafenib in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Sunitinib or Bevacizumab",[90],[1229],[3440],{"trials":3463,"activeCount":100},[],{"trials":3465,"activeCount":100},[],{"trials":3467,"activeCount":100},[],{"intervention":3469,"totalTrials":96,"cells":3470},"ipilimumab",{"EARLY_PHASE1":3471,"PHASE1":3482,"PHASE2":3484,"PHASE3":3490,"PHASE4":3492,"NA":3494},{"trials":3472,"activeCount":100},[3473],{"nctId":3474,"briefTitle":3475,"status":265,"phases":3476,"primaryCompletion":370,"completion":370,"start":1346,"enrollment":851,"conditions":3477,"interventions":3481},"NCT01730157","Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases",[88],[3153,3154,3478,3155,1159,3479,3156,3480],"Extraocular Extension Melanoma","Metastatic Intraocular Melanoma","Stage IV Intraocular Melanoma",[3469],{"trials":3483,"activeCount":100},[],{"trials":3485,"activeCount":100},[3486],{"nctId":2574,"briefTitle":2575,"status":144,"phases":3487,"primaryCompletion":2577,"completion":2577,"start":2578,"enrollment":1279,"conditions":3488,"interventions":3489},[90],[2580],[2475,2582],{"trials":3491,"activeCount":100},[],{"trials":3493,"activeCount":100},[],{"trials":3495,"activeCount":100},[],{"intervention":1526,"totalTrials":96,"cells":3497},{"EARLY_PHASE1":3498,"PHASE1":3500,"PHASE2":3506,"PHASE3":3512,"PHASE4":3514,"NA":3516},{"trials":3499,"activeCount":100},[],{"trials":3501,"activeCount":100},[3502],{"nctId":1516,"briefTitle":1517,"status":144,"phases":3503,"primaryCompletion":1519,"completion":1520,"start":174,"enrollment":243,"conditions":3504,"interventions":3505},[89],[1522],[1524,346,1525,1526,1527],{"trials":3507,"activeCount":100},[3508],{"nctId":3145,"briefTitle":3146,"status":144,"phases":3509,"primaryCompletion":3148,"completion":3149,"start":3150,"enrollment":3151,"conditions":3510,"interventions":3511},[90],[3153,3154,3155,3156],[1524,1526],{"trials":3513,"activeCount":100},[],{"trials":3515,"activeCount":100},[],{"trials":3517,"activeCount":100},[],{"intervention":3519,"totalTrials":96,"cells":3520},"Topical aminolevulinate",{"EARLY_PHASE1":3521,"PHASE1":3523,"PHASE2":3525,"PHASE3":3545,"PHASE4":3547,"NA":3549},{"trials":3522,"activeCount":100},[],{"trials":3524,"activeCount":100},[],{"trials":3526,"activeCount":100},[3527,3535],{"nctId":3528,"briefTitle":3529,"status":144,"phases":3530,"primaryCompletion":3531,"completion":3531,"start":3532,"enrollment":440,"conditions":3533,"interventions":3534},"NCT06027619","Short Contact Protocols to Reduce Pain During 10% ALA Gel Red-light Photodynamic Therapy of Actinic Keratoses",[90],"2024-07-08","2023-10-02",[3430],[3519],{"nctId":3536,"briefTitle":3537,"status":144,"phases":3538,"primaryCompletion":3539,"completion":3539,"start":3540,"enrollment":149,"conditions":3541,"interventions":3543},"NCT05923060","Imaging Techniques to Monitor Photosensitizer and sO2 Levels During Photodynamic Therapy of Actinic Keratoses",[90],"2025-10-31","2024-08-25",[3542],"Actinic Keratoses",[3544],"Topical Aminolevulinate",{"trials":3546,"activeCount":100},[],{"trials":3548,"activeCount":100},[],{"trials":3550,"activeCount":100},[],{"intervention":3552,"totalTrials":96,"cells":3553},"Azacitidine",{"EARLY_PHASE1":3554,"PHASE1":3556,"PHASE2":3558,"PHASE3":3574,"PHASE4":3576,"NA":3578},{"trials":3555,"activeCount":100},[],{"trials":3557,"activeCount":100},[],{"trials":3559,"activeCount":100},[3560,3570],{"nctId":3561,"briefTitle":3562,"status":144,"phases":3563,"primaryCompletion":3564,"completion":3565,"start":3566,"enrollment":9,"conditions":3567,"interventions":3568},"NCT03397173","TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid",[90],"2021-01-03","2021-01-21","2018-03-16",[32,218,151],[3552,3569],"Ascorbic acid",{"nctId":2536,"briefTitle":2537,"status":144,"phases":3571,"primaryCompletion":2539,"completion":2540,"start":267,"enrollment":2541,"conditions":3572,"interventions":3573},[89,90],[1763],[2544,1258,2545],{"trials":3575,"activeCount":100},[],{"trials":3577,"activeCount":100},[],{"trials":3579,"activeCount":100},[],{"intervention":2953,"totalTrials":96,"cells":3581},{"EARLY_PHASE1":3582,"PHASE1":3584,"PHASE2":3597,"PHASE3":3603,"PHASE4":3605,"NA":3607},{"trials":3583,"activeCount":100},[],{"trials":3585,"activeCount":100},[3586],{"nctId":3587,"briefTitle":3588,"status":144,"phases":3589,"primaryCompletion":3590,"completion":3590,"start":3591,"enrollment":135,"conditions":3592,"interventions":3596},"NCT02065596","Hematopoietic Stem Cell Transplant for Sickle Cell Disease",[89],"2023-02-17","2015-10-19",[3593,3594,3595],"Sickle Cell Disease","Sickle Cell Anemia","SCD",[2953],{"trials":3598,"activeCount":100},[3599],{"nctId":2944,"briefTitle":2945,"status":144,"phases":3600,"primaryCompletion":2947,"completion":2947,"start":2948,"enrollment":112,"conditions":3601,"interventions":3602},[90],[29],[2951,2952,2953],{"trials":3604,"activeCount":100},[],{"trials":3606,"activeCount":100},[],{"trials":3608,"activeCount":100},[],{"intervention":2427,"totalTrials":96,"cells":3610},{"EARLY_PHASE1":3611,"PHASE1":3613,"PHASE2":3615,"PHASE3":3631,"PHASE4":3633,"NA":3635},{"trials":3612,"activeCount":100},[],{"trials":3614,"activeCount":100},[],{"trials":3616,"activeCount":100},[3617,3621],{"nctId":2418,"briefTitle":2419,"status":1144,"phases":3618,"primaryCompletion":2421,"completion":2422,"start":2423,"enrollment":100,"conditions":3619,"interventions":3620},[90],[2425],[1498,2427],{"nctId":3622,"briefTitle":3623,"status":144,"phases":3624,"primaryCompletion":3625,"completion":3626,"start":3627,"enrollment":112,"conditions":3628,"interventions":3630},"NCT02579811","Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer",[90],"2019-08-21","2023-06-20","2015-12-30",[3629],"Metastatic Renal Cell Cancer",[2427],{"trials":3632,"activeCount":100},[],{"trials":3634,"activeCount":100},[],{"trials":3636,"activeCount":100},[],{"intervention":3638,"totalTrials":96,"cells":3639},"pegylated liposomal doxorubicin hydrochloride",{"EARLY_PHASE1":3640,"PHASE1":3642,"PHASE2":3649,"PHASE3":3657,"PHASE4":3659,"NA":3661},{"trials":3641,"activeCount":100},[],{"trials":3643,"activeCount":100},[3644],{"nctId":3645,"briefTitle":238,"status":144,"phases":3646,"primaryCompletion":1473,"completion":1562,"start":1876,"enrollment":230,"conditions":3647,"interventions":3648},"NCT00006372",[89],[24],[1359,3638,1930],{"trials":3650,"activeCount":100},[3651],{"nctId":3652,"briefTitle":3653,"status":144,"phases":3654,"primaryCompletion":846,"completion":1292,"start":3312,"enrollment":230,"conditions":3655,"interventions":3656},"NCT00004014","Liposomal Doxorubicin in Treating Patients With Prostate Cancer",[90],[18],[3638],{"trials":3658,"activeCount":100},[],{"trials":3660,"activeCount":100},[],{"trials":3662,"activeCount":100},[],{"intervention":3664,"totalTrials":119,"cells":3665},"brostallicin",{"EARLY_PHASE1":3666,"PHASE1":3668,"PHASE2":3670,"PHASE3":3678,"PHASE4":3680,"NA":3682},{"trials":3667,"activeCount":100},[],{"trials":3669,"activeCount":100},[],{"trials":3671,"activeCount":100},[3672],{"nctId":3673,"briefTitle":3674,"status":144,"phases":3675,"primaryCompletion":1419,"completion":1706,"start":2834,"enrollment":1406,"conditions":3676,"interventions":3677},"NCT00060203","Brostallicin in Treating Patients With Recurrent or Refractory Multiple Myeloma",[89,90],[181],[3664],{"trials":3679,"activeCount":100},[],{"trials":3681,"activeCount":100},[],{"trials":3683,"activeCount":100},[],{"intervention":2533,"totalTrials":119,"cells":3685},{"EARLY_PHASE1":3686,"PHASE1":3688,"PHASE2":3690,"PHASE3":3696,"PHASE4":3698,"NA":3700},{"trials":3687,"activeCount":100},[],{"trials":3689,"activeCount":100},[],{"trials":3691,"activeCount":100},[3692],{"nctId":2526,"briefTitle":2527,"status":144,"phases":3693,"primaryCompletion":2529,"completion":2529,"start":2530,"enrollment":176,"conditions":3694,"interventions":3695},[90],[18],[2533,1258,2534],{"trials":3697,"activeCount":100},[],{"trials":3699,"activeCount":100},[],{"trials":3701,"activeCount":100},[],{"intervention":2534,"totalTrials":119,"cells":3703},{"EARLY_PHASE1":3704,"PHASE1":3706,"PHASE2":3708,"PHASE3":3714,"PHASE4":3716,"NA":3718},{"trials":3705,"activeCount":100},[],{"trials":3707,"activeCount":100},[],{"trials":3709,"activeCount":100},[3710],{"nctId":2526,"briefTitle":2527,"status":144,"phases":3711,"primaryCompletion":2529,"completion":2529,"start":2530,"enrollment":176,"conditions":3712,"interventions":3713},[90],[18],[2533,1258,2534],{"trials":3715,"activeCount":100},[],{"trials":3717,"activeCount":100},[],{"trials":3719,"activeCount":100},[],{"intervention":3721,"totalTrials":119,"cells":3722},"Phase Ib - nivolumab",{"EARLY_PHASE1":3723,"PHASE1":3725,"PHASE2":3727,"PHASE3":3740,"PHASE4":3742,"NA":3744},{"trials":3724,"activeCount":100},[],{"trials":3726,"activeCount":100},[],{"trials":3728,"activeCount":100},[3729],{"nctId":3730,"briefTitle":3731,"status":1144,"phases":3732,"primaryCompletion":3733,"completion":3734,"start":3735,"enrollment":100,"conditions":3736,"interventions":3738},"NCT03307603","Yttrium-90 Radioembolization + Nivolumab for Liver + Extra-hepatic Metastases From Colorectal Cancer",[89,90],"2019-03","2021-03","2018-12",[3737],"Metastatic Colorectal Cancer",[3721,3739],"Phase II - nivolumab",{"trials":3741,"activeCount":100},[],{"trials":3743,"activeCount":100},[],{"trials":3745,"activeCount":100},[],{"intervention":3739,"totalTrials":119,"cells":3747},{"EARLY_PHASE1":3748,"PHASE1":3750,"PHASE2":3752,"PHASE3":3758,"PHASE4":3760,"NA":3762},{"trials":3749,"activeCount":100},[],{"trials":3751,"activeCount":100},[],{"trials":3753,"activeCount":100},[3754],{"nctId":3730,"briefTitle":3731,"status":1144,"phases":3755,"primaryCompletion":3733,"completion":3734,"start":3735,"enrollment":100,"conditions":3756,"interventions":3757},[89,90],[3737],[3721,3739],{"trials":3759,"activeCount":100},[],{"trials":3761,"activeCount":100},[],{"trials":3763,"activeCount":100},[],{"intervention":3079,"totalTrials":119,"cells":3765},{"EARLY_PHASE1":3766,"PHASE1":3768,"PHASE2":3770,"PHASE3":3776,"PHASE4":3778,"NA":3780},{"trials":3767,"activeCount":100},[],{"trials":3769,"activeCount":100},[],{"trials":3771,"activeCount":100},[3772],{"nctId":3071,"briefTitle":3072,"status":144,"phases":3773,"primaryCompletion":3074,"completion":3075,"start":3076,"enrollment":512,"conditions":3774,"interventions":3775},[89,90],[2208,2220,2236,2268,2289],[3079,3080,3081,3082,3083,3084,3085,3086],{"trials":3777,"activeCount":100},[],{"trials":3779,"activeCount":100},[],{"trials":3781,"activeCount":100},[],{"intervention":3086,"totalTrials":119,"cells":3783},{"EARLY_PHASE1":3784,"PHASE1":3786,"PHASE2":3788,"PHASE3":3794,"PHASE4":3796,"NA":3798},{"trials":3785,"activeCount":100},[],{"trials":3787,"activeCount":100},[],{"trials":3789,"activeCount":100},[3790],{"nctId":3071,"briefTitle":3072,"status":144,"phases":3791,"primaryCompletion":3074,"completion":3075,"start":3076,"enrollment":512,"conditions":3792,"interventions":3793},[89,90],[2208,2220,2236,2268,2289],[3079,3080,3081,3082,3083,3084,3085,3086],{"trials":3795,"activeCount":100},[],{"trials":3797,"activeCount":100},[],{"trials":3799,"activeCount":100},[],{"intervention":1304,"totalTrials":119,"cells":3801},{"EARLY_PHASE1":3802,"PHASE1":3804,"PHASE2":3806,"PHASE3":3812,"PHASE4":3814,"NA":3816},{"trials":3803,"activeCount":100},[],{"trials":3805,"activeCount":100},[],{"trials":3807,"activeCount":100},[3808],{"nctId":1297,"briefTitle":1298,"status":144,"phases":3809,"primaryCompletion":1292,"completion":1241,"start":1300,"enrollment":1301,"conditions":3810,"interventions":3811},[90],[15],[894,1304,274,1267,1305],{"trials":3813,"activeCount":100},[],{"trials":3815,"activeCount":100},[],{"trials":3817,"activeCount":100},[],{"intervention":2164,"totalTrials":119,"cells":3819},{"EARLY_PHASE1":3820,"PHASE1":3822,"PHASE2":3824,"PHASE3":3830,"PHASE4":3832,"NA":3834},{"trials":3821,"activeCount":100},[],{"trials":3823,"activeCount":100},[],{"trials":3825,"activeCount":100},[3826],{"nctId":2156,"briefTitle":2157,"status":144,"phases":3827,"primaryCompletion":2159,"completion":2160,"start":2161,"enrollment":243,"conditions":3828,"interventions":3829},[89,90],[18],[2164,258,2165],{"trials":3831,"activeCount":100},[],{"trials":3833,"activeCount":100},[],{"trials":3835,"activeCount":100},[],{"intervention":1547,"totalTrials":119,"cells":3837},{"EARLY_PHASE1":3838,"PHASE1":3840,"PHASE2":3842,"PHASE3":3848,"PHASE4":3850,"NA":3852},{"trials":3839,"activeCount":100},[],{"trials":3841,"activeCount":100},[],{"trials":3843,"activeCount":100},[3844],{"nctId":1540,"briefTitle":1541,"status":144,"phases":3845,"primaryCompletion":1227,"completion":1543,"start":1355,"enrollment":1544,"conditions":3846,"interventions":3847},[90],[272],[346,260,1547],{"trials":3849,"activeCount":100},[],{"trials":3851,"activeCount":100},[],{"trials":3853,"activeCount":100},[],{"intervention":3432,"totalTrials":119,"cells":3855},{"EARLY_PHASE1":3856,"PHASE1":3858,"PHASE2":3860,"PHASE3":3866,"PHASE4":3868,"NA":3870},{"trials":3857,"activeCount":100},[],{"trials":3859,"activeCount":100},[],{"trials":3861,"activeCount":100},[3862],{"nctId":3423,"briefTitle":3424,"status":144,"phases":3863,"primaryCompletion":3426,"completion":1090,"start":3427,"enrollment":3428,"conditions":3864,"interventions":3865},[90],[3430],[3432,3404],{"trials":3867,"activeCount":100},[],{"trials":3869,"activeCount":100},[],{"trials":3871,"activeCount":100},[],{"intervention":3873,"totalTrials":119,"cells":3874},"enzalutamide",{"EARLY_PHASE1":3875,"PHASE1":3877,"PHASE2":3879,"PHASE3":3890,"PHASE4":3892,"NA":3894},{"trials":3876,"activeCount":100},[],{"trials":3878,"activeCount":100},[],{"trials":3880,"activeCount":100},[3881],{"nctId":3882,"briefTitle":3883,"status":144,"phases":3884,"primaryCompletion":1319,"completion":3885,"start":3886,"enrollment":1462,"conditions":3887,"interventions":3889},"NCT01927627","Enzalutamide in Patients With High-risk Prostate Cancer",[90],"2017-04-26","2013-11-11",[3888],"Adenocarcinoma of the Prostate",[3873],{"trials":3891,"activeCount":100},[],{"trials":3893,"activeCount":100},[],{"trials":3895,"activeCount":100},[],{"intervention":3569,"totalTrials":119,"cells":3897},{"EARLY_PHASE1":3898,"PHASE1":3900,"PHASE2":3902,"PHASE3":3908,"PHASE4":3910,"NA":3912},{"trials":3899,"activeCount":100},[],{"trials":3901,"activeCount":100},[],{"trials":3903,"activeCount":100},[3904],{"nctId":3561,"briefTitle":3562,"status":144,"phases":3905,"primaryCompletion":3564,"completion":3565,"start":3566,"enrollment":9,"conditions":3906,"interventions":3907},[90],[32,218,151],[3552,3569],{"trials":3909,"activeCount":100},[],{"trials":3911,"activeCount":100},[],{"trials":3913,"activeCount":100},[],{"intervention":3915,"totalTrials":119,"cells":3916},"ritonavir",{"EARLY_PHASE1":3917,"PHASE1":3919,"PHASE2":3921,"PHASE3":3937,"PHASE4":3939,"NA":3941},{"trials":3918,"activeCount":100},[],{"trials":3920,"activeCount":100},[],{"trials":3922,"activeCount":100},[3923],{"nctId":3924,"briefTitle":3925,"status":265,"phases":3926,"primaryCompletion":267,"completion":3927,"start":2161,"enrollment":33,"conditions":3928,"interventions":3935},"NCT01095094","Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma",[90],"2011-11",[515,3929,3930,3931,3932,3933,514,2124,3934],"Anaplastic Astrocytoma","Anaplastic Ependymoma","Anaplastic Oligodendroglioma","Brain Stem Glioma","Giant Cell Glioblastoma","Mixed Glioma",[3915,3936],"lopinavir",{"trials":3938,"activeCount":100},[],{"trials":3940,"activeCount":100},[],{"trials":3942,"activeCount":100},[],{"intervention":3936,"totalTrials":119,"cells":3944},{"EARLY_PHASE1":3945,"PHASE1":3947,"PHASE2":3949,"PHASE3":3955,"PHASE4":3957,"NA":3959},{"trials":3946,"activeCount":100},[],{"trials":3948,"activeCount":100},[],{"trials":3950,"activeCount":100},[3951],{"nctId":3924,"briefTitle":3925,"status":265,"phases":3952,"primaryCompletion":267,"completion":3927,"start":2161,"enrollment":33,"conditions":3953,"interventions":3954},[90],[515,3929,3930,3931,3932,3933,514,2124,3934],[3915,3936],{"trials":3956,"activeCount":100},[],{"trials":3958,"activeCount":100},[],{"trials":3960,"activeCount":100},[],{"intervention":1313,"totalTrials":119,"cells":3962},{"EARLY_PHASE1":3963,"PHASE1":3965,"PHASE2":3967,"PHASE3":3973,"PHASE4":3975,"NA":3977},{"trials":3964,"activeCount":100},[],{"trials":3966,"activeCount":100},[],{"trials":3968,"activeCount":100},[3969],{"nctId":1307,"briefTitle":1308,"status":1144,"phases":3970,"start":1310,"enrollment":100,"conditions":3971,"interventions":3972},[90],[15],[1313,1266,274,1267,163],{"trials":3974,"activeCount":100},[],{"trials":3976,"activeCount":100},[],{"trials":3978,"activeCount":100},[],{"intervention":1327,"totalTrials":119,"cells":3980},{"EARLY_PHASE1":3981,"PHASE1":3983,"PHASE2":3985,"PHASE3":3991,"PHASE4":3993,"NA":3995},{"trials":3982,"activeCount":100},[],{"trials":3984,"activeCount":100},[],{"trials":3986,"activeCount":100},[3987],{"nctId":1315,"briefTitle":1316,"status":144,"phases":3988,"primaryCompletion":1318,"completion":1319,"start":1320,"enrollment":1012,"conditions":3989,"interventions":3990},[90],[1322,1323,1324,1325],[1245,1327,274,364,1328,1266,365,1329],{"trials":3992,"activeCount":100},[],{"trials":3994,"activeCount":100},[],{"trials":3996,"activeCount":100},[],{"intervention":1328,"totalTrials":119,"cells":3998},{"EARLY_PHASE1":3999,"PHASE1":4001,"PHASE2":4003,"PHASE3":4009,"PHASE4":4011,"NA":4013},{"trials":4000,"activeCount":100},[],{"trials":4002,"activeCount":100},[],{"trials":4004,"activeCount":100},[4005],{"nctId":1315,"briefTitle":1316,"status":144,"phases":4006,"primaryCompletion":1318,"completion":1319,"start":1320,"enrollment":1012,"conditions":4007,"interventions":4008},[90],[1322,1323,1324,1325],[1245,1327,274,364,1328,1266,365,1329],{"trials":4010,"activeCount":100},[],{"trials":4012,"activeCount":100},[],{"trials":4014,"activeCount":100},[],{"intervention":4016,"totalTrials":119,"cells":4017},"Piperacillin\u002FTazobactam",{"EARLY_PHASE1":4018,"PHASE1":4020,"PHASE2":4022,"PHASE3":4035,"PHASE4":4037,"NA":4039},{"trials":4019,"activeCount":100},[],{"trials":4021,"activeCount":100},[],{"trials":4023,"activeCount":100},[4024],{"nctId":4025,"briefTitle":4026,"status":265,"phases":4027,"primaryCompletion":4028,"completion":4029,"start":4030,"enrollment":1406,"conditions":4031,"interventions":4033},"NCT05753735","eXtended Antibiotic Prophylaxis for Intermediate- and High-risk Glands After Pancreatoduodenectomy to Reduce CR-POPF",[90],"2024-03-14","2024-06-02","2024-01-18",[4032],"Pancreatic Fistula",[4016,4034],"Amoxicillin\u002F Clavulanic acid",{"trials":4036,"activeCount":100},[],{"trials":4038,"activeCount":100},[],{"trials":4040,"activeCount":100},[],{"intervention":4034,"totalTrials":119,"cells":4042},{"EARLY_PHASE1":4043,"PHASE1":4045,"PHASE2":4047,"PHASE3":4053,"PHASE4":4055,"NA":4057},{"trials":4044,"activeCount":100},[],{"trials":4046,"activeCount":100},[],{"trials":4048,"activeCount":100},[4049],{"nctId":4025,"briefTitle":4026,"status":265,"phases":4050,"primaryCompletion":4028,"completion":4029,"start":4030,"enrollment":1406,"conditions":4051,"interventions":4052},[90],[4032],[4016,4034],{"trials":4054,"activeCount":100},[],{"trials":4056,"activeCount":100},[],{"trials":4058,"activeCount":100},[],{"intervention":2952,"totalTrials":119,"cells":4060},{"EARLY_PHASE1":4061,"PHASE1":4063,"PHASE2":4065,"PHASE3":4071,"PHASE4":4073,"NA":4075},{"trials":4062,"activeCount":100},[],{"trials":4064,"activeCount":100},[],{"trials":4066,"activeCount":100},[4067],{"nctId":2944,"briefTitle":2945,"status":144,"phases":4068,"primaryCompletion":2947,"completion":2947,"start":2948,"enrollment":112,"conditions":4069,"interventions":4070},[90],[29],[2951,2952,2953],{"trials":4072,"activeCount":100},[],{"trials":4074,"activeCount":100},[],{"trials":4076,"activeCount":100},[],{"intervention":4078,"totalTrials":119,"cells":4079},"imatinib mesylate",{"EARLY_PHASE1":4080,"PHASE1":4082,"PHASE2":4084,"PHASE3":4096,"PHASE4":4098,"NA":4100},{"trials":4081,"activeCount":100},[],{"trials":4083,"activeCount":100},[],{"trials":4085,"activeCount":100},[4086],{"nctId":4087,"briefTitle":4088,"status":144,"phases":4089,"primaryCompletion":4090,"completion":4091,"start":268,"enrollment":19,"conditions":4092,"interventions":4093},"NCT00509093","Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy",[90],"2014-05-09","2015-04-09",[29],[4078,4094,4095,1340],"gene expression analysis","mutation analysis",{"trials":4097,"activeCount":100},[],{"trials":4099,"activeCount":100},[],{"trials":4101,"activeCount":100},[],{"intervention":4103,"totalTrials":119,"cells":4104},"Cabazitaxel",{"EARLY_PHASE1":4105,"PHASE1":4107,"PHASE2":4109,"PHASE3":4121,"PHASE4":4123,"NA":4125},{"trials":4106,"activeCount":100},[],{"trials":4108,"activeCount":100},[],{"trials":4110,"activeCount":100},[4111],{"nctId":4112,"briefTitle":4113,"status":1144,"phases":4114,"primaryCompletion":4115,"completion":4115,"start":4116,"enrollment":100,"conditions":4117,"interventions":4119},"NCT01750866","Cabazitaxel in Men 75 Years of Age or Older With Castration-Resistant Prostate Cancer",[90],"2013-10","2013-02",[4118],"Castrate-resistant Metastatic Prostate Cancer",[4103,3084,4120],"Granulocyte colony-stimulating factor",{"trials":4122,"activeCount":100},[],{"trials":4124,"activeCount":100},[],{"trials":4126,"activeCount":100},[],{"intervention":4120,"totalTrials":119,"cells":4128},{"EARLY_PHASE1":4129,"PHASE1":4131,"PHASE2":4133,"PHASE3":4139,"PHASE4":4141,"NA":4143},{"trials":4130,"activeCount":100},[],{"trials":4132,"activeCount":100},[],{"trials":4134,"activeCount":100},[4135],{"nctId":4112,"briefTitle":4113,"status":1144,"phases":4136,"primaryCompletion":4115,"completion":4115,"start":4116,"enrollment":100,"conditions":4137,"interventions":4138},[90],[4118],[4103,3084,4120],{"trials":4140,"activeCount":100},[],{"trials":4142,"activeCount":100},[],{"trials":4144,"activeCount":100},[],{"intervention":4146,"totalTrials":119,"cells":4147},"eltrombopag olamine",{"EARLY_PHASE1":4148,"PHASE1":4150,"PHASE2":4152,"PHASE3":4165,"PHASE4":4167,"NA":4169},{"trials":4149,"activeCount":100},[],{"trials":4151,"activeCount":100},[],{"trials":4153,"activeCount":100},[4154],{"nctId":4155,"briefTitle":4156,"status":351,"phases":4157,"primaryCompletion":4158,"completion":4159,"start":4160,"enrollment":1421,"conditions":4161,"interventions":4164},"NCT02071901","Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy",[90],"2018-10-20","2023-09-26","2014-08-14",[1777,4162,4163,1779,1780,1781,1782,1880,1881,1783,1784,1882,1883,1785,2755,1887,1786,1788,1839],"Adult Acute Basophilic Leukemia","Adult Acute Eosinophilic Leukemia",[4146],{"trials":4166,"activeCount":100},[],{"trials":4168,"activeCount":100},[],{"trials":4170,"activeCount":100},[],{"intervention":4172,"totalTrials":119,"cells":4173},"bleomycin sulfate",{"EARLY_PHASE1":4174,"PHASE1":4176,"PHASE2":4178,"PHASE3":4187,"PHASE4":4189,"NA":4191},{"trials":4175,"activeCount":100},[],{"trials":4177,"activeCount":100},[],{"trials":4179,"activeCount":100},[4180],{"nctId":4181,"briefTitle":4182,"status":144,"phases":4183,"primaryCompletion":4184,"completion":2834,"start":2835,"enrollment":1091,"conditions":4185,"interventions":4186},"NCT00003110","Bleomycin in Treating Patients With Non-Hodgkin's Lymphoma",[90],"2001-08",[21],[4172],{"trials":4188,"activeCount":100},[],{"trials":4190,"activeCount":100},[],{"trials":4192,"activeCount":100},[],{"intervention":3254,"totalTrials":119,"cells":4194},{"EARLY_PHASE1":4195,"PHASE1":4197,"PHASE2":4199,"PHASE3":4205,"PHASE4":4207,"NA":4209},{"trials":4196,"activeCount":100},[],{"trials":4198,"activeCount":100},[],{"trials":4200,"activeCount":100},[4201],{"nctId":3245,"briefTitle":3246,"status":1144,"phases":4202,"primaryCompletion":3248,"completion":3249,"start":3250,"enrollment":100,"conditions":4203,"interventions":4204},[89,90],[3252],[3254,2474,3255],{"trials":4206,"activeCount":100},[],{"trials":4208,"activeCount":100},[],{"trials":4210,"activeCount":100},[],{"intervention":3255,"totalTrials":119,"cells":4212},{"EARLY_PHASE1":4213,"PHASE1":4215,"PHASE2":4217,"PHASE3":4223,"PHASE4":4225,"NA":4227},{"trials":4214,"activeCount":100},[],{"trials":4216,"activeCount":100},[],{"trials":4218,"activeCount":100},[4219],{"nctId":3245,"briefTitle":3246,"status":1144,"phases":4220,"primaryCompletion":3248,"completion":3249,"start":3250,"enrollment":100,"conditions":4221,"interventions":4222},[89,90],[3252],[3254,2474,3255],{"trials":4224,"activeCount":100},[],{"trials":4226,"activeCount":100},[],{"trials":4228,"activeCount":100},[],{"intervention":4230,"totalTrials":119,"cells":4231},"Eribulin Mesylate",{"EARLY_PHASE1":4232,"PHASE1":4234,"PHASE2":4236,"PHASE3":4250,"PHASE4":4252,"NA":4254},{"trials":4233,"activeCount":100},[],{"trials":4235,"activeCount":100},[],{"trials":4237,"activeCount":100},[4238],{"nctId":4239,"briefTitle":4240,"status":144,"phases":4241,"primaryCompletion":4242,"completion":4243,"start":4244,"enrollment":269,"conditions":4245,"interventions":4247},"NCT02581839","Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate",[90],"2018-07-02","2020-07-02","2015-11-17",[4246,776],"Metastatic Breast Cancer",[4230,4248,4249],"Pre-Medication: Zofran","Pre-Medication: Decadron",{"trials":4251,"activeCount":100},[],{"trials":4253,"activeCount":100},[],{"trials":4255,"activeCount":100},[],{"intervention":4248,"totalTrials":119,"cells":4257},{"EARLY_PHASE1":4258,"PHASE1":4260,"PHASE2":4262,"PHASE3":4268,"PHASE4":4270,"NA":4272},{"trials":4259,"activeCount":100},[],{"trials":4261,"activeCount":100},[],{"trials":4263,"activeCount":100},[4264],{"nctId":4239,"briefTitle":4240,"status":144,"phases":4265,"primaryCompletion":4242,"completion":4243,"start":4244,"enrollment":269,"conditions":4266,"interventions":4267},[90],[4246,776],[4230,4248,4249],{"trials":4269,"activeCount":100},[],{"trials":4271,"activeCount":100},[],{"trials":4273,"activeCount":100},[],{"intervention":4249,"totalTrials":119,"cells":4275},{"EARLY_PHASE1":4276,"PHASE1":4278,"PHASE2":4280,"PHASE3":4286,"PHASE4":4288,"NA":4290},{"trials":4277,"activeCount":100},[],{"trials":4279,"activeCount":100},[],{"trials":4281,"activeCount":100},[4282],{"nctId":4239,"briefTitle":4240,"status":144,"phases":4283,"primaryCompletion":4242,"completion":4243,"start":4244,"enrollment":269,"conditions":4284,"interventions":4285},[90],[4246,776],[4230,4248,4249],{"trials":4287,"activeCount":100},[],{"trials":4289,"activeCount":100},[],{"trials":4291,"activeCount":100},[],{"intervention":4293,"totalTrials":119,"cells":4294},"decitabine",{"EARLY_PHASE1":4295,"PHASE1":4297,"PHASE2":4299,"PHASE3":4314,"PHASE4":4316,"NA":4318},{"trials":4296,"activeCount":100},[],{"trials":4298,"activeCount":100},[],{"trials":4300,"activeCount":100},[4301],{"nctId":4302,"briefTitle":4303,"status":144,"phases":4304,"primaryCompletion":2159,"completion":4305,"start":2753,"enrollment":1070,"conditions":4306,"interventions":4312},"NCT01165996","Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome",[89,90],"2012-08",[1805,1808,32,4307,4308,4309,4310,4311],"Refractory Anemia","Refractory Anemia With Excess Blasts","Refractory Anemia With Ringed Sideroblasts","Refractory Cytopenia With Multilineage Dysplasia","Thrombocytopenia",[4293,4313,4094,2165],"microarray analysis",{"trials":4315,"activeCount":100},[],{"trials":4317,"activeCount":100},[],{"trials":4319,"activeCount":100},[],{"intervention":4321,"totalTrials":119,"cells":4322},"Leuprolide acetate",{"EARLY_PHASE1":4323,"PHASE1":4325,"PHASE2":4327,"PHASE3":4338,"PHASE4":4340,"NA":4342},{"trials":4324,"activeCount":100},[],{"trials":4326,"activeCount":100},[],{"trials":4328,"activeCount":100},[4329],{"nctId":4330,"briefTitle":4331,"status":144,"phases":4332,"primaryCompletion":4333,"completion":4333,"start":4334,"enrollment":2826,"conditions":4335,"interventions":4336},"NCT02770391","Apalutamide and Leuprolide in Intermediate and High-risk Prostate Cancer",[90],"2020-04-29","2016-10-17",[18],[4321,4337],"Apalutamide",{"trials":4339,"activeCount":100},[],{"trials":4341,"activeCount":100},[],{"trials":4343,"activeCount":100},[],{"intervention":4337,"totalTrials":119,"cells":4345},{"EARLY_PHASE1":4346,"PHASE1":4348,"PHASE2":4350,"PHASE3":4356,"PHASE4":4358,"NA":4360},{"trials":4347,"activeCount":100},[],{"trials":4349,"activeCount":100},[],{"trials":4351,"activeCount":100},[4352],{"nctId":4330,"briefTitle":4331,"status":144,"phases":4353,"primaryCompletion":4333,"completion":4333,"start":4334,"enrollment":2826,"conditions":4354,"interventions":4355},[90],[18],[4321,4337],{"trials":4357,"activeCount":100},[],{"trials":4359,"activeCount":100},[],{"trials":4361,"activeCount":100},[],{"intervention":1603,"totalTrials":119,"cells":4363},{"EARLY_PHASE1":4364,"PHASE1":4366,"PHASE2":4368,"PHASE3":4374,"PHASE4":4376,"NA":4378},{"trials":4365,"activeCount":100},[],{"trials":4367,"activeCount":100},[],{"trials":4369,"activeCount":100},[4370],{"nctId":1589,"briefTitle":1590,"status":1144,"phases":4371,"primaryCompletion":1592,"completion":1593,"start":1594,"enrollment":100,"conditions":4372,"interventions":4373},[90],[1596,1597,1598,1599,1600],[1602,1603],{"trials":4375,"activeCount":100},[],{"trials":4377,"activeCount":100},[],{"trials":4379,"activeCount":100},[],{"intervention":4381,"totalTrials":119,"cells":4382},"Obinutuzumab",{"EARLY_PHASE1":4383,"PHASE1":4385,"PHASE2":4387,"PHASE3":4399,"PHASE4":4401,"NA":4403},{"trials":4384,"activeCount":100},[],{"trials":4386,"activeCount":100},[],{"trials":4388,"activeCount":100},[4389],{"nctId":4390,"briefTitle":4391,"status":1144,"phases":4392,"primaryCompletion":4393,"completion":4394,"start":4395,"enrollment":100,"conditions":4396,"interventions":4398},"NCT03086395","Single Agent Obinutuzumab in Relapsed\u002FRefractory Post-Transplant Lymphoproliferative Disorder (PTLD)",[90],"2018-01-01","2021-01-01","2017-04-01",[1899,4397],"PTLD",[4381],{"trials":4400,"activeCount":100},[],{"trials":4402,"activeCount":100},[],{"trials":4404,"activeCount":100},[],{"intervention":4406,"totalTrials":119,"cells":4407},"recombinant interferon alpha-1b",{"EARLY_PHASE1":4408,"PHASE1":4410,"PHASE2":4412,"PHASE3":4421,"PHASE4":4423,"NA":4425},{"trials":4409,"activeCount":100},[],{"trials":4411,"activeCount":100},[],{"trials":4413,"activeCount":100},[4414],{"nctId":4415,"briefTitle":4416,"status":144,"phases":4417,"primaryCompletion":4418,"completion":4418,"start":1562,"enrollment":1681,"conditions":4419,"interventions":4420},"NCT00278174","Interferon Alfa (IFN-Alpha-1b) in Renal Cancer With Metastatic Kidney Cancer",[90],"2007-04",[1229],[4406],{"trials":4422,"activeCount":100},[],{"trials":4424,"activeCount":100},[],{"trials":4426,"activeCount":100},[],{"intervention":4428,"totalTrials":119,"cells":4429},"Escitalopram",{"EARLY_PHASE1":4430,"PHASE1":4432,"PHASE2":4434,"PHASE3":4445,"PHASE4":4447,"NA":4449},{"trials":4431,"activeCount":100},[],{"trials":4433,"activeCount":100},[],{"trials":4435,"activeCount":100},[4436],{"nctId":4437,"briefTitle":4438,"status":265,"phases":4439,"primaryCompletion":4440,"completion":4440,"start":4441,"enrollment":135,"conditions":4442,"interventions":4444},"NCT05289830","Escitalopram to Placebo in Patients With Localized Pancreatic Cancer",[90],"2023-08-27","2022-08-05",[1014,4443],"Periampullary Cancer",[4428],{"trials":4446,"activeCount":100},[],{"trials":4448,"activeCount":100},[],{"trials":4450,"activeCount":100},[],{"intervention":4452,"totalTrials":119,"cells":4453},"Natalizumab",{"EARLY_PHASE1":4454,"PHASE1":4456,"PHASE2":4458,"PHASE3":4468,"PHASE4":4470,"NA":4472},{"trials":4455,"activeCount":100},[],{"trials":4457,"activeCount":100},[],{"trials":4459,"activeCount":100},[4460],{"nctId":4461,"briefTitle":4462,"status":1144,"phases":4463,"primaryCompletion":326,"completion":437,"start":4464,"enrollment":100,"conditions":4465,"interventions":4467},"NCT03811886","Natalizumab in Recurrent, Refractory or Progressive Pulmonary Metastatic Osteosarcoma",[89,90],"2024-12-01",[4466],"Pulmonary Metastatic Osteosarcoma (pOS)",[4452],{"trials":4469,"activeCount":100},[],{"trials":4471,"activeCount":100},[],{"trials":4473,"activeCount":100},[],{"intervention":4475,"totalTrials":119,"cells":4476},"aminocamptothecin colloidal dispersion",{"EARLY_PHASE1":4477,"PHASE1":4479,"PHASE2":4481,"PHASE3":4489,"PHASE4":4491,"NA":4493},{"trials":4478,"activeCount":100},[],{"trials":4480,"activeCount":100},[],{"trials":4482,"activeCount":100},[4483],{"nctId":4484,"briefTitle":4485,"status":144,"phases":4486,"primaryCompletion":844,"completion":1584,"start":2356,"enrollment":33,"conditions":4487,"interventions":4488},"NCT00003154","Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer",[90],[26],[4475],{"trials":4490,"activeCount":100},[],{"trials":4492,"activeCount":100},[],{"trials":4494,"activeCount":100},[],{"intervention":2804,"totalTrials":119,"cells":4496},{"EARLY_PHASE1":4497,"PHASE1":4499,"PHASE2":4501,"PHASE3":4507,"PHASE4":4509,"NA":4511},{"trials":4498,"activeCount":100},[],{"trials":4500,"activeCount":100},[],{"trials":4502,"activeCount":100},[4503],{"nctId":2799,"briefTitle":2800,"status":144,"phases":4504,"primaryCompletion":1775,"completion":1146,"start":1355,"enrollment":36,"conditions":4505,"interventions":4506},[90],[178,29,32,182],[2804,2545,1283],{"trials":4508,"activeCount":100},[],{"trials":4510,"activeCount":100},[],{"trials":4512,"activeCount":100},[],{"intervention":4514,"totalTrials":119,"cells":4515},"Captopril",{"EARLY_PHASE1":4516,"PHASE1":4518,"PHASE2":4520,"PHASE3":4531,"PHASE4":4533,"NA":4535},{"trials":4517,"activeCount":100},[],{"trials":4519,"activeCount":100},[],{"trials":4521,"activeCount":100},[4522],{"nctId":4523,"briefTitle":4524,"status":1144,"phases":4525,"primaryCompletion":4526,"completion":4526,"start":4527,"enrollment":100,"conditions":4528,"interventions":4530},"NCT04629651","Captopril Use on the Degree of Marrow Fibrosis in Bone Marrow Fibrosis\u002FMyeloproliferative Neoplasms",[89,90],"2024-10","2024-04",[4529,218],"Bone Marrow Fibrosis",[4514],{"trials":4532,"activeCount":100},[],{"trials":4534,"activeCount":100},[],{"trials":4536,"activeCount":100},[],{"intervention":4538,"totalTrials":119,"cells":4539},"graft-versus-tumor induction therapy",{"EARLY_PHASE1":4540,"PHASE1":4542,"PHASE2":4544,"PHASE3":4557,"PHASE4":4559,"NA":4561},{"trials":4541,"activeCount":100},[],{"trials":4543,"activeCount":100},[],{"trials":4545,"activeCount":100},[4546],{"nctId":4547,"briefTitle":4548,"status":144,"phases":4549,"primaryCompletion":4550,"completion":4551,"start":1552,"enrollment":4552,"conditions":4553,"interventions":4556},"NCT00006379","Non-Ablative Allo HSCT For Hematologic Malignancies or SAA",[90],"2004-01","2011-10",58,[178,29,21,181,32,182,4554,4555],"Precancerous\u002FNonmalignant Condition","Small Intestine Cancer",[165,4538,1266,163],{"trials":4558,"activeCount":100},[],{"trials":4560,"activeCount":100},[],{"trials":4562,"activeCount":100},[],{"intervention":2593,"totalTrials":119,"cells":4564},{"EARLY_PHASE1":4565,"PHASE1":4567,"PHASE2":4569,"PHASE3":4575,"PHASE4":4577,"NA":4579},{"trials":4566,"activeCount":100},[],{"trials":4568,"activeCount":100},[],{"trials":4570,"activeCount":100},[4571],{"nctId":2584,"briefTitle":2585,"status":144,"phases":4572,"primaryCompletion":2587,"completion":2588,"start":2589,"enrollment":404,"conditions":4573,"interventions":4574},[90],[26,2591],[2475,2593,2594],{"trials":4576,"activeCount":100},[],{"trials":4578,"activeCount":100},[],{"trials":4580,"activeCount":100},[],{"intervention":2594,"totalTrials":119,"cells":4582},{"EARLY_PHASE1":4583,"PHASE1":4585,"PHASE2":4587,"PHASE3":4593,"PHASE4":4595,"NA":4597},{"trials":4584,"activeCount":100},[],{"trials":4586,"activeCount":100},[],{"trials":4588,"activeCount":100},[4589],{"nctId":2584,"briefTitle":2585,"status":144,"phases":4590,"primaryCompletion":2587,"completion":2588,"start":2589,"enrollment":404,"conditions":4591,"interventions":4592},[90],[26,2591],[2475,2593,2594],{"trials":4594,"activeCount":100},[],{"trials":4596,"activeCount":100},[],{"trials":4598,"activeCount":100},[],{"intervention":2461,"totalTrials":119,"cells":4600},{"EARLY_PHASE1":4601,"PHASE1":4603,"PHASE2":4605,"PHASE3":4611,"PHASE4":4613,"NA":4615},{"trials":4602,"activeCount":100},[],{"trials":4604,"activeCount":100},[],{"trials":4606,"activeCount":100},[4607],{"nctId":2449,"briefTitle":2450,"status":1144,"phases":4608,"primaryCompletion":2452,"completion":2452,"start":2453,"enrollment":100,"conditions":4609,"interventions":4610},[89,90],[2392,2455,2456,2457,2458,2459],[1498,2461,2462],{"trials":4612,"activeCount":100},[],{"trials":4614,"activeCount":100},[],{"trials":4616,"activeCount":100},[],{"intervention":2462,"totalTrials":119,"cells":4618},{"EARLY_PHASE1":4619,"PHASE1":4621,"PHASE2":4623,"PHASE3":4629,"PHASE4":4631,"NA":4633},{"trials":4620,"activeCount":100},[],{"trials":4622,"activeCount":100},[],{"trials":4624,"activeCount":100},[4625],{"nctId":2449,"briefTitle":2450,"status":1144,"phases":4626,"primaryCompletion":2452,"completion":2452,"start":2453,"enrollment":100,"conditions":4627,"interventions":4628},[89,90],[2392,2455,2456,2457,2458,2459],[1498,2461,2462],{"trials":4630,"activeCount":100},[],{"trials":4632,"activeCount":100},[],{"trials":4634,"activeCount":100},[],{"intervention":4636,"totalTrials":119,"cells":4637},"Carboplatin AUC",{"EARLY_PHASE1":4638,"PHASE1":4640,"PHASE2":4642,"PHASE3":4652,"PHASE4":4654,"NA":4656},{"trials":4639,"activeCount":100},[],{"trials":4641,"activeCount":100},[],{"trials":4643,"activeCount":100},[4644],{"nctId":4645,"briefTitle":4646,"status":265,"phases":4647,"primaryCompletion":2122,"completion":2122,"start":4648,"enrollment":404,"conditions":4649,"interventions":4650},"NCT01395537","Lapatinib With Carboplatin and Paclitaxel in Esophagus and Gastroesophageal Junction (GEJ)",[89,90],"2011-08",[358,271],[4636,301,4651],"lapatinib",{"trials":4653,"activeCount":100},[],{"trials":4655,"activeCount":100},[],{"trials":4657,"activeCount":100},[],{"intervention":4651,"totalTrials":119,"cells":4659},{"EARLY_PHASE1":4660,"PHASE1":4662,"PHASE2":4664,"PHASE3":4670,"PHASE4":4672,"NA":4674},{"trials":4661,"activeCount":100},[],{"trials":4663,"activeCount":100},[],{"trials":4665,"activeCount":100},[4666],{"nctId":4645,"briefTitle":4646,"status":265,"phases":4667,"primaryCompletion":2122,"completion":2122,"start":4648,"enrollment":404,"conditions":4668,"interventions":4669},[89,90],[358,271],[4636,301,4651],{"trials":4671,"activeCount":100},[],{"trials":4673,"activeCount":100},[],{"trials":4675,"activeCount":100},[],{"intervention":2473,"totalTrials":119,"cells":4677},{"EARLY_PHASE1":4678,"PHASE1":4680,"PHASE2":4682,"PHASE3":4688,"PHASE4":4690,"NA":4692},{"trials":4679,"activeCount":100},[],{"trials":4681,"activeCount":100},[],{"trials":4683,"activeCount":100},[4684],{"nctId":2464,"briefTitle":2465,"status":265,"phases":4685,"primaryCompletion":2467,"completion":2468,"start":2469,"enrollment":135,"conditions":4686,"interventions":4687},[90],[2471],[1498,2473,2474,2475,2476],{"trials":4689,"activeCount":100},[],{"trials":4691,"activeCount":100},[],{"trials":4693,"activeCount":100},[],{"intervention":2476,"totalTrials":119,"cells":4695},{"EARLY_PHASE1":4696,"PHASE1":4698,"PHASE2":4700,"PHASE3":4706,"PHASE4":4708,"NA":4710},{"trials":4697,"activeCount":100},[],{"trials":4699,"activeCount":100},[],{"trials":4701,"activeCount":100},[4702],{"nctId":2464,"briefTitle":2465,"status":265,"phases":4703,"primaryCompletion":2467,"completion":2468,"start":2469,"enrollment":135,"conditions":4704,"interventions":4705},[90],[2471],[1498,2473,2474,2475,2476],{"trials":4707,"activeCount":100},[],{"trials":4709,"activeCount":100},[],{"trials":4711,"activeCount":100},[],{"intervention":4713,"totalTrials":119,"cells":4714},"recombinant interferon beta",{"EARLY_PHASE1":4715,"PHASE1":4717,"PHASE2":4719,"PHASE3":4728,"PHASE4":4730,"NA":4732},{"trials":4716,"activeCount":100},[],{"trials":4718,"activeCount":100},[],{"trials":4720,"activeCount":100},[4721],{"nctId":4722,"briefTitle":4723,"status":144,"phases":4724,"primaryCompletion":1146,"completion":1146,"start":1706,"enrollment":30,"conditions":4725,"interventions":4727},"NCT00085306","Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma",[90],[1522,4726],"Recurrent Melanoma",[4713],{"trials":4729,"activeCount":100},[],{"trials":4731,"activeCount":100},[],{"trials":4733,"activeCount":100},[],{"intervention":4735,"totalTrials":119,"cells":4736},"Liposomal Bupivacaine",{"EARLY_PHASE1":4737,"PHASE1":4739,"PHASE2":4741,"PHASE3":4754,"PHASE4":4756,"NA":4758},{"trials":4738,"activeCount":100},[],{"trials":4740,"activeCount":100},[],{"trials":4742,"activeCount":100},[4743],{"nctId":4744,"briefTitle":4745,"status":1144,"phases":4746,"primaryCompletion":4747,"completion":4747,"start":4748,"enrollment":100,"conditions":4749,"interventions":4750},"NCT03393117","Bupivacaine Versus Liposomal Bupivacaine For Breast Pain Management After Breast Recontruction",[90],"2020-07-01","2018-03-30",[15],[4735,4751,4752,4753],"Bupivacaine","Patient-Controlled Analgesia Pump","Oral Narcotic",{"trials":4755,"activeCount":100},[],{"trials":4757,"activeCount":100},[],{"trials":4759,"activeCount":100},[],{"intervention":4751,"totalTrials":119,"cells":4761},{"EARLY_PHASE1":4762,"PHASE1":4764,"PHASE2":4766,"PHASE3":4772,"PHASE4":4774,"NA":4776},{"trials":4763,"activeCount":100},[],{"trials":4765,"activeCount":100},[],{"trials":4767,"activeCount":100},[4768],{"nctId":4744,"briefTitle":4745,"status":1144,"phases":4769,"primaryCompletion":4747,"completion":4747,"start":4748,"enrollment":100,"conditions":4770,"interventions":4771},[90],[15],[4735,4751,4752,4753],{"trials":4773,"activeCount":100},[],{"trials":4775,"activeCount":100},[],{"trials":4777,"activeCount":100},[],{"intervention":4752,"totalTrials":119,"cells":4779},{"EARLY_PHASE1":4780,"PHASE1":4782,"PHASE2":4784,"PHASE3":4790,"PHASE4":4792,"NA":4794},{"trials":4781,"activeCount":100},[],{"trials":4783,"activeCount":100},[],{"trials":4785,"activeCount":100},[4786],{"nctId":4744,"briefTitle":4745,"status":1144,"phases":4787,"primaryCompletion":4747,"completion":4747,"start":4748,"enrollment":100,"conditions":4788,"interventions":4789},[90],[15],[4735,4751,4752,4753],{"trials":4791,"activeCount":100},[],{"trials":4793,"activeCount":100},[],{"trials":4795,"activeCount":100},[],{"intervention":4753,"totalTrials":119,"cells":4797},{"EARLY_PHASE1":4798,"PHASE1":4800,"PHASE2":4802,"PHASE3":4808,"PHASE4":4810,"NA":4812},{"trials":4799,"activeCount":100},[],{"trials":4801,"activeCount":100},[],{"trials":4803,"activeCount":100},[4804],{"nctId":4744,"briefTitle":4745,"status":1144,"phases":4805,"primaryCompletion":4747,"completion":4747,"start":4748,"enrollment":100,"conditions":4806,"interventions":4807},[90],[15],[4735,4751,4752,4753],{"trials":4809,"activeCount":100},[],{"trials":4811,"activeCount":100},[],{"trials":4813,"activeCount":100},[],{"intervention":2608,"totalTrials":119,"cells":4815},{"EARLY_PHASE1":4816,"PHASE1":4818,"PHASE2":4820,"PHASE3":4826,"PHASE4":4828,"NA":4830},{"trials":4817,"activeCount":100},[],{"trials":4819,"activeCount":100},[],{"trials":4821,"activeCount":100},[4822],{"nctId":2600,"briefTitle":2601,"status":144,"phases":4823,"primaryCompletion":2603,"completion":2603,"start":2604,"enrollment":890,"conditions":4824,"interventions":4825},[90],[2606],[2475,2608],{"trials":4827,"activeCount":100},[],{"trials":4829,"activeCount":100},[],{"trials":4831,"activeCount":100},[],{"intervention":1376,"totalTrials":119,"cells":4833},{"EARLY_PHASE1":4834,"PHASE1":4836,"PHASE2":4838,"PHASE3":4844,"PHASE4":4846,"NA":4848},{"trials":4835,"activeCount":100},[],{"trials":4837,"activeCount":100},[],{"trials":4839,"activeCount":100},[4840],{"nctId":1368,"briefTitle":1369,"status":144,"phases":4841,"primaryCompletion":1371,"completion":1372,"start":1252,"enrollment":1373,"conditions":4842,"interventions":4843},[90],[26],[259,1376,274],{"trials":4845,"activeCount":100},[],{"trials":4847,"activeCount":100},[],{"trials":4849,"activeCount":100},[],{"intervention":1611,"totalTrials":119,"cells":4851},{"EARLY_PHASE1":4852,"PHASE1":4854,"PHASE2":4856,"PHASE3":4862,"PHASE4":4864,"NA":4866},{"trials":4853,"activeCount":100},[],{"trials":4855,"activeCount":100},[],{"trials":4857,"activeCount":100},[4858],{"nctId":1605,"briefTitle":1606,"status":144,"phases":4859,"primaryCompletion":175,"start":1608,"enrollment":11,"conditions":4860,"interventions":4861},[90],[15],[346,1557,1611,1612],{"trials":4863,"activeCount":100},[],{"trials":4865,"activeCount":100},[],{"trials":4867,"activeCount":100},[],{"intervention":1612,"totalTrials":119,"cells":4869},{"EARLY_PHASE1":4870,"PHASE1":4872,"PHASE2":4874,"PHASE3":4880,"PHASE4":4882,"NA":4884},{"trials":4871,"activeCount":100},[],{"trials":4873,"activeCount":100},[],{"trials":4875,"activeCount":100},[4876],{"nctId":1605,"briefTitle":1606,"status":144,"phases":4877,"primaryCompletion":175,"start":1608,"enrollment":11,"conditions":4878,"interventions":4879},[90],[15],[346,1557,1611,1612],{"trials":4881,"activeCount":100},[],{"trials":4883,"activeCount":100},[],{"trials":4885,"activeCount":100},[],{"intervention":4887,"totalTrials":119,"cells":4888},"ZD1839",{"EARLY_PHASE1":4889,"PHASE1":4891,"PHASE2":4893,"PHASE3":4901,"PHASE4":4903,"NA":4905},{"trials":4890,"activeCount":100},[],{"trials":4892,"activeCount":100},[],{"trials":4894,"activeCount":100},[4895],{"nctId":4896,"briefTitle":4897,"status":144,"phases":4898,"primaryCompletion":252,"completion":4648,"start":1355,"enrollment":4552,"conditions":4899,"interventions":4900},"NCT00268346","Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer",[90],[272],[4887],{"trials":4902,"activeCount":100},[],{"trials":4904,"activeCount":100},[],{"trials":4906,"activeCount":100},[],{"intervention":4908,"totalTrials":119,"cells":4909},"Abemaciclib,",{"EARLY_PHASE1":4910,"PHASE1":4912,"PHASE2":4914,"PHASE3":4926,"PHASE4":4928,"NA":4930},{"trials":4911,"activeCount":100},[],{"trials":4913,"activeCount":100},[],{"trials":4915,"activeCount":100},[4916],{"nctId":4917,"briefTitle":4918,"status":144,"phases":4919,"primaryCompletion":4920,"completion":4920,"start":3427,"enrollment":149,"conditions":4921,"interventions":4925},"NCT04010357","Targeted Therapy With CDK4\u002F6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC",[90],"2026-04-30",[4922,4923,4924],"Small-cell Lung Cancer","Large Cell Neuroendocrine Carcinoma of the Lung","Extrapulmonary Small Cell Carcinoma",[4908],{"trials":4927,"activeCount":100},[],{"trials":4929,"activeCount":100},[],{"trials":4931,"activeCount":100},[],{"intervention":1497,"totalTrials":119,"cells":4933},{"EARLY_PHASE1":4934,"PHASE1":4936,"PHASE2":4938,"PHASE3":4944,"PHASE4":4946,"NA":4948},{"trials":4935,"activeCount":100},[],{"trials":4937,"activeCount":100},[],{"trials":4939,"activeCount":100},[4940],{"nctId":1488,"briefTitle":1489,"status":144,"phases":4941,"primaryCompletion":1491,"completion":1492,"start":1493,"enrollment":440,"conditions":4942,"interventions":4943},[90],[1495],[302,1497,1498],{"trials":4945,"activeCount":100},[],{"trials":4947,"activeCount":100},[],{"trials":4949,"activeCount":100},[],{"intervention":4951,"totalTrials":119,"cells":4952},"everolimus",{"EARLY_PHASE1":4953,"PHASE1":4955,"PHASE2":4957,"PHASE3":4966,"PHASE4":4968,"NA":4970},{"trials":4954,"activeCount":100},[],{"trials":4956,"activeCount":100},[],{"trials":4958,"activeCount":100},[4959],{"nctId":4960,"briefTitle":4961,"status":265,"phases":4962,"primaryCompletion":4963,"completion":3450,"start":1999,"enrollment":1681,"conditions":4964,"interventions":4965},"NCT00809185","RAD001(Everolimus) in Treating Patients With Myelodysplastic Syndromes",[90],"2009-02",[32],[4951],{"trials":4967,"activeCount":100},[],{"trials":4969,"activeCount":100},[],{"trials":4971,"activeCount":100},[],{"intervention":4973,"totalTrials":1406,"cells":4974},"semaxanib",{"EARLY_PHASE1":4975,"PHASE1":4977,"PHASE2":4998,"PHASE3":5000,"PHASE4":5002,"NA":5004},{"trials":4976,"activeCount":100},[],{"trials":4978,"activeCount":100},[4979,4985,4991],{"nctId":4980,"briefTitle":4981,"status":144,"phases":4982,"primaryCompletion":2834,"completion":1364,"start":1310,"enrollment":9,"conditions":4983,"interventions":4984},"NCT00005647","SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck",[89],[35],[365,4973],{"nctId":4986,"briefTitle":4987,"status":144,"phases":4988,"primaryCompletion":2834,"completion":1999,"start":1310,"enrollment":33,"conditions":4989,"interventions":4990},"NCT00005642","SU5416 in Treating Patients With Advanced Solid Tumors",[89],[24],[4973],{"nctId":4992,"briefTitle":4993,"status":144,"phases":4994,"primaryCompletion":2834,"completion":1364,"start":1533,"enrollment":30,"conditions":4995,"interventions":4996},"NCT00005822","SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV Inflammatory Breast Cancer",[89],[15],[1267,4973,4997],"tamoxifen",{"trials":4999,"activeCount":100},[],{"trials":5001,"activeCount":100},[],{"trials":5003,"activeCount":100},[],{"trials":5005,"activeCount":100},[],{"intervention":5007,"totalTrials":96,"cells":5008},"methoxyamine",{"EARLY_PHASE1":5009,"PHASE1":5011,"PHASE2":5026,"PHASE3":5028,"PHASE4":5030,"NA":5032},{"trials":5010,"activeCount":100},[],{"trials":5012,"activeCount":100},[5013,5022],{"nctId":5014,"briefTitle":5015,"status":144,"phases":5016,"primaryCompletion":292,"completion":5017,"start":281,"enrollment":129,"conditions":5018,"interventions":5019},"NCT01658319","Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies",[89],"2015-05",[1787,1889,1890,1807,1809,1896,1897,1812,2232,1817,1818,1819,1820,1821,1900,1822,1823,1902,1831,1832,1833,1834,1835,1836,1837,816,817,1763,1838,1903,1842,818,1904,2309],[163,5007,5020,5021],"western blotting","DNA analysis",{"nctId":874,"briefTitle":875,"status":144,"phases":5023,"primaryCompletion":877,"completion":877,"start":878,"enrollment":879,"conditions":5024,"interventions":5025},[89],[24],[882,850],{"trials":5027,"activeCount":100},[],{"trials":5029,"activeCount":100},[],{"trials":5031,"activeCount":100},[],{"trials":5033,"activeCount":100},[],{"intervention":5035,"totalTrials":96,"cells":5036},"silicon phthalocyanine 4",{"EARLY_PHASE1":5037,"PHASE1":5039,"PHASE2":5058,"PHASE3":5060,"PHASE4":5062,"NA":5064},{"trials":5038,"activeCount":100},[],{"trials":5040,"activeCount":100},[5041,5050],{"nctId":5042,"briefTitle":5043,"status":144,"phases":5044,"primaryCompletion":5045,"completion":1291,"start":1927,"enrollment":1336,"conditions":5046,"interventions":5049},"NCT00103246","Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides",[89],"2008-12",[21,5047,5048],"Non-melanomatous Skin Cancer","Precancerous Condition",[5035],{"nctId":5051,"briefTitle":5052,"status":265,"phases":5053,"primaryCompletion":1290,"completion":1705,"start":4184,"enrollment":1406,"conditions":5054,"interventions":5057},"NCT00023790","Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin",[89],[15,35,21,5055,5047,5056],"Metastatic Cancer","Sarcoma",[5035],{"trials":5059,"activeCount":100},[],{"trials":5061,"activeCount":100},[],{"trials":5063,"activeCount":100},[],{"trials":5065,"activeCount":100},[],{"intervention":2570,"totalTrials":119,"cells":5067},{"EARLY_PHASE1":5068,"PHASE1":5070,"PHASE2":5076,"PHASE3":5078,"PHASE4":5080,"NA":5082},{"trials":5069,"activeCount":100},[],{"trials":5071,"activeCount":100},[5072],{"nctId":2559,"briefTitle":2560,"status":1144,"phases":5073,"primaryCompletion":2562,"completion":2563,"start":2564,"enrollment":100,"conditions":5074,"interventions":5075},[89],[2566,2567,2568],[2570,2475],{"trials":5077,"activeCount":100},[],{"trials":5079,"activeCount":100},[],{"trials":5081,"activeCount":100},[],{"trials":5083,"activeCount":100},[],{"intervention":5085,"totalTrials":119,"cells":5086},"X-ACT",{"EARLY_PHASE1":5087,"PHASE1":5089,"PHASE2":5100,"PHASE3":5102,"PHASE4":5104,"NA":5106},{"trials":5088,"activeCount":100},[],{"trials":5090,"activeCount":100},[5091],{"nctId":5092,"briefTitle":5093,"status":265,"phases":5094,"primaryCompletion":5095,"completion":5095,"start":5096,"enrollment":1406,"conditions":5097,"interventions":5099},"NCT02327390","Ex Vivo-Activated Lymph Node Lymphocytes in Treating Patients With Stage IIIC-IV Melanoma",[89],"2016-07-18","2015-03-17",[5098,1522],"Stage IIIC Skin Melanoma",[5085],{"trials":5101,"activeCount":100},[],{"trials":5103,"activeCount":100},[],{"trials":5105,"activeCount":100},[],{"trials":5107,"activeCount":100},[],{"intervention":5020,"totalTrials":119,"cells":5109},{"EARLY_PHASE1":5110,"PHASE1":5112,"PHASE2":5118,"PHASE3":5120,"PHASE4":5122,"NA":5124},{"trials":5111,"activeCount":100},[],{"trials":5113,"activeCount":100},[5114],{"nctId":5014,"briefTitle":5015,"status":144,"phases":5115,"primaryCompletion":292,"completion":5017,"start":281,"enrollment":129,"conditions":5116,"interventions":5117},[89],[1787,1889,1890,1807,1809,1896,1897,1812,2232,1817,1818,1819,1820,1821,1900,1822,1823,1902,1831,1832,1833,1834,1835,1836,1837,816,817,1763,1838,1903,1842,818,1904,2309],[163,5007,5020,5021],{"trials":5119,"activeCount":100},[],{"trials":5121,"activeCount":100},[],{"trials":5123,"activeCount":100},[],{"trials":5125,"activeCount":100},[],{"intervention":3453,"totalTrials":119,"cells":5127},{"EARLY_PHASE1":5128,"PHASE1":5130,"PHASE2":5136,"PHASE3":5138,"PHASE4":5140,"NA":5142},{"trials":5129,"activeCount":100},[],{"trials":5131,"activeCount":100},[5132],{"nctId":3447,"briefTitle":3448,"status":265,"phases":5133,"primaryCompletion":1519,"completion":267,"start":3450,"enrollment":1406,"conditions":5134,"interventions":5135},[89],[1160],[3453,3440],{"trials":5137,"activeCount":100},[],{"trials":5139,"activeCount":100},[],{"trials":5141,"activeCount":100},[],{"trials":5143,"activeCount":100},[],{"intervention":2503,"totalTrials":119,"cells":5145},{"EARLY_PHASE1":5146,"PHASE1":5148,"PHASE2":5154,"PHASE3":5156,"PHASE4":5158,"NA":5160},{"trials":5147,"activeCount":100},[],{"trials":5149,"activeCount":100},[5150],{"nctId":2494,"briefTitle":2495,"status":265,"phases":5151,"primaryCompletion":2497,"completion":2498,"start":2499,"enrollment":1091,"conditions":5152,"interventions":5153},[89],[2501,2204,2207,2208,2209,2210,2211,2212,2213,2214,2215,2216,2217,2218,1807,1809,1812,2219,2220,2221,2222,2223,2224,2225,2226,2227,2228,2229,2230,1817,1818,1819,1820,1821,1822,1823,1832,1833,1834,1835,1836,816,1842,2235,2236,2237,2238,2240,2241,2249,2250,2251,2252,2253,2254,2267,2268,2269,2270,2272,2273,2281,2282,2283,2284,2285,819,2288,2289,2290,2291,2293,2294,2302,2303,2304,2305,2306,821,1848],[1258,1556,1340,2503,2165],{"trials":5155,"activeCount":100},[],{"trials":5157,"activeCount":100},[],{"trials":5159,"activeCount":100},[],{"trials":5161,"activeCount":100},[],{"intervention":1525,"totalTrials":119,"cells":5163},{"EARLY_PHASE1":5164,"PHASE1":5166,"PHASE2":5172,"PHASE3":5174,"PHASE4":5176,"NA":5178},{"trials":5165,"activeCount":100},[],{"trials":5167,"activeCount":100},[5168],{"nctId":1516,"briefTitle":1517,"status":144,"phases":5169,"primaryCompletion":1519,"completion":1520,"start":174,"enrollment":243,"conditions":5170,"interventions":5171},[89],[1522],[1524,346,1525,1526,1527],{"trials":5173,"activeCount":100},[],{"trials":5175,"activeCount":100},[],{"trials":5177,"activeCount":100},[],{"trials":5179,"activeCount":100},[],{"intervention":1527,"totalTrials":119,"cells":5181},{"EARLY_PHASE1":5182,"PHASE1":5184,"PHASE2":5190,"PHASE3":5192,"PHASE4":5194,"NA":5196},{"trials":5183,"activeCount":100},[],{"trials":5185,"activeCount":100},[5186],{"nctId":1516,"briefTitle":1517,"status":144,"phases":5187,"primaryCompletion":1519,"completion":1520,"start":174,"enrollment":243,"conditions":5188,"interventions":5189},[89],[1522],[1524,346,1525,1526,1527],{"trials":5191,"activeCount":100},[],{"trials":5193,"activeCount":100},[],{"trials":5195,"activeCount":100},[],{"trials":5197,"activeCount":100},[],{"intervention":5199,"totalTrials":119,"cells":5200},"BMS-214662",{"EARLY_PHASE1":5201,"PHASE1":5203,"PHASE2":5212,"PHASE3":5214,"PHASE4":5216,"NA":5218},{"trials":5202,"activeCount":100},[],{"trials":5204,"activeCount":100},[5205],{"nctId":5206,"briefTitle":5207,"status":144,"phases":5208,"primaryCompletion":5209,"completion":1418,"start":914,"enrollment":1091,"conditions":5210,"interventions":5211},"NCT00006018","Paclitaxel and BMS-214662 in Treating Patients With Advanced Solid Tumors",[89],"2001-12",[24],[5199,365],{"trials":5213,"activeCount":100},[],{"trials":5215,"activeCount":100},[],{"trials":5217,"activeCount":100},[],{"trials":5219,"activeCount":100},[],{"intervention":5221,"totalTrials":119,"cells":5222},"CC-4047",{"EARLY_PHASE1":5223,"PHASE1":5225,"PHASE2":5233,"PHASE3":5235,"PHASE4":5237,"NA":5239},{"trials":5224,"activeCount":100},[],{"trials":5226,"activeCount":100},[5227],{"nctId":5228,"briefTitle":5229,"status":144,"phases":5230,"primaryCompletion":1937,"completion":4305,"start":1460,"enrollment":1462,"conditions":5231,"interventions":5232},"NCT00482521","CC-4047 in Treating Patients With Advanced Solid Tumors That Did Not Respond to Treatment",[89],[24],[5221],{"trials":5234,"activeCount":100},[],{"trials":5236,"activeCount":100},[],{"trials":5238,"activeCount":100},[],{"trials":5240,"activeCount":100},[],{"intervention":2747,"totalTrials":119,"cells":5242},{"EARLY_PHASE1":5243,"PHASE1":5245,"PHASE2":5251,"PHASE3":5253,"PHASE4":5255,"NA":5257},{"trials":5244,"activeCount":100},[],{"trials":5246,"activeCount":100},[5247],{"nctId":2739,"briefTitle":2740,"status":144,"phases":5248,"primaryCompletion":2742,"completion":2743,"start":2744,"enrollment":440,"conditions":5249,"interventions":5250},[89],[1816,406],[2747,2748,1557,2330],{"trials":5252,"activeCount":100},[],{"trials":5254,"activeCount":100},[],{"trials":5256,"activeCount":100},[],{"trials":5258,"activeCount":100},[],{"intervention":1536,"totalTrials":119,"cells":5260},{"EARLY_PHASE1":5261,"PHASE1":5263,"PHASE2":5269,"PHASE3":5271,"PHASE4":5273,"NA":5275},{"trials":5262,"activeCount":100},[],{"trials":5264,"activeCount":100},[5265],{"nctId":1529,"briefTitle":238,"status":144,"phases":5266,"primaryCompletion":1531,"completion":1532,"start":1533,"enrollment":30,"conditions":5267,"interventions":5268},[89],[24],[346,1536,365],{"trials":5270,"activeCount":100},[],{"trials":5272,"activeCount":100},[],{"trials":5274,"activeCount":100},[],{"trials":5276,"activeCount":100},[],{"intervention":5278,"totalTrials":119,"cells":5279},"Dietary Vitamin D3 pre-treatment",{"EARLY_PHASE1":5280,"PHASE1":5282,"PHASE2":5294,"PHASE3":5296,"PHASE4":5298,"NA":5300},{"trials":5281,"activeCount":100},[],{"trials":5283,"activeCount":100},[5284],{"nctId":5285,"briefTitle":5286,"status":144,"phases":5287,"primaryCompletion":5288,"completion":5288,"start":5289,"enrollment":1553,"conditions":5290,"interventions":5292},"NCT03467789","Vitamin D as a Nutritional Neoadjuvant During Photodynamic Therapy of Basal Cell Carcinoma",[89],"2023-01-06","2018-10-01",[751,5291],"Basal Cell Nevus Syndrome",[5278,5293],"Serum Maintenance Vitamin D3",{"trials":5295,"activeCount":100},[],{"trials":5297,"activeCount":100},[],{"trials":5299,"activeCount":100},[],{"trials":5301,"activeCount":100},[],{"intervention":5293,"totalTrials":119,"cells":5303},{"EARLY_PHASE1":5304,"PHASE1":5306,"PHASE2":5312,"PHASE3":5314,"PHASE4":5316,"NA":5318},{"trials":5305,"activeCount":100},[],{"trials":5307,"activeCount":100},[5308],{"nctId":5285,"briefTitle":5286,"status":144,"phases":5309,"primaryCompletion":5288,"completion":5288,"start":5289,"enrollment":1553,"conditions":5310,"interventions":5311},[89],[751,5291],[5278,5293],{"trials":5313,"activeCount":100},[],{"trials":5315,"activeCount":100},[],{"trials":5317,"activeCount":100},[],{"trials":5319,"activeCount":100},[],{"intervention":2701,"totalTrials":119,"cells":5321},{"EARLY_PHASE1":5322,"PHASE1":5324,"PHASE2":5330,"PHASE3":5332,"PHASE4":5334,"NA":5336},{"trials":5323,"activeCount":100},[],{"trials":5325,"activeCount":100},[5326],{"nctId":2693,"briefTitle":2694,"status":144,"phases":5327,"primaryCompletion":914,"completion":2696,"start":2697,"enrollment":2698,"conditions":5328,"interventions":5329},[89],[24],[897,898,2701],{"trials":5331,"activeCount":100},[],{"trials":5333,"activeCount":100},[],{"trials":5335,"activeCount":100},[],{"trials":5337,"activeCount":100},[],{"intervention":896,"totalTrials":119,"cells":5339},{"EARLY_PHASE1":5340,"PHASE1":5342,"PHASE2":5348,"PHASE3":5350,"PHASE4":5352,"NA":5354},{"trials":5341,"activeCount":100},[],{"trials":5343,"activeCount":100},[5344],{"nctId":884,"briefTitle":885,"status":265,"phases":5345,"primaryCompletion":887,"completion":888,"start":889,"enrollment":890,"conditions":5346,"interventions":5347},[89],[892,21,24],[894,895,896,897,898,899],{"trials":5349,"activeCount":100},[],{"trials":5351,"activeCount":100},[],{"trials":5353,"activeCount":100},[],{"trials":5355,"activeCount":100},[],{"intervention":823,"totalTrials":119,"cells":5357},{"EARLY_PHASE1":5358,"PHASE1":5360,"PHASE2":5366,"PHASE3":5368,"PHASE4":5370,"NA":5372},{"trials":5359,"activeCount":100},[],{"trials":5361,"activeCount":100},[5362],{"nctId":809,"briefTitle":810,"status":265,"phases":5363,"primaryCompletion":812,"completion":813,"start":814,"enrollment":269,"conditions":5364,"interventions":5365},[89],[816,817,818,819,820,821],[823,201],{"trials":5367,"activeCount":100},[],{"trials":5369,"activeCount":100},[],{"trials":5371,"activeCount":100},[],{"trials":5373,"activeCount":100},[],{"intervention":2518,"totalTrials":119,"cells":5375},{"EARLY_PHASE1":5376,"PHASE1":5378,"PHASE2":5384,"PHASE3":5386,"PHASE4":5388,"NA":5390},{"trials":5377,"activeCount":100},[],{"trials":5379,"activeCount":100},[5380],{"nctId":2509,"briefTitle":2510,"status":265,"phases":5381,"primaryCompletion":2512,"completion":2513,"start":280,"enrollment":1406,"conditions":5382,"interventions":5383},[89],[2515,2516],[1258,2518,2165],{"trials":5385,"activeCount":100},[],{"trials":5387,"activeCount":100},[],{"trials":5389,"activeCount":100},[],{"trials":5391,"activeCount":100},[],{"intervention":5393,"totalTrials":119,"cells":5394},"Osimertinib",{"EARLY_PHASE1":5395,"PHASE1":5397,"PHASE2":5408,"PHASE3":5410,"PHASE4":5412,"NA":5414},{"trials":5396,"activeCount":100},[],{"trials":5398,"activeCount":100},[5399],{"nctId":5400,"briefTitle":5401,"status":144,"phases":5402,"primaryCompletion":5403,"completion":5403,"start":5404,"enrollment":851,"conditions":5405,"interventions":5407},"NCT03535363","Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLC",[89],"2022-04-01","2018-10-26",[5406,2591],"NSCLC",[5393],{"trials":5409,"activeCount":100},[],{"trials":5411,"activeCount":100},[],{"trials":5413,"activeCount":100},[],{"trials":5415,"activeCount":100},[],{"intervention":4997,"totalTrials":119,"cells":5417},{"EARLY_PHASE1":5418,"PHASE1":5420,"PHASE2":5426,"PHASE3":5428,"PHASE4":5430,"NA":5432},{"trials":5419,"activeCount":100},[],{"trials":5421,"activeCount":100},[5422],{"nctId":4992,"briefTitle":4993,"status":144,"phases":5423,"primaryCompletion":2834,"completion":1364,"start":1533,"enrollment":30,"conditions":5424,"interventions":5425},[89],[15],[1267,4973,4997],{"trials":5427,"activeCount":100},[],{"trials":5429,"activeCount":100},[],{"trials":5431,"activeCount":100},[],{"trials":5433,"activeCount":100},[],{"intervention":275,"totalTrials":119,"cells":5435},{"EARLY_PHASE1":5436,"PHASE1":5438,"PHASE2":5444,"PHASE3":5446,"PHASE4":5448,"NA":5450},{"trials":5437,"activeCount":100},[],{"trials":5439,"activeCount":100},[5440],{"nctId":263,"briefTitle":264,"status":265,"phases":5441,"primaryCompletion":267,"start":268,"enrollment":269,"conditions":5442,"interventions":5443},[89],[271,272],[274,229,275],{"trials":5445,"activeCount":100},[],{"trials":5447,"activeCount":100},[],{"trials":5449,"activeCount":100},[],{"trials":5451,"activeCount":100},[],{"intervention":5453,"totalTrials":119,"cells":5454},"HER-2\u002Fneu peptide vaccine",{"EARLY_PHASE1":5455,"PHASE1":5457,"PHASE2":5465,"PHASE3":5467,"PHASE4":5469,"NA":5471},{"trials":5456,"activeCount":100},[],{"trials":5458,"activeCount":100},[5459],{"nctId":5460,"briefTitle":5461,"status":144,"phases":5462,"primaryCompletion":1355,"start":3305,"conditions":5463,"interventions":5464},"NCT00068614","HER-2 Protein Vaccine in Treating Women With Breast Cancer",[89],[15],[5453],{"trials":5466,"activeCount":100},[],{"trials":5468,"activeCount":100},[],{"trials":5470,"activeCount":100},[],{"trials":5472,"activeCount":100},[],{"intervention":5474,"totalTrials":119,"cells":5475},"graft versus host disease prophylaxis\u002Ftherapy",{"EARLY_PHASE1":5476,"PHASE1":5478,"PHASE2":5486,"PHASE3":5488,"PHASE4":5490,"NA":5492},{"trials":5477,"activeCount":100},[],{"trials":5479,"activeCount":100},[5480],{"nctId":5481,"briefTitle":5482,"status":144,"phases":5483,"primaryCompletion":2336,"completion":2512,"start":1927,"enrollment":1293,"conditions":5484,"interventions":5485},"NCT00361049","Donor Mesenchymal Stem Cell Infusion in Treating Patients With Acute or Chronic Graft-Versus-Host Disease After Undergoing a Donor Stem Cell Transplant",[89],[1281],[5474,1339],{"trials":5487,"activeCount":100},[],{"trials":5489,"activeCount":100},[],{"trials":5491,"activeCount":100},[],{"trials":5493,"activeCount":100},[],{"intervention":5495,"totalTrials":119,"cells":5496},"Cesium 131",{"EARLY_PHASE1":5497,"PHASE1":5507,"PHASE2":5509,"PHASE3":5511,"PHASE4":5513,"NA":5515},{"trials":5498,"activeCount":100},[5499],{"nctId":5500,"briefTitle":5501,"status":144,"phases":5502,"primaryCompletion":5503,"completion":5503,"start":5504,"enrollment":36,"conditions":5505,"interventions":5506},"NCT02794675","Intraoperative Placement of Cesium-131 Permanent Interstitial Brachytherapy in Head and Neck Cancer",[88],"2020-07-24","2016-12-21",[35,2568],[5495],{"trials":5508,"activeCount":100},[],{"trials":5510,"activeCount":100},[],{"trials":5512,"activeCount":100},[],{"trials":5514,"activeCount":100},[],{"trials":5516,"activeCount":100},[],{"intervention":1411,"totalTrials":119,"cells":5518},{"EARLY_PHASE1":5519,"PHASE1":5525,"PHASE2":5527,"PHASE3":5529,"PHASE4":5531,"NA":5533},{"trials":5520,"activeCount":100},[5521],{"nctId":1400,"briefTitle":1401,"status":265,"phases":5522,"primaryCompletion":1403,"completion":1404,"start":1405,"enrollment":1406,"conditions":5523,"interventions":5524},[88],[1408,1409],[302,1411],{"trials":5526,"activeCount":100},[],{"trials":5528,"activeCount":100},[],{"trials":5530,"activeCount":100},[],{"trials":5532,"activeCount":100},[],{"trials":5534,"activeCount":100},[],{"intervention":5536,"totalTrials":119,"cells":5537},"Aspirin",{"EARLY_PHASE1":5538,"PHASE1":5550,"PHASE2":5552,"PHASE3":5554,"PHASE4":5556,"NA":5558},{"trials":5539,"activeCount":100},[5540],{"nctId":5541,"briefTitle":5542,"status":144,"phases":5543,"primaryCompletion":5544,"completion":5289,"start":5545,"enrollment":254,"conditions":5546,"interventions":5548},"NCT02285738","Anti-Platelet and Statin Therapy to Prevent Cancer-Associated Thrombosis",[88],"2017-07-17","2014-12-30",[5547,1281],"Solid Tumor",[5536,5549],"Simvastatin",{"trials":5551,"activeCount":100},[],{"trials":5553,"activeCount":100},[],{"trials":5555,"activeCount":100},[],{"trials":5557,"activeCount":100},[],{"trials":5559,"activeCount":100},[],{"intervention":5549,"totalTrials":119,"cells":5561},{"EARLY_PHASE1":5562,"PHASE1":5568,"PHASE2":5570,"PHASE3":5572,"PHASE4":5574,"NA":5576},{"trials":5563,"activeCount":100},[5564],{"nctId":5541,"briefTitle":5542,"status":144,"phases":5565,"primaryCompletion":5544,"completion":5289,"start":5545,"enrollment":254,"conditions":5566,"interventions":5567},[88],[5547,1281],[5536,5549],{"trials":5569,"activeCount":100},[],{"trials":5571,"activeCount":100},[],{"trials":5573,"activeCount":100},[],{"trials":5575,"activeCount":100},[],{"trials":5577,"activeCount":100},[],{"intervention":3416,"totalTrials":119,"cells":5579},{"EARLY_PHASE1":5580,"PHASE1":5586,"PHASE2":5588,"PHASE3":5590,"PHASE4":5592,"NA":5594},{"trials":5581,"activeCount":100},[5582],{"nctId":3409,"briefTitle":3410,"status":144,"phases":5583,"primaryCompletion":370,"completion":370,"start":1519,"enrollment":1279,"conditions":5584,"interventions":5585},[88],[3413,3414],[3416,3404,3404,3417],{"trials":5587,"activeCount":100},[],{"trials":5589,"activeCount":100},[],{"trials":5591,"activeCount":100},[],{"trials":5593,"activeCount":100},[],{"trials":5595,"activeCount":100},[],{"intervention":3417,"totalTrials":119,"cells":5597},{"EARLY_PHASE1":5598,"PHASE1":5604,"PHASE2":5606,"PHASE3":5608,"PHASE4":5610,"NA":5612},{"trials":5599,"activeCount":100},[5600],{"nctId":3409,"briefTitle":3410,"status":144,"phases":5601,"primaryCompletion":370,"completion":370,"start":1519,"enrollment":1279,"conditions":5602,"interventions":5603},[88],[3413,3414],[3416,3404,3404,3417],{"trials":5605,"activeCount":100},[],{"trials":5607,"activeCount":100},[],{"trials":5609,"activeCount":100},[],{"trials":5611,"activeCount":100},[],{"trials":5613,"activeCount":100},[],{"intervention":5615,"totalTrials":119,"cells":5616},"Nexavar",{"EARLY_PHASE1":5617,"PHASE1":5626,"PHASE2":5628,"PHASE3":5630,"PHASE4":5632,"NA":5634},{"trials":5618,"activeCount":100},[5619],{"nctId":5620,"briefTitle":5621,"status":265,"phases":5622,"primaryCompletion":281,"completion":1520,"start":1937,"enrollment":96,"conditions":5623,"interventions":5625},"NCT01337492","Pilot Study Sorafenib as Bridge to Orthotopic Liver Transplantation (OLT)",[88],[5624],"Carcinoma, Hepatocellular",[5615],{"trials":5627,"activeCount":100},[],{"trials":5629,"activeCount":100},[],{"trials":5631,"activeCount":100},[],{"trials":5633,"activeCount":100},[],{"trials":5635,"activeCount":100},[],{"intervention":5637,"totalTrials":119,"cells":5638},"Nicotine Replacement Therapy",{"EARLY_PHASE1":5639,"PHASE1":5651,"PHASE2":5653,"PHASE3":5655,"PHASE4":5657,"NA":5659},{"trials":5640,"activeCount":100},[5641],{"nctId":5642,"briefTitle":5643,"status":144,"phases":5644,"primaryCompletion":5645,"completion":5646,"start":5647,"enrollment":16,"conditions":5648,"interventions":5650},"NCT03290430","End Nicotine Dependence Clinic",[88],"2019-12-06","2020-01-06","2018-01-09",[5649],"Smoking Cessation",[5637],{"trials":5652,"activeCount":100},[],{"trials":5654,"activeCount":100},[],{"trials":5656,"activeCount":100},[],{"trials":5658,"activeCount":100},[],{"trials":5660,"activeCount":100},[],{"intervention":5662,"totalTrials":119,"cells":5663},"DKK1",{"EARLY_PHASE1":5664,"PHASE1":5677,"PHASE2":5679,"PHASE3":5681,"PHASE4":5683,"NA":5685},{"trials":5665,"activeCount":100},[5666],{"nctId":5667,"briefTitle":5668,"status":1144,"phases":5669,"primaryCompletion":5670,"completion":1592,"start":5671,"enrollment":100,"conditions":5672,"interventions":5676},"NCT03591614","Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma",[88],"2024-08-01","2023-12-01",[5673,5674,5675],"Monoclonal Gammopathy","Smoldering Myeloma","Myeloma",[5662],{"trials":5678,"activeCount":100},[],{"trials":5680,"activeCount":100},[],{"trials":5682,"activeCount":100},[],{"trials":5684,"activeCount":100},[],{"trials":5686,"activeCount":100},[],{"intervention":5688,"totalTrials":119,"cells":5689},"Fluvastatin",{"EARLY_PHASE1":5690,"PHASE1":5700,"PHASE2":5702,"PHASE3":5704,"PHASE4":5706,"NA":5708},{"trials":5691,"activeCount":100},[5692],{"nctId":5693,"briefTitle":5694,"status":1144,"phases":5695,"primaryCompletion":5696,"completion":5696,"start":5697,"enrollment":100,"conditions":5698,"interventions":5699},"NCT04285749","Prevention of Recurrence and Metastasis in Genetically High-Risk Melanomas",[88],"2021-04-01","2020-11-06",[2459],[5688],{"trials":5701,"activeCount":100},[],{"trials":5703,"activeCount":100},[],{"trials":5705,"activeCount":100},[],{"trials":5707,"activeCount":100},[],{"trials":5709,"activeCount":100},[],{"intervention":5711,"totalTrials":119,"cells":5712},"18F-fluciclovine",{"EARLY_PHASE1":5713,"PHASE1":5723,"PHASE2":5725,"PHASE3":5727,"PHASE4":5729,"NA":5731},{"trials":5714,"activeCount":100},[5715],{"nctId":5716,"briefTitle":5717,"status":144,"phases":5718,"primaryCompletion":5719,"completion":5719,"start":2587,"enrollment":749,"conditions":5720,"interventions":5722},"NCT03930173","18F-Fluciclovine PET to Distinguish Tumor Progression From Radiation Necrosis",[88],"2021-03-01",[5721],"Secondary Malignant Neoplasm of Brain and Cerebral Meninges",[5711],{"trials":5724,"activeCount":100},[],{"trials":5726,"activeCount":100},[],{"trials":5728,"activeCount":100},[],{"trials":5730,"activeCount":100},[],{"trials":5732,"activeCount":100},[],{"intervention":1266,"totalTrials":1279,"cells":5734},{"EARLY_PHASE1":5735,"PHASE1":5745,"PHASE2":5758,"PHASE3":5841,"PHASE4":5843,"NA":5845},{"trials":5736,"activeCount":100},[5737,5741],{"nctId":1740,"briefTitle":1741,"status":144,"phases":5738,"primaryCompletion":1743,"completion":1744,"start":1745,"enrollment":851,"conditions":5739,"interventions":5740},[88],[216,470,32,160,1747,1748,155,1749,1750,817,1751,215],[1266,163,1753,1735],{"nctId":2197,"briefTitle":2198,"status":144,"phases":5742,"primaryCompletion":2200,"completion":2201,"start":2202,"enrollment":1255,"conditions":5743,"interventions":5744},[88],[2204,1787,1889,1890,2205,1801,2206,1802,1804,2207,2208,2209,2210,2211,2212,2213,2214,2215,2216,2217,2218,1807,1809,1896,1897,1812,2219,2220,2221,2222,2223,2224,2225,2226,2227,2228,2229,2230,2231,2232,1817,1818,1819,1820,1821,1900,1822,1823,1902,1826,1827,1828,1829,1830,1831,1832,1833,1834,1835,1836,1837,816,2233,2234,1903,1842,2235,2236,2237,2238,2239,2240,2241,2242,2243,2244,2245,2246,2247,2248,2249,2250,2251,2252,2253,2254,2255,2256,2257,2258,2259,2260,2261,2262,2263,2264,2265,2266,2267,2268,2269,2270,2271,2272,2273,2274,2275,2276,2277,2278,2279,2280,2281,2282,2283,2284,2285,819,2286,2287,2288,2289,2290,2291,2292,2293,2294,2295,2296,2297,2298,2299,2300,2301,2302,2303,2304,2305,2306,821,2307,2308,1847,1904,2309],[164,1557,1266],{"trials":5746,"activeCount":100},[5747,5754],{"nctId":5748,"briefTitle":5749,"status":144,"phases":5750,"primaryCompletion":2497,"completion":2497,"start":845,"enrollment":5751,"conditions":5752,"interventions":5753},"NCT00054236","Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia",[89],55,[178,29,21,181,32,182],[165,894,1266,163,188],{"nctId":1260,"briefTitle":1261,"status":1144,"phases":5755,"primaryCompletion":1263,"completion":1263,"start":913,"enrollment":100,"conditions":5756,"interventions":5757},[89],[15],[1266,274,1267],{"trials":5759,"activeCount":100},[5760,5764,5768,5772,5776,5780,5784,5788,5792,5796,5800,5804,5813,5817,5821,5825,5829,5833,5837],{"nctId":1287,"briefTitle":1288,"status":144,"phases":5761,"primaryCompletion":1290,"completion":1291,"start":1292,"enrollment":1293,"conditions":5762,"interventions":5763},[90],[15],[258,1266,274,1267],{"nctId":3071,"briefTitle":3072,"status":144,"phases":5765,"primaryCompletion":3074,"completion":3075,"start":3076,"enrollment":512,"conditions":5766,"interventions":5767},[89,90],[2208,2220,2236,2268,2289],[3079,3080,3081,3082,3083,3084,3085,3086],{"nctId":1549,"briefTitle":1550,"status":144,"phases":5769,"primaryCompletion":253,"start":1552,"enrollment":1553,"conditions":5770,"interventions":5771},[90],[21],[894,1556,898,346,1266,1557],{"nctId":1873,"briefTitle":1874,"status":144,"phases":5773,"primaryCompletion":1876,"completion":1543,"start":1877,"enrollment":404,"conditions":5774,"interventions":5775},[90],[1879,1778,1779,1781,1782,1880,1881,1783,1784,1882,1883,1884,1885,1886,1887,1888,1786,1787,1788,1889,1890,1792,1793,1794,1795,1797,1798,1891,1892,1799,1893,1894,1800,1803,1806,1807,1895,1809,1896,1897,1812,1898,1899,1813,1815,1816,1817,1818,1819,1820,1821,1900,1822,1823,1901,1902,1824,1825,1831,1832,1833,1834,1835,1836,1837,816,1763,1838,1840,1903,1842,1904,1848],[164,1266,188,166,1753],{"nctId":2324,"briefTitle":2325,"status":144,"phases":5777,"primaryCompletion":2022,"completion":2022,"start":2327,"enrollment":176,"conditions":5778,"interventions":5779},[90],[29,21,32,182],[164,1266,2330,2331],{"nctId":2821,"briefTitle":2822,"status":144,"phases":5781,"primaryCompletion":1355,"completion":2824,"start":2825,"enrollment":2826,"conditions":5782,"interventions":5783},[90],[21],[894,1266,1557,2812,2829],{"nctId":2831,"briefTitle":2832,"status":265,"phases":5785,"primaryCompletion":2834,"completion":2834,"start":2835,"enrollment":851,"conditions":5786,"interventions":5787},[90],[21],[894,1266,1557,2812,2829],{"nctId":1307,"briefTitle":1308,"status":1144,"phases":5789,"start":1310,"enrollment":100,"conditions":5790,"interventions":5791},[90],[15],[1313,1266,274,1267,163],{"nctId":1315,"briefTitle":1316,"status":144,"phases":5793,"primaryCompletion":1318,"completion":1319,"start":1320,"enrollment":1012,"conditions":5794,"interventions":5795},[90],[1322,1323,1324,1325],[1245,1327,274,364,1328,1266,365,1329],{"nctId":2333,"briefTitle":2334,"status":144,"phases":5797,"primaryCompletion":282,"completion":2336,"start":1608,"enrollment":879,"conditions":5798,"interventions":5799},[90],[29,21,181,32,182],[894,164,1266,1753],{"nctId":1772,"briefTitle":1773,"status":144,"phases":5801,"primaryCompletion":291,"completion":291,"start":1775,"enrollment":149,"conditions":5802,"interventions":5803},[90],[1777,1778,1779,1780,1781,1782,1783,1784,1785,1786,1787,1788,1789,1790,1791,1792,1793,1794,1795,1796,1797,1798,1799,1800,1801,1802,1803,1804,1805,1806,1807,1808,1809,1810,1811,1812,1813,1814,1815,1816,1817,1818,1819,1820,1821,1822,1823,1824,1825,1826,1827,1828,1829,1830,1831,1832,1833,1834,1835,1836,1837,816,817,1838,1839,1840,1841,1842,1843,1844,818,820,1845,1846,1847,1848],[164,1266,165,188,1753,1735],{"nctId":5805,"briefTitle":5806,"status":144,"phases":5807,"primaryCompletion":241,"completion":282,"start":5808,"enrollment":269,"conditions":5809,"interventions":5810},"NCT00055640","Molecular Risk Assessment in Planning Treatment for Patients With Non-Hodgkin's Lymphoma",[90],"2002-10",[21],[1556,1266,1267,5811,5812,4313],"prednisone","vincristine sulfate",{"nctId":4547,"briefTitle":4548,"status":144,"phases":5814,"primaryCompletion":4550,"completion":4551,"start":1552,"enrollment":4552,"conditions":5815,"interventions":5816},[90],[178,29,21,181,32,182,4554,4555],[165,4538,1266,163],{"nctId":2344,"briefTitle":2345,"status":144,"phases":5818,"primaryCompletion":2347,"completion":2347,"start":2348,"enrollment":2349,"conditions":5819,"interventions":5820},[90],[181],[164,1266],{"nctId":2353,"briefTitle":2354,"status":144,"phases":5822,"primaryCompletion":1290,"completion":1705,"start":2356,"enrollment":851,"conditions":5823,"interventions":5824},[90],[29,32,182],[165,164,1266,2359,188],{"nctId":3216,"briefTitle":3217,"status":1144,"phases":5826,"primaryCompletion":1626,"start":2201,"enrollment":100,"conditions":5827,"interventions":5828},[90],[1764,1765,1766],[1768,1266,2545],{"nctId":3392,"briefTitle":3393,"status":144,"phases":5830,"primaryCompletion":173,"completion":812,"start":914,"enrollment":1012,"conditions":5831,"interventions":5832},[90],[15],[894,1266,1267,365,1305],{"nctId":2361,"briefTitle":2362,"status":144,"phases":5834,"primaryCompletion":2364,"completion":2364,"start":2365,"enrollment":1462,"conditions":5835,"interventions":5836},[90],[21],[894,164,1266,1557,2359],{"nctId":2847,"briefTitle":2848,"status":144,"phases":5838,"primaryCompletion":2850,"completion":2851,"start":2835,"enrollment":1091,"conditions":5839,"interventions":5840},[90],[21],[894,1266,1557,2812,2829],{"trials":5842,"activeCount":100},[],{"trials":5844,"activeCount":100},[],{"trials":5846,"activeCount":100},[5847,5856,5864],{"nctId":5848,"briefTitle":5849,"status":144,"phases":5850,"primaryCompletion":1371,"completion":1371,"start":5851,"enrollment":230,"conditions":5852,"interventions":5853},"NCT00795678","Chemotherapeutic Agents in Brain\u002FBreast",[],"2008-09",[15,5055],[246,1266,1267,1359,5854,365,1930,5855],"lapatinib ditosylate","Trastuzumab",{"nctId":5857,"briefTitle":5858,"status":144,"phases":5859,"primaryCompletion":5860,"start":5861,"enrollment":230,"conditions":5862,"interventions":5863},"NCT00068523","Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies",[93],"2004-03","2003-06",[178,29,21,181,32,182],[165,1266,1753,163,188],{"nctId":5865,"briefTitle":5866,"status":1144,"phases":5867,"start":1276,"enrollment":100,"conditions":5868,"interventions":5869},"NCT00110006","Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma",[93],[21],[1556,1266,1267,5811,5812],{"intervention":894,"totalTrials":36,"cells":5871},{"EARLY_PHASE1":5872,"PHASE1":5874,"PHASE2":5884,"PHASE3":5930,"PHASE4":5941,"NA":5943},{"trials":5873,"activeCount":100},[],{"trials":5875,"activeCount":100},[5876,5880],{"nctId":884,"briefTitle":885,"status":265,"phases":5877,"primaryCompletion":887,"completion":888,"start":889,"enrollment":890,"conditions":5878,"interventions":5879},[89],[892,21,24],[894,895,896,897,898,899],{"nctId":5748,"briefTitle":5749,"status":144,"phases":5881,"primaryCompletion":2497,"completion":2497,"start":845,"enrollment":5751,"conditions":5882,"interventions":5883},[89],[178,29,21,181,32,182],[165,894,1266,163,188],{"trials":5885,"activeCount":100},[5886,5890,5894,5898,5902,5906,5910,5914,5918,5922,5926],{"nctId":1297,"briefTitle":1298,"status":144,"phases":5887,"primaryCompletion":1292,"completion":1241,"start":1300,"enrollment":1301,"conditions":5888,"interventions":5889},[90],[15],[894,1304,274,1267,1305],{"nctId":1549,"briefTitle":1550,"status":144,"phases":5891,"primaryCompletion":253,"start":1552,"enrollment":1553,"conditions":5892,"interventions":5893},[90],[21],[894,1556,898,346,1266,1557],{"nctId":2821,"briefTitle":2822,"status":144,"phases":5895,"primaryCompletion":1355,"completion":2824,"start":2825,"enrollment":2826,"conditions":5896,"interventions":5897},[90],[21],[894,1266,1557,2812,2829],{"nctId":2831,"briefTitle":2832,"status":265,"phases":5899,"primaryCompletion":2834,"completion":2834,"start":2835,"enrollment":851,"conditions":5900,"interventions":5901},[90],[21],[894,1266,1557,2812,2829],{"nctId":1572,"briefTitle":1573,"status":265,"phases":5903,"primaryCompletion":888,"completion":1575,"start":240,"enrollment":135,"conditions":5904,"interventions":5905},[89,90],[35],[894,1578,346,1267,1579],{"nctId":2333,"briefTitle":2334,"status":144,"phases":5907,"primaryCompletion":282,"completion":2336,"start":1608,"enrollment":879,"conditions":5908,"interventions":5909},[90],[29,21,181,32,182],[894,164,1266,1753],{"nctId":1581,"briefTitle":1582,"status":1144,"phases":5911,"primaryCompletion":1584,"completion":1584,"start":1585,"enrollment":100,"conditions":5912,"interventions":5913},[90],[26],[894,346,1557,365,1424],{"nctId":2839,"briefTitle":2840,"status":1144,"phases":5915,"primaryCompletion":2842,"start":2843,"enrollment":100,"conditions":5916,"interventions":5917},[90],[21],[894,2812,2829],{"nctId":3392,"briefTitle":3393,"status":144,"phases":5919,"primaryCompletion":173,"completion":812,"start":914,"enrollment":1012,"conditions":5920,"interventions":5921},[90],[15],[894,1266,1267,365,1305],{"nctId":2361,"briefTitle":2362,"status":144,"phases":5923,"primaryCompletion":2364,"completion":2364,"start":2365,"enrollment":1462,"conditions":5924,"interventions":5925},[90],[21],[894,164,1266,1557,2359],{"nctId":2847,"briefTitle":2848,"status":144,"phases":5927,"primaryCompletion":2850,"completion":2851,"start":2835,"enrollment":1091,"conditions":5928,"interventions":5929},[90],[21],[894,1266,1557,2812,2829],{"trials":5931,"activeCount":100},[5932],{"nctId":5933,"briefTitle":5934,"status":265,"phases":5935,"primaryCompletion":5936,"start":5937,"enrollment":269,"conditions":5938,"interventions":5939},"NCT01301963","Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide",[91],"2013-06","2011-07",[1763],[5940,894],"plerixafor",{"trials":5942,"activeCount":100},[],{"trials":5944,"activeCount":100},[5945],{"nctId":5946,"briefTitle":5947,"status":265,"phases":5948,"primaryCompletion":5949,"completion":5949,"start":4551,"enrollment":1070,"conditions":5950,"interventions":5951},"NCT01408043","Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma",[93],"2016-05",[1778,2204,1787,1889,1890,1807,1809,1896,1812,2231,2232,1817,1818,1819,1820,1821,1822,1823,1902,1831,1832,1833,1834,1835,1836,1837,816,817,2234,1903,1842,1847,1904,2309],[5940,894,1557],{"intervention":1557,"totalTrials":149,"cells":5953},{"EARLY_PHASE1":5954,"PHASE1":5960,"PHASE2":5974,"PHASE3":6008,"PHASE4":6014,"NA":6016},{"trials":5955,"activeCount":100},[5956],{"nctId":2197,"briefTitle":2198,"status":144,"phases":5957,"primaryCompletion":2200,"completion":2201,"start":2202,"enrollment":1255,"conditions":5958,"interventions":5959},[88],[2204,1787,1889,1890,2205,1801,2206,1802,1804,2207,2208,2209,2210,2211,2212,2213,2214,2215,2216,2217,2218,1807,1809,1896,1897,1812,2219,2220,2221,2222,2223,2224,2225,2226,2227,2228,2229,2230,2231,2232,1817,1818,1819,1820,1821,1900,1822,1823,1902,1826,1827,1828,1829,1830,1831,1832,1833,1834,1835,1836,1837,816,2233,2234,1903,1842,2235,2236,2237,2238,2239,2240,2241,2242,2243,2244,2245,2246,2247,2248,2249,2250,2251,2252,2253,2254,2255,2256,2257,2258,2259,2260,2261,2262,2263,2264,2265,2266,2267,2268,2269,2270,2271,2272,2273,2274,2275,2276,2277,2278,2279,2280,2281,2282,2283,2284,2285,819,2286,2287,2288,2289,2290,2291,2292,2293,2294,2295,2296,2297,2298,2299,2300,2301,2302,2303,2304,2305,2306,821,2307,2308,1847,1904,2309],[164,1557,1266],{"trials":5961,"activeCount":100},[5962,5966,5970],{"nctId":1688,"briefTitle":1689,"status":144,"phases":5963,"primaryCompletion":914,"completion":1691,"start":1692,"enrollment":440,"conditions":5964,"interventions":5965},[89],[29],[1557,1424],{"nctId":2739,"briefTitle":2740,"status":144,"phases":5967,"primaryCompletion":2742,"completion":2743,"start":2744,"enrollment":440,"conditions":5968,"interventions":5969},[89],[1816,406],[2747,2748,1557,2330],{"nctId":2750,"briefTitle":2751,"status":144,"phases":5971,"primaryCompletion":1429,"completion":1429,"start":2753,"enrollment":1406,"conditions":5972,"interventions":5973},[89],[1779,1780,1781,1782,1880,1881,1784,1882,1883,1785,2755,1887,1786,1788,1816],[1768,2748,1557,2330],{"trials":5975,"activeCount":100},[5976,5980,5984,5988,5992,5996,6000,6004],{"nctId":1549,"briefTitle":1550,"status":144,"phases":5977,"primaryCompletion":253,"start":1552,"enrollment":1553,"conditions":5978,"interventions":5979},[90],[21],[894,1556,898,346,1266,1557],{"nctId":2324,"briefTitle":2325,"status":144,"phases":5981,"primaryCompletion":2022,"completion":2022,"start":2327,"enrollment":176,"conditions":5982,"interventions":5983},[90],[29,21,32,182],[164,1266,2330,2331],{"nctId":2821,"briefTitle":2822,"status":144,"phases":5985,"primaryCompletion":1355,"completion":2824,"start":2825,"enrollment":2826,"conditions":5986,"interventions":5987},[90],[21],[894,1266,1557,2812,2829],{"nctId":2831,"briefTitle":2832,"status":265,"phases":5989,"primaryCompletion":2834,"completion":2834,"start":2835,"enrollment":851,"conditions":5990,"interventions":5991},[90],[21],[894,1266,1557,2812,2829],{"nctId":1581,"briefTitle":1582,"status":1144,"phases":5993,"primaryCompletion":1584,"completion":1584,"start":1585,"enrollment":100,"conditions":5994,"interventions":5995},[90],[26],[894,346,1557,365,1424],{"nctId":2361,"briefTitle":2362,"status":144,"phases":5997,"primaryCompletion":2364,"completion":2364,"start":2365,"enrollment":1462,"conditions":5998,"interventions":5999},[90],[21],[894,164,1266,1557,2359],{"nctId":1605,"briefTitle":1606,"status":144,"phases":6001,"primaryCompletion":175,"start":1608,"enrollment":11,"conditions":6002,"interventions":6003},[90],[15],[346,1557,1611,1612],{"nctId":2847,"briefTitle":2848,"status":144,"phases":6005,"primaryCompletion":2850,"completion":2851,"start":2835,"enrollment":1091,"conditions":6006,"interventions":6007},[90],[21],[894,1266,1557,2812,2829],{"trials":6009,"activeCount":100},[6010],{"nctId":1616,"briefTitle":1582,"status":144,"phases":6011,"primaryCompletion":1618,"completion":1618,"start":1619,"enrollment":135,"conditions":6012,"interventions":6013},[91],[26],[346,1557,1424],{"trials":6015,"activeCount":100},[],{"trials":6017,"activeCount":100},[6018],{"nctId":5946,"briefTitle":5947,"status":265,"phases":6019,"primaryCompletion":5949,"completion":5949,"start":4551,"enrollment":1070,"conditions":6020,"interventions":6021},[93],[1778,2204,1787,1889,1890,1807,1809,1896,1812,2231,2232,1817,1818,1819,1820,1821,1822,1823,1902,1831,1832,1833,1834,1835,1836,1837,816,817,2234,1903,1842,1847,1904,2309],[5940,894,1557],{"intervention":365,"totalTrials":404,"cells":6023},{"EARLY_PHASE1":6024,"PHASE1":6026,"PHASE2":6040,"PHASE3":6083,"PHASE4":6085,"NA":6087},{"trials":6025,"activeCount":100},[],{"trials":6027,"activeCount":100},[6028,6032,6036],{"nctId":4980,"briefTitle":4981,"status":144,"phases":6029,"primaryCompletion":2834,"completion":1364,"start":1310,"enrollment":9,"conditions":6030,"interventions":6031},[89],[35],[365,4973],{"nctId":5206,"briefTitle":5207,"status":144,"phases":6033,"primaryCompletion":5209,"completion":1418,"start":914,"enrollment":1091,"conditions":6034,"interventions":6035},[89],[24],[5199,365],{"nctId":1529,"briefTitle":238,"status":144,"phases":6037,"primaryCompletion":1531,"completion":1532,"start":1533,"enrollment":30,"conditions":6038,"interventions":6039},[89],[24],[346,1536,365],{"trials":6041,"activeCount":100},[6042,6046,6050,6054,6058,6062,6066,6070,6074],{"nctId":288,"briefTitle":289,"status":265,"phases":6043,"primaryCompletion":291,"completion":291,"start":292,"enrollment":119,"conditions":6044,"interventions":6045},[90],[294,295,296,297,298,299],[301,302,303,304,305],{"nctId":1315,"briefTitle":1316,"status":144,"phases":6047,"primaryCompletion":1318,"completion":1319,"start":1320,"enrollment":1012,"conditions":6048,"interventions":6049},[90],[1322,1323,1324,1325],[1245,1327,274,364,1328,1266,365,1329],{"nctId":349,"briefTitle":350,"status":351,"phases":6051,"primaryCompletion":353,"completion":354,"start":355,"enrollment":356,"conditions":6052,"interventions":6053},[90],[358,271,359,360,361,362],[229,261,260,364,365],{"nctId":1581,"briefTitle":1582,"status":1144,"phases":6055,"primaryCompletion":1584,"completion":1584,"start":1585,"enrollment":100,"conditions":6056,"interventions":6057},[90],[26],[894,346,1557,365,1424],{"nctId":1470,"briefTitle":1471,"status":144,"phases":6059,"primaryCompletion":1473,"completion":1473,"start":1474,"enrollment":1091,"conditions":6060,"interventions":6061},[90],[26],[364,365],{"nctId":1478,"briefTitle":1479,"status":265,"phases":6063,"primaryCompletion":1481,"completion":1482,"start":1483,"enrollment":1406,"conditions":6064,"interventions":6065},[90],[1485],[301,302],{"nctId":4645,"briefTitle":4646,"status":265,"phases":6067,"primaryCompletion":2122,"completion":2122,"start":4648,"enrollment":404,"conditions":6068,"interventions":6069},[89,90],[358,271],[4636,301,4651],{"nctId":3392,"briefTitle":3393,"status":144,"phases":6071,"primaryCompletion":173,"completion":812,"start":914,"enrollment":1012,"conditions":6072,"interventions":6073},[90],[15],[894,1266,1267,365,1305],{"nctId":6075,"briefTitle":6076,"status":144,"phases":6077,"primaryCompletion":6078,"completion":6079,"start":6080,"enrollment":627,"conditions":6081,"interventions":6082},"NCT00006256","Paclitaxel Plus Radiation Therapy in Treating Women With Stage II or Stage III Breast Cancer",[90],"2005-11-30","2023-11-20","2000-06-08",[15],[365],{"trials":6084,"activeCount":100},[],{"trials":6086,"activeCount":100},[],{"trials":6088,"activeCount":100},[6089],{"nctId":5848,"briefTitle":5849,"status":144,"phases":6090,"primaryCompletion":1371,"completion":1371,"start":5851,"enrollment":230,"conditions":6091,"interventions":6092},[],[15,5055],[246,1266,1267,1359,5854,365,1930,5855],{"intervention":1267,"totalTrials":2106,"cells":6094},{"EARLY_PHASE1":6095,"PHASE1":6097,"PHASE2":6107,"PHASE3":6137,"PHASE4":6139,"NA":6141},{"trials":6096,"activeCount":100},[],{"trials":6098,"activeCount":100},[6099,6103],{"nctId":1260,"briefTitle":1261,"status":1144,"phases":6100,"primaryCompletion":1263,"completion":1263,"start":913,"enrollment":100,"conditions":6101,"interventions":6102},[89],[15],[1266,274,1267],{"nctId":4992,"briefTitle":4993,"status":144,"phases":6104,"primaryCompletion":2834,"completion":1364,"start":1533,"enrollment":30,"conditions":6105,"interventions":6106},[89],[15],[1267,4973,4997],{"trials":6108,"activeCount":100},[6109,6113,6117,6121,6125,6129,6133],{"nctId":1287,"briefTitle":1288,"status":144,"phases":6110,"primaryCompletion":1290,"completion":1291,"start":1292,"enrollment":1293,"conditions":6111,"interventions":6112},[90],[15],[258,1266,274,1267],{"nctId":3071,"briefTitle":3072,"status":144,"phases":6114,"primaryCompletion":3074,"completion":3075,"start":3076,"enrollment":512,"conditions":6115,"interventions":6116},[89,90],[2208,2220,2236,2268,2289],[3079,3080,3081,3082,3083,3084,3085,3086],{"nctId":1297,"briefTitle":1298,"status":144,"phases":6118,"primaryCompletion":1292,"completion":1241,"start":1300,"enrollment":1301,"conditions":6119,"interventions":6120},[90],[15],[894,1304,274,1267,1305],{"nctId":1307,"briefTitle":1308,"status":1144,"phases":6122,"start":1310,"enrollment":100,"conditions":6123,"interventions":6124},[90],[15],[1313,1266,274,1267,163],{"nctId":1572,"briefTitle":1573,"status":265,"phases":6126,"primaryCompletion":888,"completion":1575,"start":240,"enrollment":135,"conditions":6127,"interventions":6128},[89,90],[35],[894,1578,346,1267,1579],{"nctId":5805,"briefTitle":5806,"status":144,"phases":6130,"primaryCompletion":241,"completion":282,"start":5808,"enrollment":269,"conditions":6131,"interventions":6132},[90],[21],[1556,1266,1267,5811,5812,4313],{"nctId":3392,"briefTitle":3393,"status":144,"phases":6134,"primaryCompletion":173,"completion":812,"start":914,"enrollment":1012,"conditions":6135,"interventions":6136},[90],[15],[894,1266,1267,365,1305],{"trials":6138,"activeCount":100},[],{"trials":6140,"activeCount":100},[],{"trials":6142,"activeCount":100},[6143,6147],{"nctId":5848,"briefTitle":5849,"status":144,"phases":6144,"primaryCompletion":1371,"completion":1371,"start":5851,"enrollment":230,"conditions":6145,"interventions":6146},[],[15,5055],[246,1266,1267,1359,5854,365,1930,5855],{"nctId":5865,"briefTitle":5866,"status":1144,"phases":6148,"start":1276,"enrollment":100,"conditions":6149,"interventions":6150},[93],[21],[1556,1266,1267,5811,5812],{"intervention":163,"totalTrials":230,"cells":6152},{"EARLY_PHASE1":6153,"PHASE1":6159,"PHASE2":6181,"PHASE3":6195,"PHASE4":6197,"NA":6199},{"trials":6154,"activeCount":100},[6155],{"nctId":1740,"briefTitle":1741,"status":144,"phases":6156,"primaryCompletion":1743,"completion":1744,"start":1745,"enrollment":851,"conditions":6157,"interventions":6158},[88],[216,470,32,160,1747,1748,155,1749,1750,817,1751,215],[1266,163,1753,1735],{"trials":6160,"activeCount":100},[6161,6165,6169,6173,6177],{"nctId":5014,"briefTitle":5015,"status":144,"phases":6162,"primaryCompletion":292,"completion":5017,"start":281,"enrollment":129,"conditions":6163,"interventions":6164},[89],[1787,1889,1890,1807,1809,1896,1897,1812,2232,1817,1818,1819,1820,1821,1900,1822,1823,1902,1831,1832,1833,1834,1835,1836,1837,816,817,1763,1838,1903,1842,818,1904,2309],[163,5007,5020,5021],{"nctId":142,"briefTitle":143,"status":144,"phases":6166,"primaryCompletion":146,"completion":147,"start":148,"enrollment":149,"conditions":6167,"interventions":6168},[89],[151,152,153,154,155,156,157,158,159,160,161],[163,164,165,134,166],{"nctId":5748,"briefTitle":5749,"status":144,"phases":6170,"primaryCompletion":2497,"completion":2497,"start":845,"enrollment":5751,"conditions":6171,"interventions":6172},[89],[178,29,21,181,32,182],[165,894,1266,163,188],{"nctId":1415,"briefTitle":1416,"status":144,"phases":6174,"primaryCompletion":1418,"completion":1419,"start":1420,"enrollment":1421,"conditions":6175,"interventions":6176},[89],[29,32],[364,163,1424],{"nctId":1757,"briefTitle":1758,"status":265,"phases":6178,"primaryCompletion":1760,"completion":1760,"start":1761,"enrollment":890,"conditions":6179,"interventions":6180},[89],[1763,1764,1765,1766],[163,1753,1735,1768,1258],{"trials":6182,"activeCount":100},[6183,6187,6191],{"nctId":1307,"briefTitle":1308,"status":1144,"phases":6184,"start":1310,"enrollment":100,"conditions":6185,"interventions":6186},[90],[15],[1313,1266,274,1267,163],{"nctId":1457,"briefTitle":1458,"status":144,"phases":6188,"primaryCompletion":887,"completion":1460,"start":1461,"enrollment":1462,"conditions":6189,"interventions":6190},[90],[29,32,182],[364,163,1283,1424],{"nctId":4547,"briefTitle":4548,"status":144,"phases":6192,"primaryCompletion":4550,"completion":4551,"start":1552,"enrollment":4552,"conditions":6193,"interventions":6194},[90],[178,29,21,181,32,182,4554,4555],[165,4538,1266,163],{"trials":6196,"activeCount":100},[],{"trials":6198,"activeCount":100},[],{"trials":6200,"activeCount":100},[6201],{"nctId":5857,"briefTitle":5858,"status":144,"phases":6202,"primaryCompletion":5860,"start":5861,"enrollment":230,"conditions":6203,"interventions":6204},[93],[178,29,21,181,32,182],[165,1266,1753,163,188],{"intervention":1753,"totalTrials":1681,"cells":6206},{"EARLY_PHASE1":6207,"PHASE1":6213,"PHASE2":6219,"PHASE3":6237,"PHASE4":6239,"NA":6241},{"trials":6208,"activeCount":100},[6209],{"nctId":1740,"briefTitle":1741,"status":144,"phases":6210,"primaryCompletion":1743,"completion":1744,"start":1745,"enrollment":851,"conditions":6211,"interventions":6212},[88],[216,470,32,160,1747,1748,155,1749,1750,817,1751,215],[1266,163,1753,1735],{"trials":6214,"activeCount":100},[6215],{"nctId":1757,"briefTitle":1758,"status":265,"phases":6216,"primaryCompletion":1760,"completion":1760,"start":1761,"enrollment":890,"conditions":6217,"interventions":6218},[89],[1763,1764,1765,1766],[163,1753,1735,1768,1258],{"trials":6220,"activeCount":100},[6221,6225,6229,6233],{"nctId":1873,"briefTitle":1874,"status":144,"phases":6222,"primaryCompletion":1876,"completion":1543,"start":1877,"enrollment":404,"conditions":6223,"interventions":6224},[90],[1879,1778,1779,1781,1782,1880,1881,1783,1784,1882,1883,1884,1885,1886,1887,1888,1786,1787,1788,1889,1890,1792,1793,1794,1795,1797,1798,1891,1892,1799,1893,1894,1800,1803,1806,1807,1895,1809,1896,1897,1812,1898,1899,1813,1815,1816,1817,1818,1819,1820,1821,1900,1822,1823,1901,1902,1824,1825,1831,1832,1833,1834,1835,1836,1837,816,1763,1838,1840,1903,1842,1904,1848],[164,1266,188,166,1753],{"nctId":2333,"briefTitle":2334,"status":144,"phases":6226,"primaryCompletion":282,"completion":2336,"start":1608,"enrollment":879,"conditions":6227,"interventions":6228},[90],[29,21,181,32,182],[894,164,1266,1753],{"nctId":1772,"briefTitle":1773,"status":144,"phases":6230,"primaryCompletion":291,"completion":291,"start":1775,"enrollment":149,"conditions":6231,"interventions":6232},[90],[1777,1778,1779,1780,1781,1782,1783,1784,1785,1786,1787,1788,1789,1790,1791,1792,1793,1794,1795,1796,1797,1798,1799,1800,1801,1802,1803,1804,1805,1806,1807,1808,1809,1810,1811,1812,1813,1814,1815,1816,1817,1818,1819,1820,1821,1822,1823,1824,1825,1826,1827,1828,1829,1830,1831,1832,1833,1834,1835,1836,1837,816,817,1838,1839,1840,1841,1842,1843,1844,818,820,1845,1846,1847,1848],[164,1266,165,188,1753,1735],{"nctId":2369,"briefTitle":2370,"status":144,"phases":6234,"primaryCompletion":2372,"completion":1520,"start":2356,"enrollment":627,"conditions":6235,"interventions":6236},[90],[180,29,21,32,182],[165,164,1753,2359,188],{"trials":6238,"activeCount":100},[],{"trials":6240,"activeCount":100},[],{"trials":6242,"activeCount":100},[6243],{"nctId":5857,"briefTitle":5858,"status":144,"phases":6244,"primaryCompletion":5860,"start":5861,"enrollment":230,"conditions":6245,"interventions":6246},[93],[178,29,21,181,32,182],[165,1266,1753,163,188],{"intervention":246,"totalTrials":1681,"cells":6248},{"EARLY_PHASE1":6249,"PHASE1":6251,"PHASE2":6277,"PHASE3":6288,"PHASE4":6290,"NA":6292},{"trials":6250,"activeCount":100},[],{"trials":6252,"activeCount":100},[6253,6257,6265,6269,6273],{"nctId":237,"briefTitle":238,"status":144,"phases":6254,"primaryCompletion":240,"completion":241,"start":242,"enrollment":243,"conditions":6255,"interventions":6256},[89],[24],[246,247,229],{"nctId":6258,"briefTitle":6259,"status":1144,"phases":6260,"start":241,"enrollment":100,"conditions":6261,"interventions":6264},"NCT00118300","Capecitabine and Radiation Therapy in Treating Patients With Locally Advanced Cervical Cancer or Other Pelvic Cancer",[89],[6262,2025,184,6263],"Cervical Cancer","Vaginal Cancer",[246],{"nctId":2133,"briefTitle":2134,"status":144,"phases":6266,"primaryCompletion":2136,"completion":2136,"start":2137,"enrollment":9,"conditions":6267,"interventions":6268},[89],[514],[2140,1329],{"nctId":2397,"briefTitle":2398,"status":144,"phases":6270,"primaryCompletion":2400,"completion":2400,"start":2401,"enrollment":851,"conditions":6271,"interventions":6272},[89],[2403],[1498,2140],{"nctId":277,"briefTitle":278,"status":265,"phases":6274,"primaryCompletion":280,"completion":281,"start":282,"enrollment":9,"conditions":6275,"interventions":6276},[89],[256,24],[258,246,247,229],{"trials":6278,"activeCount":100},[6279],{"nctId":6280,"briefTitle":6281,"status":1144,"phases":6282,"primaryCompletion":194,"completion":6283,"start":4464,"enrollment":100,"conditions":6284,"interventions":6287},"NCT06110598","CAPEcitabine eXtension of Adjuvant Therapy for Pancreatic Adenocarcinoma: (CAPE-X)",[90],"2027-12-31",[6285,6286],"Pancreas Cancer","Pancreas Adenocarcinoma",[2140],{"trials":6289,"activeCount":100},[],{"trials":6291,"activeCount":100},[],{"trials":6293,"activeCount":100},[6294],{"nctId":5848,"briefTitle":5849,"status":144,"phases":6295,"primaryCompletion":1371,"completion":1371,"start":5851,"enrollment":230,"conditions":6296,"interventions":6297},[],[15,5055],[246,1266,1267,1359,5854,365,1930,5855],{"intervention":188,"totalTrials":1681,"cells":6299},{"EARLY_PHASE1":6300,"PHASE1":6302,"PHASE2":6308,"PHASE3":6330,"PHASE4":6332,"NA":6334},{"trials":6301,"activeCount":100},[],{"trials":6303,"activeCount":100},[6304],{"nctId":5748,"briefTitle":5749,"status":144,"phases":6305,"primaryCompletion":2497,"completion":2497,"start":845,"enrollment":5751,"conditions":6306,"interventions":6307},[89],[178,29,21,181,32,182],[165,894,1266,163,188],{"trials":6309,"activeCount":100},[6310,6314,6318,6322,6326],{"nctId":1873,"briefTitle":1874,"status":144,"phases":6311,"primaryCompletion":1876,"completion":1543,"start":1877,"enrollment":404,"conditions":6312,"interventions":6313},[90],[1879,1778,1779,1781,1782,1880,1881,1783,1784,1882,1883,1884,1885,1886,1887,1888,1786,1787,1788,1889,1890,1792,1793,1794,1795,1797,1798,1891,1892,1799,1893,1894,1800,1803,1806,1807,1895,1809,1896,1897,1812,1898,1899,1813,1815,1816,1817,1818,1819,1820,1821,1900,1822,1823,1901,1902,1824,1825,1831,1832,1833,1834,1835,1836,1837,816,1763,1838,1840,1903,1842,1904,1848],[164,1266,188,166,1753],{"nctId":1772,"briefTitle":1773,"status":144,"phases":6315,"primaryCompletion":291,"completion":291,"start":1775,"enrollment":149,"conditions":6316,"interventions":6317},[90],[1777,1778,1779,1780,1781,1782,1783,1784,1785,1786,1787,1788,1789,1790,1791,1792,1793,1794,1795,1796,1797,1798,1799,1800,1801,1802,1803,1804,1805,1806,1807,1808,1809,1810,1811,1812,1813,1814,1815,1816,1817,1818,1819,1820,1821,1822,1823,1824,1825,1826,1827,1828,1829,1830,1831,1832,1833,1834,1835,1836,1837,816,817,1838,1839,1840,1841,1842,1843,1844,818,820,1845,1846,1847,1848],[164,1266,165,188,1753,1735],{"nctId":170,"briefTitle":171,"status":144,"phases":6319,"primaryCompletion":173,"completion":174,"start":175,"enrollment":176,"conditions":6320,"interventions":6321},[90],[15,178,179,180,29,21,181,32,182,183,184,185],[187,188,134],{"nctId":2353,"briefTitle":2354,"status":144,"phases":6323,"primaryCompletion":1290,"completion":1705,"start":2356,"enrollment":851,"conditions":6324,"interventions":6325},[90],[29,32,182],[165,164,1266,2359,188],{"nctId":2369,"briefTitle":2370,"status":144,"phases":6327,"primaryCompletion":2372,"completion":1520,"start":2356,"enrollment":627,"conditions":6328,"interventions":6329},[90],[180,29,21,32,182],[165,164,1753,2359,188],{"trials":6331,"activeCount":100},[],{"trials":6333,"activeCount":100},[],{"trials":6335,"activeCount":100},[6336],{"nctId":5857,"briefTitle":5858,"status":144,"phases":6337,"primaryCompletion":5860,"start":5861,"enrollment":230,"conditions":6338,"interventions":6339},[93],[178,29,21,181,32,182],[165,1266,1753,163,188],{"intervention":1359,"totalTrials":1681,"cells":6341},{"EARLY_PHASE1":6342,"PHASE1":6344,"PHASE2":6354,"PHASE3":6368,"PHASE4":6374,"NA":6376},{"trials":6343,"activeCount":100},[],{"trials":6345,"activeCount":100},[6346,6350],{"nctId":3645,"briefTitle":238,"status":144,"phases":6347,"primaryCompletion":1473,"completion":1562,"start":1876,"enrollment":230,"conditions":6348,"interventions":6349},[89],[24],[1359,3638,1930],{"nctId":1426,"briefTitle":1427,"status":144,"phases":6351,"primaryCompletion":1429,"completion":1430,"start":1431,"enrollment":9,"conditions":6352,"interventions":6353},[89],[1433,1434,1435,199,1436,1437,1438,1439,1440,1441,1442,1443,1444],[364,1359],{"trials":6355,"activeCount":100},[6356,6360,6364],{"nctId":1559,"briefTitle":1560,"status":144,"phases":6357,"primaryCompletion":1562,"completion":1563,"start":1564,"enrollment":19,"conditions":6358,"interventions":6359},[90],[1229],[346,1359],{"nctId":3341,"briefTitle":3342,"status":265,"phases":6361,"primaryCompletion":3344,"completion":3345,"start":3346,"enrollment":96,"conditions":6362,"interventions":6363},[90],[3348],[3324,3350],{"nctId":1351,"briefTitle":1352,"status":144,"phases":6365,"primaryCompletion":1354,"completion":1354,"start":1355,"enrollment":1356,"conditions":6366,"interventions":6367},[90],[18],[274,1359],{"trials":6369,"activeCount":100},[6370],{"nctId":1380,"briefTitle":1381,"status":144,"phases":6371,"primaryCompletion":1383,"completion":1384,"start":1364,"enrollment":254,"conditions":6372,"interventions":6373},[91],[26],[364,274,1359],{"trials":6375,"activeCount":100},[],{"trials":6377,"activeCount":100},[6378],{"nctId":5848,"briefTitle":5849,"status":144,"phases":6379,"primaryCompletion":1371,"completion":1371,"start":5851,"enrollment":230,"conditions":6380,"interventions":6381},[],[15,5055],[246,1266,1267,1359,5854,365,1930,5855],{"intervention":4094,"totalTrials":1681,"cells":6383},{"EARLY_PHASE1":6384,"PHASE1":6386,"PHASE2":6388,"PHASE3":6398,"PHASE4":6400,"NA":6402},{"trials":6385,"activeCount":100},[],{"trials":6387,"activeCount":100},[],{"trials":6389,"activeCount":100},[6390,6394],{"nctId":4087,"briefTitle":4088,"status":144,"phases":6391,"primaryCompletion":4090,"completion":4091,"start":268,"enrollment":19,"conditions":6392,"interventions":6393},[90],[29],[4078,4094,4095,1340],{"nctId":4302,"briefTitle":4303,"status":144,"phases":6395,"primaryCompletion":2159,"completion":4305,"start":2753,"enrollment":1070,"conditions":6396,"interventions":6397},[89,90],[1805,1808,32,4307,4308,4309,4310,4311],[4293,4313,4094,2165],{"trials":6399,"activeCount":100},[],{"trials":6401,"activeCount":100},[],{"trials":6403,"activeCount":100},[6404,6413,6421,6428,6436],{"nctId":6405,"briefTitle":6406,"status":144,"phases":6407,"primaryCompletion":6408,"completion":6408,"start":6409,"enrollment":6410,"conditions":6411,"interventions":6412},"NCT00918892","Assessment of Candidate Protein Expression in Breast Cancer Specimens",[],"2021-09-23","2011-01-01",460,[15],[4094],{"nctId":6414,"briefTitle":6415,"status":265,"phases":6416,"primaryCompletion":371,"completion":371,"start":6417,"enrollment":1091,"conditions":6418,"interventions":6420},"NCT00991991","Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma",[],"2009-07",[6419],"Melanoma (Skin)",[4094,1340,2165],{"nctId":6422,"briefTitle":6423,"status":1144,"phases":6424,"primaryCompletion":5851,"start":6425,"enrollment":100,"conditions":6426,"interventions":6427},"NCT00908739","Studying Tumor Tissue Samples From Patients Who Have Undergone Surgery for Localized Kidney Cancer",[],"2008-05",[1229],[4094],{"nctId":6429,"briefTitle":6430,"status":1144,"phases":6431,"start":6432,"enrollment":100,"conditions":6433,"interventions":6434},"NCT00898573","Lapatinib Resistance in Patients With Breast Cancer",[],"2008-07",[15],[5854,1339,4094,4095,1340,6435],"reverse transcriptase-polymerase chain reaction",{"nctId":6437,"briefTitle":6438,"status":1144,"phases":6439,"primaryCompletion":4116,"start":6440,"enrollment":100,"conditions":6441,"interventions":6442},"NCT00907699","Laboratory Study Using Samples From Patients With Non-Small Cell Lung Cancer Treated on Clinical Trial CASE-2507",[],"2008-08",[26],[5021,6443,1339,4094,4095,1340,6435],"RNA analysis",{"intervention":165,"totalTrials":1681,"cells":6445},{"EARLY_PHASE1":6446,"PHASE1":6448,"PHASE2":6458,"PHASE3":6476,"PHASE4":6478,"NA":6480},{"trials":6447,"activeCount":100},[],{"trials":6449,"activeCount":100},[6450,6454],{"nctId":142,"briefTitle":143,"status":144,"phases":6451,"primaryCompletion":146,"completion":147,"start":148,"enrollment":149,"conditions":6452,"interventions":6453},[89],[151,152,153,154,155,156,157,158,159,160,161],[163,164,165,134,166],{"nctId":5748,"briefTitle":5749,"status":144,"phases":6455,"primaryCompletion":2497,"completion":2497,"start":845,"enrollment":5751,"conditions":6456,"interventions":6457},[89],[178,29,21,181,32,182],[165,894,1266,163,188],{"trials":6459,"activeCount":100},[6460,6464,6468,6472],{"nctId":1772,"briefTitle":1773,"status":144,"phases":6461,"primaryCompletion":291,"completion":291,"start":1775,"enrollment":149,"conditions":6462,"interventions":6463},[90],[1777,1778,1779,1780,1781,1782,1783,1784,1785,1786,1787,1788,1789,1790,1791,1792,1793,1794,1795,1796,1797,1798,1799,1800,1801,1802,1803,1804,1805,1806,1807,1808,1809,1810,1811,1812,1813,1814,1815,1816,1817,1818,1819,1820,1821,1822,1823,1824,1825,1826,1827,1828,1829,1830,1831,1832,1833,1834,1835,1836,1837,816,817,1838,1839,1840,1841,1842,1843,1844,818,820,1845,1846,1847,1848],[164,1266,165,188,1753,1735],{"nctId":4547,"briefTitle":4548,"status":144,"phases":6465,"primaryCompletion":4550,"completion":4551,"start":1552,"enrollment":4552,"conditions":6466,"interventions":6467},[90],[178,29,21,181,32,182,4554,4555],[165,4538,1266,163],{"nctId":2353,"briefTitle":2354,"status":144,"phases":6469,"primaryCompletion":1290,"completion":1705,"start":2356,"enrollment":851,"conditions":6470,"interventions":6471},[90],[29,32,182],[165,164,1266,2359,188],{"nctId":2369,"briefTitle":2370,"status":144,"phases":6473,"primaryCompletion":2372,"completion":1520,"start":2356,"enrollment":627,"conditions":6474,"interventions":6475},[90],[180,29,21,32,182],[165,164,1753,2359,188],{"trials":6477,"activeCount":100},[],{"trials":6479,"activeCount":100},[],{"trials":6481,"activeCount":100},[6482],{"nctId":5857,"briefTitle":5858,"status":144,"phases":6483,"primaryCompletion":5860,"start":5861,"enrollment":230,"conditions":6484,"interventions":6485},[93],[178,29,21,181,32,182],[165,1266,1753,163,188],{"intervention":1556,"totalTrials":851,"cells":6487},{"EARLY_PHASE1":6488,"PHASE1":6490,"PHASE2":6496,"PHASE3":6518,"PHASE4":6520,"NA":6522},{"trials":6489,"activeCount":100},[],{"trials":6491,"activeCount":100},[6492],{"nctId":2494,"briefTitle":2495,"status":265,"phases":6493,"primaryCompletion":2497,"completion":2498,"start":2499,"enrollment":1091,"conditions":6494,"interventions":6495},[89],[2501,2204,2207,2208,2209,2210,2211,2212,2213,2214,2215,2216,2217,2218,1807,1809,1812,2219,2220,2221,2222,2223,2224,2225,2226,2227,2228,2229,2230,1817,1818,1819,1820,1821,1822,1823,1832,1833,1834,1835,1836,816,1842,2235,2236,2237,2238,2240,2241,2249,2250,2251,2252,2253,2254,2267,2268,2269,2270,2272,2273,2281,2282,2283,2284,2285,819,2288,2289,2290,2291,2293,2294,2302,2303,2304,2305,2306,821,1848],[1258,1556,1340,2503,2165],{"trials":6497,"activeCount":100},[6498,6502,6506,6514],{"nctId":3071,"briefTitle":3072,"status":144,"phases":6499,"primaryCompletion":3074,"completion":3075,"start":3076,"enrollment":512,"conditions":6500,"interventions":6501},[89,90],[2208,2220,2236,2268,2289],[3079,3080,3081,3082,3083,3084,3085,3086],{"nctId":1549,"briefTitle":1550,"status":144,"phases":6503,"primaryCompletion":253,"start":1552,"enrollment":1553,"conditions":6504,"interventions":6505},[90],[21],[894,1556,898,346,1266,1557],{"nctId":6507,"briefTitle":6508,"status":265,"phases":6509,"primaryCompletion":6510,"completion":6510,"start":2202,"enrollment":119,"conditions":6511,"interventions":6513},"NCT01973062","Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin Lymphoma",[90],"2015-06",[6512],"Primary Central Nervous System Non-Hodgkin Lymphoma",[1556],{"nctId":5805,"briefTitle":5806,"status":144,"phases":6515,"primaryCompletion":241,"completion":282,"start":5808,"enrollment":269,"conditions":6516,"interventions":6517},[90],[21],[1556,1266,1267,5811,5812,4313],{"trials":6519,"activeCount":100},[],{"trials":6521,"activeCount":100},[],{"trials":6523,"activeCount":100},[6524],{"nctId":5865,"briefTitle":5866,"status":1144,"phases":6525,"start":1276,"enrollment":100,"conditions":6526,"interventions":6527},[93],[21],[1556,1266,1267,5811,5812],{"intervention":1340,"totalTrials":851,"cells":6529},{"EARLY_PHASE1":6530,"PHASE1":6532,"PHASE2":6538,"PHASE3":6548,"PHASE4":6550,"NA":6552},{"trials":6531,"activeCount":100},[],{"trials":6533,"activeCount":100},[6534],{"nctId":2494,"briefTitle":2495,"status":265,"phases":6535,"primaryCompletion":2497,"completion":2498,"start":2499,"enrollment":1091,"conditions":6536,"interventions":6537},[89],[2501,2204,2207,2208,2209,2210,2211,2212,2213,2214,2215,2216,2217,2218,1807,1809,1812,2219,2220,2221,2222,2223,2224,2225,2226,2227,2228,2229,2230,1817,1818,1819,1820,1821,1822,1823,1832,1833,1834,1835,1836,816,1842,2235,2236,2237,2238,2240,2241,2249,2250,2251,2252,2253,2254,2267,2268,2269,2270,2272,2273,2281,2282,2283,2284,2285,819,2288,2289,2290,2291,2293,2294,2302,2303,2304,2305,2306,821,1848],[1258,1556,1340,2503,2165],{"trials":6539,"activeCount":100},[6540,6544],{"nctId":4087,"briefTitle":4088,"status":144,"phases":6541,"primaryCompletion":4090,"completion":4091,"start":268,"enrollment":19,"conditions":6542,"interventions":6543},[90],[29],[4078,4094,4095,1340],{"nctId":1331,"briefTitle":1332,"status":144,"phases":6545,"primaryCompletion":1334,"completion":1334,"start":1335,"enrollment":1336,"conditions":6546,"interventions":6547},[90],[35],[274,259,1339,1340],{"trials":6549,"activeCount":100},[],{"trials":6551,"activeCount":100},[],{"trials":6553,"activeCount":100},[6554,6558,6562],{"nctId":6414,"briefTitle":6415,"status":265,"phases":6555,"primaryCompletion":371,"completion":371,"start":6417,"enrollment":1091,"conditions":6556,"interventions":6557},[],[6419],[4094,1340,2165],{"nctId":6429,"briefTitle":6430,"status":1144,"phases":6559,"start":6432,"enrollment":100,"conditions":6560,"interventions":6561},[],[15],[5854,1339,4094,4095,1340,6435],{"nctId":6437,"briefTitle":6438,"status":1144,"phases":6563,"primaryCompletion":4116,"start":6440,"enrollment":100,"conditions":6564,"interventions":6565},[],[26],[5021,6443,1339,4094,4095,1340,6435],{"intervention":6567,"totalTrials":851,"cells":6568},"sunitinib malate",{"EARLY_PHASE1":6569,"PHASE1":6571,"PHASE2":6573,"PHASE3":6617,"PHASE4":6619,"NA":6621},{"trials":6570,"activeCount":100},[],{"trials":6572,"activeCount":100},[],{"trials":6574,"activeCount":100},[6575,6583,6591,6601,6608],{"nctId":6576,"briefTitle":6577,"status":265,"phases":6578,"primaryCompletion":1520,"completion":6579,"start":6580,"enrollment":149,"conditions":6581,"interventions":6582},"NCT00910039","Sunitinib Malate After Stereotactic Radiosurgery in Treating Patients With Newly Diagnosed Brain Metastases",[90],"2014-04","2009-04",[1148,5055,24],[6567],{"nctId":6584,"briefTitle":6585,"status":144,"phases":6586,"primaryCompletion":6587,"completion":2497,"start":1775,"enrollment":269,"conditions":6588,"interventions":6590},"NCT00526656","Sunitinib in Treating Patients With Locally Advanced Bladder Cancer",[90],"2010-03",[6589],"Bladder Cancer",[6567],{"nctId":6592,"briefTitle":6593,"status":144,"phases":6594,"primaryCompletion":6595,"completion":6596,"start":6597,"enrollment":1553,"conditions":6598,"interventions":6600},"NCT01158222","Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer",[90],"2013-06-20","2017-02-01","2010-08-18",[6599,1940],"Clear Cell Renal Cell Carcinoma",[6567],{"nctId":6602,"briefTitle":6603,"status":144,"phases":6604,"primaryCompletion":2497,"completion":6605,"start":1460,"enrollment":440,"conditions":6606,"interventions":6607},"NCT00459979","Sunitinib in Treating Patients With Kidney Cancer That Cannot Be Removed by Surgery",[90],"2013-09",[1229],[6567],{"nctId":6609,"briefTitle":6610,"status":265,"phases":6611,"primaryCompletion":6612,"completion":372,"start":268,"enrollment":33,"conditions":6613,"interventions":6616},"NCT01118351","Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer",[90],"2012-07",[6614,6615],"Recurrent Bladder Cancer","Transitional Cell Carcinoma of the Bladder",[6567],{"trials":6618,"activeCount":100},[],{"trials":6620,"activeCount":100},[],{"trials":6622,"activeCount":100},[6623],{"nctId":6624,"briefTitle":6625,"status":265,"phases":6626,"primaryCompletion":2202,"completion":2202,"start":812,"enrollment":404,"conditions":6627,"interventions":6630},"NCT01740154","Sunitinib Malate Related Fatigue in Patients With Metastatic Kidney Cancer",[93],[6628,6629,1940],"Fatigue","Recurrent Renal Cell Cancer",[6567],{"intervention":1339,"totalTrials":851,"cells":6632},{"EARLY_PHASE1":6633,"PHASE1":6635,"PHASE2":6641,"PHASE3":6647,"PHASE4":6649,"NA":6651},{"trials":6634,"activeCount":100},[],{"trials":6636,"activeCount":100},[6637],{"nctId":5481,"briefTitle":5482,"status":144,"phases":6638,"primaryCompletion":2336,"completion":2512,"start":1927,"enrollment":1293,"conditions":6639,"interventions":6640},[89],[1281],[5474,1339],{"trials":6642,"activeCount":100},[6643],{"nctId":1331,"briefTitle":1332,"status":144,"phases":6644,"primaryCompletion":1334,"completion":1334,"start":1335,"enrollment":1336,"conditions":6645,"interventions":6646},[90],[35],[274,259,1339,1340],{"trials":6648,"activeCount":100},[],{"trials":6650,"activeCount":100},[],{"trials":6652,"activeCount":100},[6653,6657,6665,6672],{"nctId":6429,"briefTitle":6430,"status":1144,"phases":6654,"start":6432,"enrollment":100,"conditions":6655,"interventions":6656},[],[15],[5854,1339,4094,4095,1340,6435],{"nctId":6658,"briefTitle":6659,"status":144,"phases":6660,"primaryCompletion":812,"completion":6661,"start":3450,"enrollment":1184,"conditions":6662,"interventions":6664},"NCT00952939","Study of Tumor Samples in Patients Undergoing Radiation Therapy or Surgery For Primary Melanoma of the Eye",[],"2014-02",[6663],"Intraocular Melanoma",[1339],{"nctId":6666,"briefTitle":6667,"status":144,"phases":6668,"primaryCompletion":4115,"completion":4115,"start":1354,"enrollment":6669,"conditions":6670,"interventions":6671},"NCT00918216","Spectroscopy of Breast Tissue",[],141,[15],[1339],{"nctId":6437,"briefTitle":6438,"status":1144,"phases":6673,"primaryCompletion":4116,"start":6440,"enrollment":100,"conditions":6674,"interventions":6675},[],[26],[5021,6443,1339,4094,4095,1340,6435],{"intervention":2165,"totalTrials":1091,"cells":6677},{"EARLY_PHASE1":6678,"PHASE1":6680,"PHASE2":6690,"PHASE3":6700,"PHASE4":6702,"NA":6704},{"trials":6679,"activeCount":100},[],{"trials":6681,"activeCount":100},[6682,6686],{"nctId":2494,"briefTitle":2495,"status":265,"phases":6683,"primaryCompletion":2497,"completion":2498,"start":2499,"enrollment":1091,"conditions":6684,"interventions":6685},[89],[2501,2204,2207,2208,2209,2210,2211,2212,2213,2214,2215,2216,2217,2218,1807,1809,1812,2219,2220,2221,2222,2223,2224,2225,2226,2227,2228,2229,2230,1817,1818,1819,1820,1821,1822,1823,1832,1833,1834,1835,1836,816,1842,2235,2236,2237,2238,2240,2241,2249,2250,2251,2252,2253,2254,2267,2268,2269,2270,2272,2273,2281,2282,2283,2284,2285,819,2288,2289,2290,2291,2293,2294,2302,2303,2304,2305,2306,821,1848],[1258,1556,1340,2503,2165],{"nctId":2509,"briefTitle":2510,"status":265,"phases":6687,"primaryCompletion":2512,"completion":2513,"start":280,"enrollment":1406,"conditions":6688,"interventions":6689},[89],[2515,2516],[1258,2518,2165],{"trials":6691,"activeCount":100},[6692,6696],{"nctId":2156,"briefTitle":2157,"status":144,"phases":6693,"primaryCompletion":2159,"completion":2160,"start":2161,"enrollment":243,"conditions":6694,"interventions":6695},[89,90],[18],[2164,258,2165],{"nctId":4302,"briefTitle":4303,"status":144,"phases":6697,"primaryCompletion":2159,"completion":4305,"start":2753,"enrollment":1070,"conditions":6698,"interventions":6699},[89,90],[1805,1808,32,4307,4308,4309,4310,4311],[4293,4313,4094,2165],{"trials":6701,"activeCount":100},[],{"trials":6703,"activeCount":100},[],{"trials":6705,"activeCount":100},[6706],{"nctId":6414,"briefTitle":6415,"status":265,"phases":6707,"primaryCompletion":371,"completion":371,"start":6417,"enrollment":1091,"conditions":6708,"interventions":6709},[],[6419],[4094,1340,2165],{"intervention":3084,"totalTrials":135,"cells":6711},{"EARLY_PHASE1":6712,"PHASE1":6714,"PHASE2":6716,"PHASE3":6730,"PHASE4":6732,"NA":6734},{"trials":6713,"activeCount":100},[],{"trials":6715,"activeCount":100},[],{"trials":6717,"activeCount":100},[6718,6722,6726],{"nctId":3071,"briefTitle":3072,"status":144,"phases":6719,"primaryCompletion":3074,"completion":3075,"start":3076,"enrollment":512,"conditions":6720,"interventions":6721},[89,90],[2208,2220,2236,2268,2289],[3079,3080,3081,3082,3083,3084,3085,3086],{"nctId":4112,"briefTitle":4113,"status":1144,"phases":6723,"primaryCompletion":4115,"completion":4115,"start":4116,"enrollment":100,"conditions":6724,"interventions":6725},[90],[4118],[4103,3084,4120],{"nctId":5805,"briefTitle":5806,"status":144,"phases":6727,"primaryCompletion":241,"completion":282,"start":5808,"enrollment":269,"conditions":6728,"interventions":6729},[90],[21],[1556,1266,1267,5811,5812,4313],{"trials":6731,"activeCount":100},[],{"trials":6733,"activeCount":100},[],{"trials":6735,"activeCount":100},[6736],{"nctId":5865,"briefTitle":5866,"status":1144,"phases":6737,"start":1276,"enrollment":100,"conditions":6738,"interventions":6739},[93],[21],[1556,1266,1267,5811,5812],{"intervention":4095,"totalTrials":135,"cells":6741},{"EARLY_PHASE1":6742,"PHASE1":6744,"PHASE2":6746,"PHASE3":6752,"PHASE4":6754,"NA":6756},{"trials":6743,"activeCount":100},[],{"trials":6745,"activeCount":100},[],{"trials":6747,"activeCount":100},[6748],{"nctId":4087,"briefTitle":4088,"status":144,"phases":6749,"primaryCompletion":4090,"completion":4091,"start":268,"enrollment":19,"conditions":6750,"interventions":6751},[90],[29],[4078,4094,4095,1340],{"trials":6753,"activeCount":100},[],{"trials":6755,"activeCount":100},[],{"trials":6757,"activeCount":100},[6758,6762,6769],{"nctId":6429,"briefTitle":6430,"status":1144,"phases":6759,"start":6432,"enrollment":100,"conditions":6760,"interventions":6761},[],[15],[5854,1339,4094,4095,1340,6435],{"nctId":6763,"briefTitle":6764,"status":1144,"phases":6765,"start":6766,"enrollment":100,"conditions":6767,"interventions":6768},"NCT00897143","Identifying Early Lung Cancer Cells in Malignant Pleural Effusion Samples From Patients With Primary Lung Cancer",[],"2007-06",[26,5055],[4313,4095],{"nctId":6437,"briefTitle":6438,"status":1144,"phases":6770,"primaryCompletion":4116,"start":6440,"enrollment":100,"conditions":6771,"interventions":6772},[],[26],[5021,6443,1339,4094,4095,1340,6435],{"intervention":5812,"totalTrials":1406,"cells":6774},{"EARLY_PHASE1":6775,"PHASE1":6777,"PHASE2":6779,"PHASE3":6789,"PHASE4":6791,"NA":6793},{"trials":6776,"activeCount":100},[],{"trials":6778,"activeCount":100},[],{"trials":6780,"activeCount":100},[6781,6785],{"nctId":3071,"briefTitle":3072,"status":144,"phases":6782,"primaryCompletion":3074,"completion":3075,"start":3076,"enrollment":512,"conditions":6783,"interventions":6784},[89,90],[2208,2220,2236,2268,2289],[3079,3080,3081,3082,3083,3084,3085,3086],{"nctId":5805,"briefTitle":5806,"status":144,"phases":6786,"primaryCompletion":241,"completion":282,"start":5808,"enrollment":269,"conditions":6787,"interventions":6788},[90],[21],[1556,1266,1267,5811,5812,4313],{"trials":6790,"activeCount":100},[],{"trials":6792,"activeCount":100},[],{"trials":6794,"activeCount":100},[6795],{"nctId":5865,"briefTitle":5866,"status":1144,"phases":6796,"start":1276,"enrollment":100,"conditions":6797,"interventions":6798},[93],[21],[1556,1266,1267,5811,5812],{"intervention":6800,"totalTrials":1406,"cells":6801},"pazopanib hydrochloride",{"EARLY_PHASE1":6802,"PHASE1":6804,"PHASE2":6812,"PHASE3":6824,"PHASE4":6826,"NA":6828},{"trials":6803,"activeCount":100},[],{"trials":6805,"activeCount":100},[6806],{"nctId":6807,"briefTitle":6808,"status":144,"phases":6809,"completion":2336,"start":2834,"conditions":6810,"interventions":6811},"NCT00060151","GW786034 in Treating Patients With Advanced Solid Tumors",[89],[24],[6800],{"trials":6813,"activeCount":100},[6814],{"nctId":6815,"briefTitle":6816,"status":144,"phases":6817,"primaryCompletion":6818,"completion":6818,"start":267,"enrollment":1070,"conditions":6819,"interventions":6823},"NCT01158521","Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer",[90],"2016-01",[6599,6820,6821,6822],"Stage I Renal Cell Cancer","Stage II Renal Cell Cancer","Stage III Renal Cell Cancer",[6800],{"trials":6825,"activeCount":100},[],{"trials":6827,"activeCount":100},[],{"trials":6829,"activeCount":100},[6830],{"nctId":6831,"briefTitle":6832,"status":1144,"phases":6833,"primaryCompletion":372,"completion":372,"start":372,"enrollment":100,"conditions":6834,"interventions":6836},"NCT02307474","A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer",[93],[6599,6835],"Renal Cell Carcinoma",[6837],"Pazopanib Hydrochloride",{"intervention":1245,"totalTrials":1406,"cells":6839},{"EARLY_PHASE1":6840,"PHASE1":6846,"PHASE2":6848,"PHASE3":6854,"PHASE4":6856,"NA":6858},{"trials":6841,"activeCount":100},[6842],{"nctId":1238,"briefTitle":1239,"status":144,"phases":6843,"primaryCompletion":1241,"completion":1241,"start":1242,"enrollment":129,"conditions":6844,"interventions":6845},[88],[15],[258,1245,364,274],{"trials":6847,"activeCount":100},[],{"trials":6849,"activeCount":100},[6850],{"nctId":1315,"briefTitle":1316,"status":144,"phases":6851,"primaryCompletion":1318,"completion":1319,"start":1320,"enrollment":1012,"conditions":6852,"interventions":6853},[90],[1322,1323,1324,1325],[1245,1327,274,364,1328,1266,365,1329],{"trials":6855,"activeCount":100},[],{"trials":6857,"activeCount":100},[],{"trials":6859,"activeCount":100},[6860],{"nctId":5848,"briefTitle":5849,"status":144,"phases":6861,"primaryCompletion":1371,"completion":1371,"start":5851,"enrollment":230,"conditions":6862,"interventions":6863},[],[15,5055],[246,1266,1267,1359,5854,365,1930,5855],{"intervention":1930,"totalTrials":1406,"cells":6865},{"EARLY_PHASE1":6866,"PHASE1":6868,"PHASE2":6878,"PHASE3":6880,"PHASE4":6882,"NA":6884},{"trials":6867,"activeCount":100},[],{"trials":6869,"activeCount":100},[6870,6874],{"nctId":3645,"briefTitle":238,"status":144,"phases":6871,"primaryCompletion":1473,"completion":1562,"start":1876,"enrollment":230,"conditions":6872,"interventions":6873},[89],[24],[1359,3638,1930],{"nctId":1924,"briefTitle":1925,"status":265,"phases":6875,"primaryCompletion":1927,"completion":1562,"start":240,"enrollment":851,"conditions":6876,"interventions":6877},[89],[15],[1917,1930],{"trials":6879,"activeCount":100},[],{"trials":6881,"activeCount":100},[],{"trials":6883,"activeCount":100},[],{"trials":6885,"activeCount":100},[6886],{"nctId":5848,"briefTitle":5849,"status":144,"phases":6887,"primaryCompletion":1371,"completion":1371,"start":5851,"enrollment":230,"conditions":6888,"interventions":6889},[],[15,5055],[246,1266,1267,1359,5854,365,1930,5855],{"intervention":6435,"totalTrials":1406,"cells":6891},{"EARLY_PHASE1":6892,"PHASE1":6907,"PHASE2":6909,"PHASE3":6911,"PHASE4":6913,"NA":6915},{"trials":6893,"activeCount":100},[6894],{"nctId":6895,"briefTitle":6896,"status":1144,"phases":6897,"primaryCompletion":3117,"completion":3117,"start":1345,"enrollment":100,"conditions":6898,"interventions":6905},"NCT01403103","Cholecalciferol(25-[OH]-Vitamin D) in Treating Patients With Colorectal Cancer",[88],[6899,6900,6901,6902,6903,6904],"Mucinous Adenocarcinoma of the Colon","Mucinous Adenocarcinoma of the Rectum","Signet Ring Adenocarcinoma of the Colon","Signet Ring Adenocarcinoma of the Rectum","Stage I Colon Cancer","Stage I Rectal Cancer",[6906,6435],"protein expression analysis",{"trials":6908,"activeCount":100},[],{"trials":6910,"activeCount":100},[],{"trials":6912,"activeCount":100},[],{"trials":6914,"activeCount":100},[],{"trials":6916,"activeCount":100},[6917,6921],{"nctId":6429,"briefTitle":6430,"status":1144,"phases":6918,"start":6432,"enrollment":100,"conditions":6919,"interventions":6920},[],[15],[5854,1339,4094,4095,1340,6435],{"nctId":6437,"briefTitle":6438,"status":1144,"phases":6922,"primaryCompletion":4116,"start":6440,"enrollment":100,"conditions":6923,"interventions":6924},[],[26],[5021,6443,1339,4094,4095,1340,6435],{"intervention":4313,"totalTrials":1406,"cells":6926},{"EARLY_PHASE1":6927,"PHASE1":6929,"PHASE2":6931,"PHASE3":6941,"PHASE4":6943,"NA":6945},{"trials":6928,"activeCount":100},[],{"trials":6930,"activeCount":100},[],{"trials":6932,"activeCount":100},[6933,6937],{"nctId":4302,"briefTitle":4303,"status":144,"phases":6934,"primaryCompletion":2159,"completion":4305,"start":2753,"enrollment":1070,"conditions":6935,"interventions":6936},[89,90],[1805,1808,32,4307,4308,4309,4310,4311],[4293,4313,4094,2165],{"nctId":5805,"briefTitle":5806,"status":144,"phases":6938,"primaryCompletion":241,"completion":282,"start":5808,"enrollment":269,"conditions":6939,"interventions":6940},[90],[21],[1556,1266,1267,5811,5812,4313],{"trials":6942,"activeCount":100},[],{"trials":6944,"activeCount":100},[],{"trials":6946,"activeCount":100},[6947],{"nctId":6763,"briefTitle":6764,"status":1144,"phases":6948,"start":6766,"enrollment":100,"conditions":6949,"interventions":6950},[],[26,5055],[4313,4095],{"intervention":5021,"totalTrials":96,"cells":6952},{"EARLY_PHASE1":6953,"PHASE1":6955,"PHASE2":6961,"PHASE3":6963,"PHASE4":6965,"NA":6967},{"trials":6954,"activeCount":100},[],{"trials":6956,"activeCount":100},[6957],{"nctId":5014,"briefTitle":5015,"status":144,"phases":6958,"primaryCompletion":292,"completion":5017,"start":281,"enrollment":129,"conditions":6959,"interventions":6960},[89],[1787,1889,1890,1807,1809,1896,1897,1812,2232,1817,1818,1819,1820,1821,1900,1822,1823,1902,1831,1832,1833,1834,1835,1836,1837,816,817,1763,1838,1903,1842,818,1904,2309],[163,5007,5020,5021],{"trials":6962,"activeCount":100},[],{"trials":6964,"activeCount":100},[],{"trials":6966,"activeCount":100},[],{"trials":6968,"activeCount":100},[6969],{"nctId":6437,"briefTitle":6438,"status":1144,"phases":6970,"primaryCompletion":4116,"start":6440,"enrollment":100,"conditions":6971,"interventions":6972},[],[26],[5021,6443,1339,4094,4095,1340,6435],{"intervention":5940,"totalTrials":96,"cells":6974},{"EARLY_PHASE1":6975,"PHASE1":6977,"PHASE2":6979,"PHASE3":6981,"PHASE4":6987,"NA":6989},{"trials":6976,"activeCount":100},[],{"trials":6978,"activeCount":100},[],{"trials":6980,"activeCount":100},[],{"trials":6982,"activeCount":100},[6983],{"nctId":5933,"briefTitle":5934,"status":265,"phases":6984,"primaryCompletion":5936,"start":5937,"enrollment":269,"conditions":6985,"interventions":6986},[91],[1763],[5940,894],{"trials":6988,"activeCount":100},[],{"trials":6990,"activeCount":100},[6991],{"nctId":5946,"briefTitle":5947,"status":265,"phases":6992,"primaryCompletion":5949,"completion":5949,"start":4551,"enrollment":1070,"conditions":6993,"interventions":6994},[93],[1778,2204,1787,1889,1890,1807,1809,1896,1812,2231,2232,1817,1818,1819,1820,1821,1822,1823,1902,1831,1832,1833,1834,1835,1836,1837,816,817,2234,1903,1842,1847,1904,2309],[5940,894,1557],{"intervention":5854,"totalTrials":96,"cells":6996},{"EARLY_PHASE1":6997,"PHASE1":6999,"PHASE2":7001,"PHASE3":7003,"PHASE4":7005,"NA":7007},{"trials":6998,"activeCount":100},[],{"trials":7000,"activeCount":100},[],{"trials":7002,"activeCount":100},[],{"trials":7004,"activeCount":100},[],{"trials":7006,"activeCount":100},[],{"trials":7008,"activeCount":100},[7009,7013],{"nctId":5848,"briefTitle":5849,"status":144,"phases":7010,"primaryCompletion":1371,"completion":1371,"start":5851,"enrollment":230,"conditions":7011,"interventions":7012},[],[15,5055],[246,1266,1267,1359,5854,365,1930,5855],{"nctId":6429,"briefTitle":6430,"status":1144,"phases":7014,"start":6432,"enrollment":100,"conditions":7015,"interventions":7016},[],[15],[5854,1339,4094,4095,1340,6435],{"intervention":6906,"totalTrials":96,"cells":7018},{"EARLY_PHASE1":7019,"PHASE1":7025,"PHASE2":7027,"PHASE3":7029,"PHASE4":7031,"NA":7033},{"trials":7020,"activeCount":100},[7021],{"nctId":6895,"briefTitle":6896,"status":1144,"phases":7022,"primaryCompletion":3117,"completion":3117,"start":1345,"enrollment":100,"conditions":7023,"interventions":7024},[88],[6899,6900,6901,6902,6903,6904],[6906,6435],{"trials":7026,"activeCount":100},[],{"trials":7028,"activeCount":100},[],{"trials":7030,"activeCount":100},[],{"trials":7032,"activeCount":100},[],{"trials":7034,"activeCount":100},[7035],{"nctId":7036,"briefTitle":7037,"status":265,"phases":7038,"primaryCompletion":812,"completion":812,"start":888,"enrollment":7039,"conditions":7040,"interventions":7042},"NCT00899132","Studying a Tumor Marker for Testicular Cancer, Skin Cancer, Small Intestine Cancer, and Pancreatic Cancer",[],180,[5047,7041,4555,185],"Pancreatic Cancer",[7043,6906],"in situ hybridization",{"intervention":7045,"totalTrials":96,"cells":7046},"indocyanine green solution",{"EARLY_PHASE1":7047,"PHASE1":7049,"PHASE2":7051,"PHASE3":7053,"PHASE4":7055,"NA":7057},{"trials":7048,"activeCount":100},[],{"trials":7050,"activeCount":100},[],{"trials":7052,"activeCount":100},[],{"trials":7054,"activeCount":100},[],{"trials":7056,"activeCount":100},[],{"trials":7058,"activeCount":100},[7059,7072],{"nctId":7060,"briefTitle":7061,"status":265,"phases":7062,"primaryCompletion":7063,"completion":7063,"start":7064,"enrollment":4552,"conditions":7065,"interventions":7070},"NCT01939028","Lymph Node Mapping in Patients With Newly Diagnosed Endometrial Cancer Undergoing Surgery",[93],"2016-10","2013-07",[7066,7067,7068,7069],"Stage I Endometrial Carcinoma","Stage II Endometrial Carcinoma","Stage III Endometrial Carcinoma","Stage IV Endometrial Carcinoma",[7071,7045],"isosulfan blue",{"nctId":7073,"briefTitle":7074,"status":144,"phases":7075,"primaryCompletion":7076,"completion":7076,"start":7077,"enrollment":7078,"conditions":7079,"interventions":7081},"NCT02419807","Comparison of Use of Indocyanine Green and 99mTc-labeled Radiotracer for Axillary Lymphatic Mapping in Patients With Breast Cancer",[93],"2019-02","2015-02-17",102,[7080,1322],"Stage I Breast Cancer",[7082],"Indocyanine Green Solution",{"intervention":7084,"totalTrials":119,"cells":7085},"SignateraTM assay",{"EARLY_PHASE1":7086,"PHASE1":7088,"PHASE2":7090,"PHASE3":7092,"PHASE4":7094,"NA":7096},{"trials":7087,"activeCount":100},[],{"trials":7089,"activeCount":100},[],{"trials":7091,"activeCount":100},[],{"trials":7093,"activeCount":100},[],{"trials":7095,"activeCount":100},[],{"trials":7097,"activeCount":100},[7098],{"nctId":7099,"briefTitle":7100,"status":1144,"phases":7101,"primaryCompletion":7102,"completion":7102,"start":7103,"enrollment":100,"conditions":7104,"interventions":7105},"NCT05356585","Circulating Tumor DNA to Monitor the Efficacy of Total Neoadjuvant Therapy for Rectal Cancer",[],"2024-06-30","2023-12-30",[256,2516],[7084],{"intervention":7043,"totalTrials":119,"cells":7107},{"EARLY_PHASE1":7108,"PHASE1":7110,"PHASE2":7112,"PHASE3":7114,"PHASE4":7116,"NA":7118},{"trials":7109,"activeCount":100},[],{"trials":7111,"activeCount":100},[],{"trials":7113,"activeCount":100},[],{"trials":7115,"activeCount":100},[],{"trials":7117,"activeCount":100},[],{"trials":7119,"activeCount":100},[7120],{"nctId":7036,"briefTitle":7037,"status":265,"phases":7121,"primaryCompletion":812,"completion":812,"start":888,"enrollment":7039,"conditions":7122,"interventions":7123},[],[5047,7041,4555,185],[7043,6906],{"intervention":7071,"totalTrials":119,"cells":7125},{"EARLY_PHASE1":7126,"PHASE1":7128,"PHASE2":7130,"PHASE3":7132,"PHASE4":7134,"NA":7136},{"trials":7127,"activeCount":100},[],{"trials":7129,"activeCount":100},[],{"trials":7131,"activeCount":100},[],{"trials":7133,"activeCount":100},[],{"trials":7135,"activeCount":100},[],{"trials":7137,"activeCount":100},[7138],{"nctId":7060,"briefTitle":7061,"status":265,"phases":7139,"primaryCompletion":7063,"completion":7063,"start":7064,"enrollment":4552,"conditions":7140,"interventions":7141},[93],[7066,7067,7068,7069],[7071,7045],{"intervention":7143,"totalTrials":119,"cells":7144},"systemic chemotherapy",{"EARLY_PHASE1":7145,"PHASE1":7147,"PHASE2":7149,"PHASE3":7151,"PHASE4":7153,"NA":7155},{"trials":7146,"activeCount":100},[],{"trials":7148,"activeCount":100},[],{"trials":7150,"activeCount":100},[],{"trials":7152,"activeCount":100},[],{"trials":7154,"activeCount":100},[],{"trials":7156,"activeCount":100},[7157],{"nctId":7158,"briefTitle":7159,"status":265,"phases":7160,"primaryCompletion":2022,"completion":2022,"start":1354,"enrollment":356,"conditions":7161,"interventions":7162},"NCT00740961","Older Patients With Newly Diagnosed Breast Cancer or Colon Cancer",[],[15,1148,256,1149],[7143],{"intervention":7164,"totalTrials":119,"cells":7165},"Automated program",{"EARLY_PHASE1":7166,"PHASE1":7168,"PHASE2":7170,"PHASE3":7172,"PHASE4":7174,"NA":7176},{"trials":7167,"activeCount":100},[],{"trials":7169,"activeCount":100},[],{"trials":7171,"activeCount":100},[],{"trials":7173,"activeCount":100},[],{"trials":7175,"activeCount":100},[],{"trials":7177,"activeCount":100},[7178],{"nctId":7179,"briefTitle":7180,"status":144,"phases":7181,"primaryCompletion":7182,"completion":7182,"start":7183,"enrollment":1356,"conditions":7184,"interventions":7185},"NCT04354675","Effectiveness of AI Genetic Counseling Program vs In-person Genetic Counseling in Breast Cancer",[93],"2023-03-30","2021-06-29",[15],[7164,7186],"Genetics counselor",{"intervention":7186,"totalTrials":119,"cells":7188},{"EARLY_PHASE1":7189,"PHASE1":7191,"PHASE2":7193,"PHASE3":7195,"PHASE4":7197,"NA":7199},{"trials":7190,"activeCount":100},[],{"trials":7192,"activeCount":100},[],{"trials":7194,"activeCount":100},[],{"trials":7196,"activeCount":100},[],{"trials":7198,"activeCount":100},[],{"trials":7200,"activeCount":100},[7201],{"nctId":7179,"briefTitle":7180,"status":144,"phases":7202,"primaryCompletion":7182,"completion":7182,"start":7183,"enrollment":1356,"conditions":7203,"interventions":7204},[93],[15],[7164,7186],{"intervention":7206,"totalTrials":119,"cells":7207},"Triamcinolone Acetonide",{"EARLY_PHASE1":7208,"PHASE1":7210,"PHASE2":7212,"PHASE3":7214,"PHASE4":7216,"NA":7218},{"trials":7209,"activeCount":100},[],{"trials":7211,"activeCount":100},[],{"trials":7213,"activeCount":100},[],{"trials":7215,"activeCount":100},[],{"trials":7217,"activeCount":100},[],{"trials":7219,"activeCount":100},[7220],{"nctId":7221,"briefTitle":7222,"status":1144,"phases":7223,"primaryCompletion":1594,"completion":7224,"start":5403,"enrollment":100,"conditions":7225,"interventions":7231},"NCT05106192","Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System.",[93],"2026-06-01",[7226,7227,154,7228,7229,7230],"Mycosis Fungoides of Skin (Diagnosis)","Cutaneous T-cell Lymphoma","Lymphomatoid Papulosis","Lymphoma, Large-Cell, Anaplastic","Lymphoma, Follicular",[7206,7232,7233],"Bexarotene 1% Top Gel","Nitrogen Mustard",{"intervention":7232,"totalTrials":119,"cells":7235},{"EARLY_PHASE1":7236,"PHASE1":7238,"PHASE2":7240,"PHASE3":7242,"PHASE4":7244,"NA":7246},{"trials":7237,"activeCount":100},[],{"trials":7239,"activeCount":100},[],{"trials":7241,"activeCount":100},[],{"trials":7243,"activeCount":100},[],{"trials":7245,"activeCount":100},[],{"trials":7247,"activeCount":100},[7248],{"nctId":7221,"briefTitle":7222,"status":1144,"phases":7249,"primaryCompletion":1594,"completion":7224,"start":5403,"enrollment":100,"conditions":7250,"interventions":7251},[93],[7226,7227,154,7228,7229,7230],[7206,7232,7233],{"intervention":7233,"totalTrials":119,"cells":7253},{"EARLY_PHASE1":7254,"PHASE1":7256,"PHASE2":7258,"PHASE3":7260,"PHASE4":7262,"NA":7264},{"trials":7255,"activeCount":100},[],{"trials":7257,"activeCount":100},[],{"trials":7259,"activeCount":100},[],{"trials":7261,"activeCount":100},[],{"trials":7263,"activeCount":100},[],{"trials":7265,"activeCount":100},[7266],{"nctId":7221,"briefTitle":7222,"status":1144,"phases":7267,"primaryCompletion":1594,"completion":7224,"start":5403,"enrollment":100,"conditions":7268,"interventions":7269},[93],[7226,7227,154,7228,7229,7230],[7206,7232,7233],{"intervention":7271,"totalTrials":119,"cells":7272},"sildenafil citrate",{"EARLY_PHASE1":7273,"PHASE1":7275,"PHASE2":7277,"PHASE3":7279,"PHASE4":7281,"NA":7283},{"trials":7274,"activeCount":100},[],{"trials":7276,"activeCount":100},[],{"trials":7278,"activeCount":100},[],{"trials":7280,"activeCount":100},[],{"trials":7282,"activeCount":100},[],{"trials":7284,"activeCount":100},[7285],{"nctId":7286,"briefTitle":7287,"status":265,"phases":7288,"primaryCompletion":1626,"completion":1626,"start":7064,"enrollment":176,"conditions":7289,"interventions":7293},"NCT01996852","Improving Erectile Function and Quality of Life After Prostate Cancer Treatment",[93],[18,7290,7291,7292],"Erectile Dysfunction Following Radical Prostatectomy","Erectile Dysfunction Following Simple Prostatectomy","Erectile Dysfunction",[7271],{"intervention":6443,"totalTrials":119,"cells":7295},{"EARLY_PHASE1":7296,"PHASE1":7298,"PHASE2":7300,"PHASE3":7302,"PHASE4":7304,"NA":7306},{"trials":7297,"activeCount":100},[],{"trials":7299,"activeCount":100},[],{"trials":7301,"activeCount":100},[],{"trials":7303,"activeCount":100},[],{"trials":7305,"activeCount":100},[],{"trials":7307,"activeCount":100},[7308],{"nctId":6437,"briefTitle":6438,"status":1144,"phases":7309,"primaryCompletion":4116,"start":6440,"enrollment":100,"conditions":7310,"interventions":7311},[],[26],[5021,6443,1339,4094,4095,1340,6435]]